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A B S T R A C T
Background
Heart failure is a condition in which the heart does not pump enough blood to meet all the needs of the body. Symptoms of heart failure
include breathlessness, fatigue and fluid retention. Outcomes for patients with heart failure are highly variable; however on average,
these patients have a poor prognosis. Prognosis can be improved with early diagnosis and appropriate use of medical treatment, use of
devices and transplantation. Patients with heart failure are high users of healthcare resources, not only due to drug and device treatments,
but due to high costs of hospitalisation care. B-type natriuretic peptide levels are already used as biomarkers for diagnosis and prognosis
of heart failure, but could offer to clinicians a possible tool to guide drug treatment. This could optimise drug management in heart
failure patients whilst allaying concerns over potential side effects due to drug intolerance.
Objectives
To assess whether treatment guided by serial BNP or NT-proBNP (collectively referred to as NP) monitoring improves outcomes
compared with treatment guided by clinical assessment alone.
Search methods
Searches were conducted up to 15 March 2016 in the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane
Library; MEDLINE (OVID), Embase (OVID), the Database of Abstracts of Reviews of Effects (DARE) and the NHS Economic
Evaluation Database in the Cochrane Library. Searches were also conducted in the Science Citation Index Expanded, the Conference
Proceedings Citation Index on Web of Science (Thomson Reuters), World Health Organization International Clinical Trials Registry
and ClinicalTrials.gov. We applied no date or language restrictions.
Selection criteria
We included randomised controlled trials of NP-guided treatment of heart failure versus treatment guided by clinical assessment alone
with no restriction on follow-up. Adults treated for heart failure, in both in-hospital and out-of-hospital settings, and trials reporting a
clinical outcome were included.
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Data collection and analysis
Two review authors independently selected studies for inclusion, extracted data and evaluated risk of bias. Risk ratios (RR)were calculated
for dichotomous data, and pooled mean differences (MD) (with 95% confidence intervals (CI)) were calculated for continuous data.
We contacted trial authors to obtain missing data. Using the Grading of Recommendations Assessment, Development and Evaluation
(GRADE) approach, we assessed the quality of the evidence and GRADE profiler (GRADEPRO) was used to import data fromReview
Manager to create a ’Summary of findings’ table.
Main results
We included 18 randomised controlled trials with 3660 participants (range ofmean age: 57 to 80 years) comparingNP-guided treatment
with clinical assessment alone. The evidence for all-cause mortality using NP-guided treatment showed uncertainty (RR 0.87, 95%
CI 0.76 to 1.01; patients = 3169; studies = 15; low quality of the evidence), and for heart failure mortality (RR 0.84, 95% CI 0.54 to
1.30; patients = 853; studies = 6; low quality of evidence).
The evidence suggested heart failure admission was reduced by NP-guided treatment (38% versus 26%, RR 0.70, 95% CI 0.61 to
0.80; patients = 1928; studies = 10; low quality of evidence), but the evidence showed uncertainty for all-cause admission (57% versus
53%, RR 0.93, 95% CI 0.84 to 1.03; patients = 1142; studies = 6; low quality of evidence).
Six studies reported on adverse events, however the results could not be pooled (patients = 1144; low quality of evidence). Only four
studies provided cost of treatment results, three of these studies reported a lower cost for NP-guided treatment, whilst one reported a
higher cost (results were not pooled; patients = 931, low quality of evidence). The evidence showed uncertainty for quality of life data
(MD -0.03, 95% CI -1.18 to 1.13; patients = 1812; studies = 8; very low quality of evidence).
We completed a ’Risk of bias’ assessment for all studies. The impact of risk of bias from lack of blinding of outcome assessment and
high attrition levels was examined by restricting analyses to only low ’Risk of bias’ studies.
Authors’ conclusions
In patients with heart failure low-quality evidence showed a reduction in heart failure admission with NP-guided treatment while low-
quality evidence showed uncertainty in the effect of NP-guided treatment for all-cause mortality, heart failure mortality, and all-cause
admission. Uncertainty in the effect was further shown by very low-quality evidence for patient’s quality of life. The evidence for adverse
events and cost of treatment was low quality and we were unable to pool results.
P L A I N L A N G U A G E S U M M A R Y
B-type natriuretic peptide-guided treatment for heart failure patients
Review question
We aimed to discover whether using B-type natriuretic-guided treatment or a health plan alone is more effective for managing patients
with heart failure.
Background
Heart failure is a complex condition that occurs when the heart does not pump blood effectively enough to meet the needs of the body.
It is caused by a range of diseases that impair the structure and function of the heart and may result in breathlessness, fatigue and fluid
retention. People with heart failure are frequently users of general practice and hospitals, particularly as inpatients. Furthermore, they
have reduced life expectancy, although medicines and other treatments can improve the chance of survival.
B-type natriuretic peptide (NP) is a substance produced in the heart. The measurement of NP can be used to indicate the condition of
the heart. For some time, NP has been used for diagnosing heart failure and predicting what is likely to happen. We wanted to discover
if NP may also offer a way to manage and make the best use of medicines.
Study selection and characteristics
We carried out a review of all studies and the evidence is current to 15 March 2016. We found 18 studies of NP-guided treatment in
which 3660 patients with heart failure took part. Patients were between 62 to 80 years old at the start of the studies. The duration of
each study ranged from one to 54 months.
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Eight out of the 18 studies were part or fully funded by pharmaceutical companies, one was funded by a national research body, five
were partially funded either by national research grants, lotteries, hospital funds and/or pharmaceutical companies and four studies did
not report the funding source.
Key results
The evidence was unclear as to whether number of deaths from any cause varied between patients with heart failure using NP-guided
treatment compared with those using a health plan alone. Nor was it clear as to whether there were less deaths when the results were
separated into patients older or younger than 75 years old (age results only included three studies). Furthermore, we found that the
evidence was unclear whether the number of deaths from heart failure alone varied between the NP-guided treatment or health plan
alone groups.
We found that hospital admission due to heart failure may be reduced in the patients using NP-guided treatment compared with a
health plan alone. Based on these results we would expect that out of 1000 patients with heart failure who are guided by a health plan
alone, 377 would experience an admission to hospital due to heart failure. Whereas, between 230 and 301 patients would experience
an admission to hospital due to heart failure if they received NP-guided treatment. However, the evidence was unclear as to whether
the numbers of hospital admission from any cause were affected.
There was limited information about either harms to patients, or the cost of the treatment. It was not possible to combine the results
from these studies for these outcomes. However, four of the six studies commented that they found no difference in harms or less
difference in harms between the patients using NP-guided treatment compared with a health plan alone, the other two studies did not
comment. Four studies reported results on costs, three of these reported there may be lower costs in the NP-guided treatment groups
compared with health plan groups. Lower costs appeared to be due to less cost for hospital stays. However, one study reported that
NP-guided treatment was unlikely to be cost-effective.
The evidence was unclear as to if a benefit was shown in the replies to quality-of-life surveys when comparing between NP-guided
treatment and health plan only groups.
Quality of evidence
Overall evidence for death from all causes, from heart failure alone and for hospital admission was of low quality. For harm to patients
and cost outcomes the quality of evidence was low, whilst evidence for patients’ quality of life surveys was very low. For all outcomes
there was little evidence due to the way the studies were conducted. In addition, for harm to patients and cost of treatment there were
differences in the type of information available.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Does treatment guided by serial BNP or NT-proBNP monitoring improve outcomes compared to treatment guided by clinical assessment alone?
Patient or population: pat ients with heart failure
Settings: in-hospital and out-of -hospital
Intervention: serial BNP or NT-proBNP-guided treatment
Comparison: no BNP or NT-proBNP-guided treament1
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No BNP or NT-proBNP-
guided treatment
Serial BNP or NT-
proBNP-guided treat-
ment
All- cause mortality
Follow-up: 3 to 54
months
218 per 1000 190 per 1000
(166 to 220)
RR 0.87
(0.76 to 1.01)
3169
(15 studies)
⊕⊕©©
low2 ,3
16 studies reported on
all-cause mortality (n
= 3292), but only 15
studies are included in
the meta-analysis (n =
3169). For one study
data could not be ex-
tracted or obtained in
a format useable in the
review
Funnel plot analysis
suggests possible lack
of small studies (ben-
ef icial control ef fect)
. Insuf f icient to just if y
downgrading the qual-
ity of evidence
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Heart failure mortality
Follow-up: 6 - 24
months
91 per 1000 76 per 1000
(49 to 118)
RR 0.84
(0.54 to 1.30)
853
(6 studies)
⊕⊕©©
low3,4
Heart failure admis-
sions
Follow-up: 12 - 54
months
377 per 10002 264 per 1000
(230 to 301)
RR 0.70
(0.61 to 0.80)
1928
(10 studies)
⊕⊕©©
low4,5
All- cause admissions
Follow-up: 3 - 54
months
573 per 10002 533 per 1000
(481 to 590)
RR 0.93
(0.84 to 1.03)
1142
(6 studies)
⊕⊕©©
low3,4
Adverse events
Follow-up: 9 - 24
months
See comment See comment Not est imable 1144
(6 studies)
⊕⊕©©
low4,6
3/ 6 studies com-
mented on the dif fer-
ence between the in-
tervent ion and control
groups: no signif icant
dif f erence in one and
two favoured the inter-
vent ion group
Cost
Follow-up: 12 - 18
months
See comment See comment Not est imable 1051
(4 studies)
⊕⊕©©
low4,7
3/ 4 studies suggested
reduced cost in the in-
tervent ion groups. One
study suggested NP-
guided treatment was
unlikely to be cost-ef -
fect ive
Quality of life
Scale f rom: 0 to 105.
Follow-up: 3 - 54
months
The mean quality of lif e
ranged across control
groups f rom
23 - 34.5 scores
The mean quality of
lif e in the intervent ion
groups was
0.03 lower
(1.18 lower to 1.13
higher)
1812
(8 studies)
⊕©©©
very low4,8,9
Lower score indicates
better quality of lif e
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 The comparisons (controls) fell into two groups: same as the intervent ion without BNP or NT-proBNP measures or usual
care
2 Allocat ion concealment was unclear in half of the studies. In two thirds of studies one or both of part icipants and personnel
were not blinded to allocated intervent ions
3 For all studies (bar one study for all-cause mortality outcome) the point est imates and conf idence intervals include the line
of no ef fect. For all studies (bar two for all-cause admissions outcome) the point est imates and conf idence intervals cross
the threshold of appreciable benef it or harm.
4 66% or more of included studies did not blind part icipants and/ or personnel
5 Heterogeneity substant ial (I2: 60%, P value: 0.004)
6 Results for adverse events were not consistent ly reported since data were either f irst event or mult iple events per individual.
7 The outcome measure dif fered for each study
8 Heterogenity substant ial (I2: 75%, P value: 0.0002)
9 95% conf idence intervals are greater than 0.5 in either direct ion
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B A C K G R O U N D
Description of the condition
Heart failure is a condition in which the heart does not pump
enough blood to meet all the needs of the body. It is caused by
dysfunction of the heart due to muscle damage (systolic or dias-
tolic dysfunction), valvular dysfunction, arrhythmias or other rare
causes (NICE 2014). Clinically, it is a syndrome in which patients
have typical symptoms (e.g. breathlessness, ankle swelling, and fa-
tigue) and signs (e.g. elevated jugular venous pressure, pulmonary
crackles, and displaced apex beat).The diagnosis can be difficult as
many of the symptoms of heart failure are non-discriminating so
the demonstration of an underlying cardiac cause is central to the
diagnosis. Identification of the underlying cardiac problem is also
crucial for therapeutic reasons, as the precise pathology determines
the specific treatment used (e.g. valve surgery for valvular disease,
specific pharmacological therapy for left ventricular systolic dys-
function, etc.) (McMurray 2012).
Heart failure due to left ventricular systolic dysfunction (LVSD) is
caused by impaired left ventricular contraction, and is usually char-
acterised by a reduced left ventricular ejection fraction (LVEF).
Heart failure with preserved ejection fraction (HFPEF) is usually
associated with impaired left ventricular relaxation, rather than
left ventricular contraction, and is characterised by a normal or
preserved left ventricular ejection fraction (NICE 2010).
Approximately 1% to 2% of the adult population in developed
countries has heart failure, with the prevalence rising to ≥10%
among persons 70 years of age or older (McMurray 2012). The
prevalence is expected to rise in future as a result of an ageing pop-
ulation, improved survival of people with ischaemic heart disease
and more effective treatments for heart failure (Owan 2006).
Heart failure has a poor prognosis: 30% to 40% of patients di-
agnosed with heart failure die within a year - but thereafter the
mortality is less than 10% per year. There is evidence of a trend
of improved prognosis in the past 10 years. The six-month mor-
tality rate decreased from 26% in 1995 to 14% in 2005. Within
the NHS, heart failure accounts for a total of 1 million inpatient
bed days - 2% of all NHS inpatient bed-days - and 5% of all
emergency medical admissions to hospital. Hospital admissions
because of heart failure are projected to rise by 50% over the next
25 years, largely as a result of the ageing population. This is despite
a progressive decline of the age-adjusted hospitalisation rate at 1%
to 1.5% per annum since 1992/1993 (NICE 2010).
Description of the intervention
All patients with chronic heart failure require monitoring, which
should include a detailed clinical assessment and a review of med-
ication, including the need for titration and optimisation in line
with guidelines and to pick up possible side effects. The pharma-
cological treatment options for patients with LVSD (New York
Heart Association (NYHA) functional class II-IV) include diuret-
ics, angiotensin-converting enzyme (ACE) inhibitors (angiotensin
receptor blockers if ACE inhibitors are not tolerated), beta-block-
ers and mineralocorticoid receptor antagonists (MRA).
The frequency of monitoring depends on the clinical status and
stability of the patient. The monitoring interval should be short
(days to two weeks) if the clinical condition or medication has
changed, but is required at least six-monthly for stable patients
with proven heart failure.
The intervention requires monitoring of B-type natriuretic pep-
tide concentrations to guide treatment of heart failure with the
aim of enhancing the management of individual patients. B-type
natriuretic peptide, along with NT-proBNP, is a natriuretic pep-
tide secreted when the heart stretches. B-type natriuretic peptide
has a shorter half life of 20 minutes compared to the one to two
hours for NT-proBNP, and both can be increased in patients with
systolic or diastolic dysfunction (Atisha 2004). Both biomarkers
have demonstrated diagnostic and prognostic utility in heart fail-
ure (Clerico 2007; Doust 2005; McMurray 2012 NICE 2014).
Monitoring NP concentration provides feedback to the physician
about intravascular volume status, which can be used in combi-
nation with the patient’s clinical condition to facilitate treatment
decisions.
How the intervention might work
BNP and NT-proBNP (collectively referred to as NP) are
biomarkers for heart failure which have been demonstrated to
have diagnostic and prognostic utility (Clerico 2007; Doust 2005,
McMurray 2012, NICE 2014). The precursor, preproBNP is
cleaved to proBNP within the cardiomyocyte and stored in se-
cretory granules; proBNP is cleaved to NT proBNP and BNP
upon secretion into the bloodstream in response to an increase in
intracardiac volume (Chen 2010; Ichiki 2013). Monitoring NP
concentrations provides feedback to the physician about intravas-
cular volume status, which can be used in combination with the
patient’s clinical condition to facilitate treatment decisions.
Why it is important to do this review
To date, five out of seven systematic reviews with meta-analyses
have demonstrated that NP-guided treatment reduces all-cause
mortality in patients with congestive heart failure compared with
usual clinical care (Felker 2009; Li 2013; Li 2014; Porapakkham
2010; Savarese 2013), especially in patients younger than 75 years
of age (Porapakkham 2010). In 2014, Troughton et al (Troughton
2014) published an individual patient meta-analysis and Xin et
al (Xin 2015) published a meta-analysis which contradicted this
finding for all-cause mortality in all patients. Uncertainty remains
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as to whether the monitoring of NP may lead to more harm than
benefit compared with usual care. No other review has examined
heart failure mortality. Fewer reviews have examined whether NP-
guided treatment increases or reduces heart failure admissions (
Li 2013; Li 2014; Savarese 2013, Troughton 2014; Xin 2015) or
all-cause hospital admissions (Porapakkham 2010; Savarese 2013;
Troughton 2014; Xin 2015) .
Two reviews have examined adverse events (Li 2014; Xin 2015)
and no review has examined the cost of treatment. Only Xin 2015
has examined quality of life data.
Monitoring with NP is recommended by NICE only for some
patients by a specialist after hospital admission or when up-titra-
tion of medication is problematic (NICE 2010). It is not recom-
mended by the European Society of Cardiology (ESC) guideline
(McMurray 2012) due to uncertainty about whether it is a more
effective approach than simply optimising treatment (combina-
tions and doses of drugs, devices) according to guidelines.
In this review, we examined the seven outcomes described above
and in addition included heart failure mortality, which has not
been examined previously. In addition, we aimed to evaluate
whether factors such as age, gender, severity of symptoms or stage
of heart failure, and context of care (community or hospital) pre-
dicted whether a patient will benefit from NP monitoring, fur-
thermore whether monitoring leads to a greater change in NP.
However, only one of these pre-specified subgroup analyses was
possible due to lack of data or inconsistency in reporting for these
factors. Four further subgroup analyses were considered post-hoc:
baseline LVEF, duration of follow-up, type of control, and type of
biomarker.
O B J E C T I V E S
Our objectives are:
1. to assess whether treatment guided* by serial BNP or NT-
proBNP (collectively referred to as NP) monitoring improves
outcomes compared with treatment guided by clinical
assessment alone;
2. to assess the extent to which improved outcomes are
explained by up-titration of medication and/or reductions in
BNP levels; and
3. to determine which groups of patients benefit most from
monitoring in terms of their age, gender, severity of symptoms or
stage of heart failure (with the use of the NYHA classification),
and baseline NP.
*Treatment guided within this review refers to lifestyle and medi-
cation changes for the management of heart failure (i.e. no device
therapy or transplantation).
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials of BNP- or NT-proBNP-guided
(collectively NP-guided) treatment of heart failure, in both in-
hospital and out-of-hospital settings, reporting a clinical outcome.
No restriction on length of follow-up.
Types of participants
All patients 18 years and older who are being treated for heart
failure.
Types of interventions
Comparison of treatment guided by NP levels versus treatment
guided by clinical assessment alone.
Types of outcome measures
Primary outcomes
The primary outcome was all-cause mortality.
Secondary outcomes
The secondary outcomes were as follows:
1. heart failure mortality;
2. heart failure admission;
3. all-cause admission;
4. adverse events;
5. cost; and
6. quality of life.
Search methods for identification of studies
Electronic searches
We searched the following databases on 15 March 2016:
1. Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library (2016, Issue 2),
2. MEDLINE (OVID, 1946 to 15 March 2016),
3. Embase (OVID, 1974 to 14 March 2016),
4. Database of Abstracts of Reviews of Effects (DARE) in the
Cochrane Library (2015, Issue 2),
5. NHS Economic Evaluation Database (NHSEED) in the
Cochrane Library (2015, Issue 2), and
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6. Science Citation Index Expanded and the Conference
Proceedings Citation Index on Web of Science (Thomson
Reuters, 1945 to 15 March 2016).
Search filters limiting searches to randomised controlled trials were
applied toMEDLINE andEmbase (Lefebvre 2011). See Appendix
1 for the detailed search strategies. We applied no date or language
restrictions.
Searching other resources
We contacted authors of relevant studies, performed citation
searches and reviewed references of all full text papers retrieved.
We also contacted experts in the field when relevant. We iden-
tified any ongoing trials that were registered with the World
Health Organization International Clinical Trials Registry Plat-
form (http://apps.who.int/trialsearch/) and ClinicalTrials.gov (
http://clinicaltrials.gov) on 15 March 2016.
Data collection and analysis
Selection of studies
We screened the title and abstract of articles obtained from the
search results (LW/JM/NP/CB) for studies that met the inclusion
criteria as well as any articles in which there was uncertainty. For
each article, two review authors (LW/JM/NP/CB) independently
reviewed the studies for final inclusion/exclusion. In cases where it
was still unclear, we contacted the study authors for clarification.
We resolved disagreements by consensus or third-party adjudica-
tion (CH/RP).
Data extraction and management
Weused data abstraction forms specifically designed for this review
to abstract data on participants, interventions, and outcomes. For
each study two review authors (LW/JM/NP) extracted trial results
independently.We resolved differences between authors’ results by
discussion and, when necessary, in consultation with a third review
author (CH/RP). Where data were insufficiently reported in the
published paper, we wrote to the original authors for clarification
and further information.
Assessment of risk of bias in included studies
Three review authors (LW/JM/NP) independently assessed
methodological information, two for each study.The specific com-
ponents assessed included allocation concealment, random se-
quence generation, blinding of participants, personnel, and out-
come assessment, incomplete outcome data, selective reporting
and source of funding. We reported our judgement for each com-
ponent usingCochrane’s tool for ’Risk of bias’ assessment (Higgins
2011).
Unit of analysis issues
No included studies had nonstandard designs such as cross-over
or cluster-randomised. If a study compared more than one type of
control group then the intervention group data were split equally
between the control groups for both outcome events and sample
size.
For continuous outcomes, if the study provided data as medians
and interquartile ranges then medians were assumed to equate
to the mean and the interquartile ranges were converted to stan-
dard deviations by dividing the difference between the two values
divided by 1.35 (approximate relationship between the two as-
suming a normal distribution). The mean difference and standard
deviation were calculated assuming a correlation of 0.5 (Higgins
2011).
Dealing with missing data
Where data were insufficiently reported in the published paper,
we wrote to the original authors for clarification and further in-
formation. We analysed only the available data and discussed the
impact of the missing data on our findings.
Assessment of heterogeneity
Where we pooled data, we used the I2 statistic to quantify the level
of statistical heterogeneity (Higgins 2011) .
Assessment of reporting biases
We assessed publication bias by the use of funnel plots where there
were sufficient studies, and reasons for asymmetry were considered
if it was noted. We addressed other potential reporting biases in
the Discussion.
Data synthesis
Where appropriate, we pooled data from all the studies using the
analysis software in Review Manager (RevMan) version 5.3. For
dichotomous outcomes, we combined data using a fixed-effect
model with theMantzel-Haenzelmethod to determine a summary
estimate of the risk ratio (RR) with 95% confidence intervals (CI).
For continuous outcomes, we used a fixed-effect model with the
inverse variance method to produce a mean difference (MD) with
95% CI for the summary estimate.Where substantial heterogene-
ity (I2 ≥ 50%) was present, we considered potential explanations
and where applicable used a random-effects model to test the ro-
bustness of the findings and also considered not combining the
results and presenting a descriptive analysis.
Subgroup analysis and investigation of heterogeneity
We considered subgroup analyses for the following:
1. age;
9B-type natriuretic peptide-guided treatment for heart failure (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
2. severity of heart failure (New York Heart Association
(NYHA) classification);
3. baseline NP;
4. target NP;
5. achieved NP decrease (as a percentage of baseline);
6. patients treated in the community compared with those
treated in secondary care;
7. gender.
Post hoc subgroup analyses were subsequently considered for:
1. baseline left ventricular ejection fraction;
2. duration of follow-up (≤ one year, one to two years, > two
years);
3. control type;
4. biomarker (BNP, NT-proBNP).
Sensitivity analysis
We incorporated the results of the ’Risk of bias’ assessment into
our interpretation of the results by performing sensitivity analyses
in which we excluded studies with the highest level of or unclear
bias and included low risk of bias studies only.
R E S U L T S
Description of studies
Results of the search
The search identified 3394 references. Once duplicates were re-
moved, the titles and abstracts of the remaining 3379 references
were screened using our inclusion /exclusion criteria and 3044
removed as not relevant to the review. Full texts were examined
for the remaining 335 references and from these 18 studies were
included in this review (see Figure 1). Full details of all the stud-
ies are given in the Characteristics of included studies, Table 1,
Table 2, Characteristics of excluded studies, and Characteristics of
ongoing studies. Each study is identified by the name of the first
author and year of publication of the main results paper (Study
ID). Additional references are listed together with this main pub-
lication under the study ID.
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Figure 1. Study flow diagram.
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Figure 4. Funnel plot of comparison: NP-guided versus no NP-guided treatment for all-cause mortality.
Included studies
The Characteristics of included studies, Table 1 and Table 2 pro-
vide details of each of the 18 included studies.
The earliest study was published in 2000 (Troughton 2000) and
the latest in 2015 (Skvortsov 2015). For two of the studies, data
were only available through conference abstracts and direct contact
with the authors (Krupicka 2010; Shochat 2012).
Ten of the studies were completed in Europe (two in Sweden/
Norway (Karlstrom 2011; Persson 2010), two in Switzerland/
Germany (Maeder 2013; Pfisterer 2009), one in Austria (Berger
2010), France (Jourdain 2007), the Netherlands (Eurlings 2010),
Spain (Anguita 2010), Denmark (Schou 2013). and the Czech
Republic (Krupicka 2010)); three studies were completed in
North America (two in the USA (Januzzi 2011; Shah 2011) and
one in Canada (Beck-da-Silva 2005)); two were completed in
New Zealand (Lainchbury 2010; Troughton 2000), one in Israel
(Shochat 2012), one in Russia (Skvortsov 2015), and one inChina
(Li 2015).
Two of the 18 studies (Berger 2010; Lainchbury 2010) had three
comparison arms comparing NP-guided treatment both to clin-
ical assessment and to usual care. For usual care there were no
scheduled visits and the participants were managed in primary
care. Studies recruited 3660 participants ranging from 41 to 499
participants per study. The average age of participants in all the
studies ranged from 62 to 80 years old. Studies followed up par-
ticipants from baseline to between one and 54 months.
Seven studies (Anguita 2010; Beck-da-Silva 2005; Jourdain 2007;
Karlstrom 2011; Krupicka 2010; Li 2015; Shah 2011) used BNP
as the biomarker; the remainder used NT-proBNP. Only seven
studies (Eurlings 2010; Maeder 2013; Persson 2010; Pfisterer
2009; Schou 2013; Shochat 2012; Skvortsov 2015) stated an NP
level as an inclusion criterion. All studies set a NP target except for
Beck-da-Silva 2005; Schou 2013 and Shochat 2012 who stated a
change in NP level (See Table 2).
Two studies (Beck-da-Silva 2005; Li 2015), compared the effect
of NP-guided treatment with clinical assessment exclusively for
the up-titration of beta-blockers. Beck-da-Silva 2005 changed the
dose of bisoprolol, but all other drugs remainedunchanged, during
a three-month follow-up period. Li 2015 started and increased the
dose of metoprolol succinate over one month; for these patients
intravenous cardiotonic, vasodilator or diuretic was applied if signs
or symptoms of heart failure were observed.
Beck-da-Silva 2005 was the only study to report an algorithm
where medication (beta blocker) was decreased for patients whom
the BNP measurement was increasing, but the clinical assessment
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was worse.
All, bar three studies (Eurlings 2010, Lainchbury 2010; Schou
2013), reported inclusion criteria for classifying participants ac-
cording to the New York Heart Association (NYHA) functional
classification. This classifies patients with heart disease into four
stages based on limitations on physical activity, symptoms with or-
dinary physical activity and status at rest. Stage four indicating the
highest severity of symptoms. At baseline, most studies grouped
participants by NYHA stage and overall, the participants ranged
between stages II and IV. Three studies reported baseline NYHA
as percentages in each stage: for Eurlings 2010 and Lainchbury
2010, over 60% of participants were in class II and for Schou 2013
over 85% were in stages I to II.
Further classification was determined by percentage left ventricu-
lar ejection fraction (LVEF); 12 of the studies stated as an inclusion
criterion a maximum level for percentage LVEF which ranged be-
tween < 35% to < 50%; five studies did not stipulate any inclusion
level (Anguita 2010; Eurlings 2010; Lainchbury 2010; Li 2015;
Shochat 2012); and Maeder 2013 was the only study to have par-
ticipants solely with percentage > 45% LVEF or preserved LVEF.
Although six of the studies did not stipulate an inclusion level per-
centage LVEF, Lainchbury 2010 was the only other study to state
participants with preserved LVEF were not excluded. At baseline,
Berger 2010 did not report LVEF percentage, Maeder 2013 re-
ported all participants averaged 56% LVEF, Karlstrom 2011 re-
ported 57% of participants were < 30% LVEF, whilst the remain-
ing studies reported overall averages ranging from 20% to 46%
LVEF.
Six studies (Felker 2014; Jourdain 2014; Metra 2012; Moe 2007;
Saraya 2015; Steinen 2014) are classified as ongoing.Of these, four
studies (Felker 2014; Jourdain 2014;Moe 2007; Steinen 2014) are
currently recruiting or have just finished recruiting. Metra 2012
finished recruiting in August 2009 and is due to publish shortly.
Saraya 2015 has been completed, but currently only published as
a conference abstract. All six are listed in the Characteristics of
ongoing studies.
Excluded studies
Thirty-five references are included in the Characteristics of
excluded studies tables where the title or abstract or both appeared
to suggest a relevant study to this review. Of these 68% were ex-
cluded as the study was not a randomised control trial. Other rea-
sons included not NP-guided treatment (20%), trial terminated,
not treatment for heart failure, or not a baseline heart failure pop-
ulation.
Risk of bias in included studies
(See Figure 2 and Figure 3)
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about methodological quality for each
included study
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about methodological quality presented as
percentages across all included studies.
Allocation
All studies clearly stated the study was randomised, but not all
studies reported on how randomisation was completed or if alloca-
tion concealment was achieved. Five studies confirmed sequence
generation and allocation concealment and methods were judged
to be at low risk of bias (Berger 2010; Karlstrom 2011; Maeder
2013; Pfisterer 2009; Shah2011). Januzzi 2011; Lainchbury 2010;
Shochat 2012; Skvortsov 2015 and Troughton 2000 were low risk
for sequence generation only and Beck-da-Silva 2005; Eurlings
2010 and Krupicka 2010 only for allocation concealment. The
remaining studies were classified as unclear.
Blinding
Blinding of participants and study personnel was only judged to
be low risk if both were blinded to the treatment allocation; only
one study met this standard (Lainchbury 2010). Five studies did
not report or it was unclear whether participants or personnel
were blinded to treatment allocation (Anguita 2010; Li 2015;
Persson 2010; Shochat 2012; Skvortsov 2015). In all the remaining
studies one or more of these groups were not blinded. Blinding
of outcome assessments was not achieved or not reported in the
majority of studies; only five studies blinded outcome assessment
(Berger 2010; Eurlings 2010; Karlstrom 2011; Lainchbury 2010;
Schou 2013).
Incomplete outcome data
For the primary outcome, all-cause mortality, eight studies (
Anguita 2010; Berger 2010; Jourdain 2007; Li 2015; Schou 2013;
Shah 2011; Skvortsov 2015; Troughton 2000) were judged to be
low risk with regard to incomplete outcome data, in fact they all
had no attrition except for Skvortsov 2015 where the numbers
and reasons were fully reported. The remaining studies either did
not report attrition, or the studies did confirm attrition with break
down by intervention arm, but did not explain how missing data
were handled. For those studies reporting dropouts, the overall
attrition rates were no more than 23%.
All of the studies, bar four, completed intention-to-treat (ITT)
analyses; Beck-da-Silva 2005 did not complete an ITT analysis,
whilst Anguita 2010; Jourdain 2007 and Li 2015 did not report
whether this method was used.
Selective reporting
Nine out of 18 studies reported on all stated outcomes and were
considered low risk for reporting bias. Six studies have not yet re-
ported on some secondary outcomes (Berger 2010 on heart failure
mortality and all-cause admission, Eurlings 2010 on all-cause ad-
mission, Persson 2010 and Maeder 2013 on quality of life, Schou
2013 and Shah 2011 on treatment costs). Lainchbury 2010 par-
tially reported quality of life data. Skvortsov 2015 is currently
awaiting further publications. It was not possible to assess report-
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ing bias for Shochat 2012 as data were provided from conference
abstracts and direct contact with the author and any pre-specified
outcomes were not stated.
Other potential sources of bias
Eight of the studies were part or fully funded by pharmaceutical
companies (Berger 2010; Januzzi 2011; Jourdain 2007; Krupicka
2010;Maeder 2013; Persson 2010; Pfisterer 2009; Shochat 2012).
Five studies (Eurlings 2010; Karlstrom 2011; Schou 2013; Shah
2011;Troughton 2000)were partially fundedby either national re-
search grants, lotteries, hospital funds and/or pharmaceutical com-
panies. Four studies did report funding sources (Anguita 2010,
Beck-da-Silva 2005; Li 2015; Skvortsov 2015). These studies were
judged to be of unclear risk of bias.
One study (Lainchbury 2010) was solely funded from a national
research body and therefore considered at low risk of bias from the
funding source.
Effects of interventions
See: Summary of findings for the main comparison Does
treatment guided by serial BNP or NT-proBNP monitoring
improve outcomes compared to treatment guided by clinical
assessment alone?
(See Summary of findings for the main comparison)
All-cause mortality
(See Analysis 1.1)
Sixteen studies (Anguita 2010; Beck-da-Silva 2005; Berger
2010; Eurlings 2010; Jourdain 2007; Karlstrom 2011; Krupicka
2010; Lainchbury 2010; Maeder 2013; Persson 2010; Pfisterer
2009; Schou 2013; Shah 2011; Shochat 2012; Skvortsov 2015;
Troughton 2000) with 3292 participants recruited, reported re-
sults for all-cause mortality. Follow-up ranged from one month
to four and a half years. However, data for Maeder 2013 was pre-
sented as survival curves and it was not possible to extract or obtain
data for this study. Therefore meta-analysis was only possible for
the remaining 15 studies: During the follow-up period, 265 (18%)
participants died in the NP-guided treatment groups compared to
368 (22%) in the control groups. When the data were pooled for
all studies using a fixed-effect model, the evidence favoured the
guided treatment groups, but overall the evidence showed uncer-
tainty (risk ratio (RR) 0.87, 95% confidence interval (CI) 0.76
to 1.01; patients = 3169; studies = 15; low quality of evidence).
Heterogeneity was low (I2 = 16%).
The two studies that did not report results for all-cause mortality
were Januzzi 2011 and Li 2015.
Heart failure mortality
(See Analysis 1.2)
Only six studies (Jourdain 2007; Karlstrom 2011; Krupicka 2010;
Li 2015; Skvortsov 2015; Troughton 2000) with 853 participants
recruited reported results for heart failure mortality. In the NP-
guided treatment groups, 34 participants died and in the control
groups 38 participants died due to heart failure, representing 8%
and 9% respectively. Similar to all-cause mortality, the pooled
result, using a fixed-effect model, favoured the intervention, but
overall, the evidence showed uncertainty (RR 0.84, 95% CI 0.54
to 1.30; participants = 853; studies = 6; low quality of evidence).
The heterogeneity was low (I2 = 21%).
Heart failure admission
(See Analysis 1.3)
Ten studies (Anguita 2010; Berger 2010; Januzzi 2011; Jourdain
2007; Karlstrom 2011; Krupicka 2010; Lainchbury 2010; Schou
2013; Skvortsov 2015; Troughton 2000) with 1928 participants
reported on heart failure admission. Out of 858 participants, 219
(26%) experienced a heart failure event causing an admission in
the NP-guided treatment groups; this compared to 403 out of
1070 (38%) participants in the control groups.Overall, the pooled
evidence for all 10 studies, with a fixed-effect model, showed an
effect favouring NP-guided treatment (RR 0.70, 95% CI 0.61 to
0.80; participants = 1928; studies = 10; low quality of evidence).
Heterogeneity was substantial (I2 = 60%). The robustness of this
finding was tested by converting to a random-effects model; the
effect remained consistent (RR 0.67, 95% CI 0.53 to 0.84; par-
ticipants = 1928; studies = 10; low quality of evidence).
All-cause admission
(See Analysis 1.4)
Six studies (Beck-da-Silva 2005; Jourdain 2007; Karlstrom 2011;
Schou 2013; Shah 2011; Troughton 2000) with 1142 participants
recruited reported data for all-cause admission. During the follow-
up, 304 (53%) participants experienced an event requiring admis-
sion in the NP-guided treatment groups. This compared to 327
(57%) participants in the control groups. The pooled results for
all studies, with a fixed-effect model, favoured the intervention,
but overall, the evidence showed uncertainty (RR 0.93, 95% CI
0.84 to 1.03; participants = 1142; studies = 6; low quality of ev-
idence). No heterogeneity was identified (I2 = 0%). Lainchbury
2010 commented that no difference was seen between interven-
tion and control groups for all-cause admission, but the data were
not provided.
Adverse events
(See Table 3)
Six studies (Januzzi 2011; Krupicka 2010; Maeder 2013; Persson
2010; Pfisterer 2009; Troughton 2000) with 1144 participants re-
ported number of adverse events during follow-up. Maeder 2013
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did not report the number of adverse events broken down by in-
tervention group, only as a total for the study. For the remaining
five studies, the NP-guided treatment groups (511 participants)
experienced 215 compared to 184 adverse events in the control
groups (510 participants). Meta-analysis was not viable for this
outcome since it was possible to have multiple events per individ-
ual. Therefore, the results have been tabulated.Quality of evidence
was low.
Nevertheless, three studies (Januzzi 2011; Pfisterer 2009;
Troughton 2000) commented there was no difference between the
NP-guided treatment and control groups: Januzzi 2011 reported
that therewas no significant differences between the groups, whilst
Pfisterer 2009 and Troughton 2000 reported P values greater than
0.05. Maeder 2013 reported the number of patients experiencing
a serious adverse event did not differ between the groups. Two
studies (Januzzi 2011; Krupicka 2010) reported a complete break-
down of the nature of the adverse events, whilst Pfisterer 2009
and Maeder 2013 only highlighted two areas (renal impairment
and hypotension). For Maeder 2013, adverse events for renal fail-
ure were more frequent in the NP-guided group, where as events
were less frequent for hypotension compared to the control group.
However, both Januzzi 2011 and Pfisterer 2009 confirmed no dif-
ference between the groups based on specific adverse events. In-
complete data meant it was not possible to comment on the most
frequent types of adverse events.
Cost
Four studies (Berger 2010; Januzzi 2011; Maeder 2013; Pfisterer
2009) presented data on costs, two only as conference abstracts.
It was not possible to pool results for these four studies because
the outcome measure differed for each study. Pfisterer 2009 re-
ported on total overall costs per intervention arm: $20,949 for
the NT-proBNP-guided treatment group versus $23,928 in the
symptom-guided group (control). Generally, costs were compara-
ble, the main difference occurred in the residency costs (staying
in a nursing home or home for the elderly): $4157 in the NT-
proBNP-guided treatment group versus $7564 in the symptom-
guided group.
Januzzi 2011 examined themean costs in the duration of the study.
Overall costs for the NT-proBNP group totaled $35,262 ($451
per day) versus overall costs for the standard of care management
(control) group of $42, 629 ($580 per day). Similar to Pfisterer
2009, the lower costs in the NT-proBNP group was predomi-
nantly due to inpatient costs. Januzzi et al concluded that costs
were reduced by approximately 20% in the NT-proBNP-guided
treatment group over the 10-month follow-up period.
In Berger 2010 an economic analysis was completed for a sub-
group of participants (n = 190) who had complete follow-up data.
This analysis suggested NP-guided treatment was cost-effective
and cheaper than in the usual care control group (for the multi-
disciplinary care control group this was cost neutral).
In contrast to the above three studies Maeder 2013 reported NP-
guided therapy as unlikely to be cost-effective. Overall costs be-
ing $38,876 per patient for the NP-guided group compared to
$21,419 per patient in the control group over 18 months.
Quality of evidence was low.
Quality of Life
(See Analysis 1.5)
Quality of life data were reported in eight studies ((Beck-da-Silva
2005; Eurlings 2010; Karlstrom 2011; Lainchbury 2010; Pfisterer
2009; Schou 2013; Skvortsov 2015; Troughton 2000) with 1812
participants recruited using theMinnesota Living with Heart Fail-
ure questionnaire. Lainchbury 2010 is only represented by one
data set as data were only reported for the usual care control group.
The pooled evidence for all studies, using a fixed-effect model,
marginally favoured NP-guided groups, but overall, the evidence
showed uncertainty (mean difference (MD) -0.03, 95% CI -1.18
to 1.13; very low quality of evidence). Heterogeneity was judged
to be substantial (I2 = 75%).
Pfisterer 2009 also reported results for quality of life using the
Short Form 12 and Duke Activity Status Index questionnaires;
though not included due to incompatibility, both of these showed
an improvement in both guided treatment and control groups
with no differences in the degree of improvement.
In Karlstrom 2011, changes in quality of life for participants was
measured using the Swedish and Norwegian Short Form Health
Survey 36; 68% from the NP-guided group and 74% from the
control group completed the survey at both the start and end of
the study. For these participants NP-guided treatment did not
improve quality of life compared to clinical assessment alone.
Participants in Persson 2010 completed theKanasCityCardiomy-
opathy Questionnaire at baseline and follow-up. This symptom
score tool contains a quality of life element. In Persson 2010, the
scores improved in both groups (+3.6 (SEM 1.65) in the NT-
proBNP group and +6.2 (SEM 1.66) in the control group). There
was no differences between the groups (P = 0.28).
Subgroup analysis
Except for age, it was not possible to explore subgroups within the
study populations. Data were reported for severity of heart failure,
baseline NT-proBNP, target NT-proBNP, achievedNT-proBNP/
BNP drop and gender, but generally only as totals, in varying cat-
egories, or as averages, for intervention and control groups (Table
1, Table 2). Post hoc, consideration was given to subgrouping by
left ventricular ejection fraction, (LVEF), but this too was not re-
ported in an appropriate form (Table 1). All studies were com-
pleted under supervision of the hospital, except for Berger 2010
and Lainchbury 2010 where supervision was jointly in hospital
and the community, and therefore subgroup analysis for this factor
was not completed.
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Subgroup analysis was only possible by age for three studies
(Eurlings 2010; Lainchbury 2010; Shochat 2012) and only for
the primary outcome of all-cause mortality (see Analysis 3.1).
From the three studies, including Lainchbury 2010 with two con-
trol groups, there were 830 participants. For this analysis, the age
threshold was set as equal or greater than 75 years old versus under
75 years old, though the data from Eurlings 2010 are reported
marginally different as greater than 74 versus equal to or less than
74 years old. When the data from these three studies were pooled,
the evidence showed uncertainty for either age subgroup. How-
ever, whilst showing uncertainty for either age subgroup the re-
sults suggest that for participants equal to or greater than 75 years
old, the effect favoured the control groups (RR 1.23, 95% CI
0.96 to 1.57; participants = 410; studies = 3) whilst for partici-
pants less than 75, the effect favoured the guided-treatment groups
((RR 0.73, 95% CI 0.49 to 1.10; participants = 420; studies = 3)
(Analysis 3.1).
Lainchbury 2010 further reported data by age for heart failure ad-
mission (=/< 75 years: RR 1.13, 95%CI 0.77 to 1.64; participants
= 188; < 75 years: RR 0.73, 95% CI 0.45 to 1.17; participants
= 177) (Analysis 3.2). The data followed a similar trend to the
pooled data for age and all-cause mortality.
Despite data not being available to pool, three further studies
did comment on the age of participants in their results. Januzzi
2011 concluded for their study that ’no interaction between NT-
proBNP-guided care and age was found (P = 0.11)’. Persson 2010
commented ’levels of NT-proBNP tended to decrease more in pa-
tients younger than 75 years than in patients older than 75 years
(change -2.4% ≥75 versus -20.3% <75 years, P = 0.06). Finally,
Pfisterer 2009 reported that in the first six months the BNP levels
decreased similarly for both guided treatment and control groups
and were similar for participants under 75 and equal to or over
75 years of age. Though Pfisterer 2009 did state that “there was
a significant interaction between treatment and age groups, i.e.
patients aged ≥ 75 years in the NT-proBNP group had a smaller
relative benefit on NT-proBNP levels (p = 0.04) and symptoms
(p = 0.05) than younger patients”. At eighteen months, the inter-
action between treatment and age was significant for mortality (P
= 0.01, Cox regression adjusting for baseline characteristics) indi-
cating that ’NT-proBNP-guided treatment differed significantly
between younger and older patients’.
Post hoc subgroup analysis was carried out to explore whether
data from two studies (Berger 2010; Lainchbury 2010) using usual
care differed to all other studies using clinical assessment as the
comparator to NP-guided treatment (Analysis 2.1). This was only
possible for two outcomes. For the primary outcome of all-cause
mortality, the evidence showed very little difference for either sub-
group (usual care RR 0.79, 95% CI 0.56 to 1.13; participants
= 319; studies =2; clinical assessment RR 0.89, 95% CI 0.76 to
1.04; participants = 2850; studies = 15) to each other or com-
pared to the overall pooled result (RR 0.87, 95% CI 0.76 to 1.01;
participants = 3169; studies = 15; low quality evidence) (Analysis
1.1). Similarly, for heart failure admission there was very little dif-
ference for either subgroup (usual care RR 0.72, 95% CI 0.53 to
0.99; participants = 319, studies = 2; clinical assessment RR 0.70,
95% CI 0.60 to 0.81; participants = 1609, studies = 10) to each
other or the overall pooled result (RR 0.70, 95% CI 0.61 to 0.80;
participants = 1928; studies = 10; low quality evidence) (Analysis
1.3).
Post-hoc we explored the effect of duration of the intervention
on outcomes. Analysis 6.1 shows that both at ≤ one year (RR
0.46, 95% CI 0.25 to 0.85; participants = 555; studies = 5; P =
0.01; I2 = 0%) and between one and two years (RR 0.83, 95%
CI 0.69 to 0.99; participants = 1842; studies = 8; P =0.04; I2 =
0%), there was a potential reduction for all-cause mortality, but
the evidence showed uncertainty at > two years (RR 1.11, 95% CI
0.87 to 1.41; participants = 772; studies = 2; P = 0.41; I2 = 0%)
and the subgroup test for difference was significant (P =0.02). The
effect of duration on heart failure admission shows a similar trend
for each subgroup (≤ one year: RR 0.37, 95% CI 0.23 to 0.58;
participants = 278; studies = 3, one to two years: RR 0.65, 95%
CI 0.54 to 0.79; participants = 878; studies = 5; > two years: RR
0.97, 95% CI 0.77 to 1.23; participants = 772; studies = 2), again
the test for subgroup effect was significant (P = 0.0004) Analysis
6.3. For heart failure mortality (Analysis 6.2), all-cause admission
(Analysis 6.4) and quality of life (Analysis 6.5), the subgroups all
showed uncertainty similar to the overall pooled result for each
outcome.
Post hoc we also explored the assumption that the two biomark-
ers were sufficiently biologically and clinical similar to evaluate
together. We investigated this by separating the pooled data by
each biomarker. For all-cause mortality (Analysis 7.1), heart fail-
uremortality (Analysis 7.2), all-cause admission (Analysis 7.4) and
quality of life (Analysis 7.5), the pooled data for each biomarker
showed uncertainty and were similar to the overall pooled re-
sult for each outcome. For heart failure admission, using a fixed-
effect model, the result grouping the trials by BNP (Anguita
2010; Jourdain 2007; Karlstrom 2011; Krupicka 2010), or NT-
ProBNP (Berger 2010; Januzzi 2011; Lainchbury 2010; Schou
2013; Skvortsov 2015; Troughton 2000) did notmake a difference
to the main findings (BNP: RR 0.70, 95% CI 0.56 to 0.87; par-
ticipants = 600; studies = 4; NT-proBNP: RR 0.70, 95% CI 0.59
to 0.84; participants = 1328; studies 6) Analysis 7.3. In view of the
substantial heterogeneity we tested the robustness of this finding
using a random-effects model and found that the pooled result
for studies using the BNP marker continued to favour NP-guided
treatment but now showed uncertainty (BNP: RR 0.68, 95% CI
0.43 to 1.05; participants = 600; studies = 4; NT-proBNP: RR
0.65, 95% CI 0.48 to 0.89; participants = 1328; studies 6).
Sensitivity analysis
Risk of bias within the studies varied across the aspects of bias
assessed. Blinding of participants and study personnel appeared to
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be poor (see Figure 2 and Figure 3), nevertheless, it was not always
practical to blind participants and personnel in some studies. High
risk in this category could still mean one party was blinded. Blind-
ing of outcome assessment and attrition was judged to potentially
impact on the pooled results.
Sensitivity analyses were completed restricting studies to those
with low risk of bias for blinding of outcome assessment (Berger
2010; Eurlings 2010; Karlstrom 2011; Lainchbury 2010; Schou
2013) and for attrition (Anguita 2010; Berger 2010; Jourdain
2007; Li 2015; Schou 2013; Shah 2011; Skvortsov 2015;
Troughton 2000). For all outcomes, the analyses produced a sim-
ilar effect to the main findings (see Table 4). Though there was
only one study (Karlstrom 2011) assessed as low risk for detection
bias for heart failure mortality and therefore no comparison with
the main findings could be made in this instance.
D I S C U S S I O N
Summary of main results
We found the evidence for NP-guided treatment in patients with
heart failure showed uncertainty for all-cause mortality or heart
failure mortality. Furthermore, it showed uncertainty for all-cause
mortality when examining subgroups under or over 75 years of
age. Heart failure admission was reduced, but evidence for all-
cause admission showed uncertainty. In addition, the evidence
showed uncertainty for NP-guided treatment improving quality
of life. We were not able to pool results for adverse events and
cost. All results were pooled from low-quality evidence except the
outcome quality of life where the quality level of evidence was
very low (see Summary of findings for the main comparison). The
up- or down-titration of medication varied across studies in terms
of the guidelines or algorithms used and changes in medication;
neither was the reporting of NT levels consistent across studies.
This meant we were unable to evaluate the impact of either of
these for heart failure admission.
Overall completeness and applicability of
evidence
Our review included 18 studies, which recruited 3660 partici-
pants. The age of the participants in the studies may have favoured
younger patients as the average age of participants ranged from 62
to 80 years old; however, New York Heart Association (NYHA)
functional classification varied sufficiently across trials to ensure a
broad range of severity. We were unable to assess a number of im-
portant subgroups; particularly, severity of heart failure at baseline,
which may underpin an important effect of NP-guided treatment
on mortality outcomes. A systematic review in heart failure pa-
tients including 19 studies reported for each 100 pg/mL increase
in BNP there was an associated 35% increase in the relative risk of
death (Doust 2005). Further to this, subgroup analysis of baseline
NP, and NP decrease, which could underpin the mechanism of
effect, was not possible. In addition, a number of analyses were
limited by lack of reporting: only six studies reported on all-cause
admission, there were limited data on costs and only six studies
reported on adverse events.
Quality of the evidence
All included studies were reported as randomised, but not all re-
ported on the methods of randomisation. Eight confirmed allo-
cation concealment and were judged to be at low risk of bias, and
the other 10 were classified as unclear. Blinding was often poorly
done with only one study reporting blinding of both participants
and study personnel to treatment allocation, and only five stud-
ies reported blinding outcome assessors. Fourteen studies reported
outcomes on an intention-to-treat basis and attrition bias, eight
studies were judged to be low risk as seven studies had no losses
to follow-up, and the one fully documented the reported losses.
Using the Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) approach, we assessed the qual-
ity of the evidence and GRADE profiler (GRADEPRO) was used
to import data from Review Manager to create a ’Summary of
findings’ (SoF) table. For overall quality of evidence, the primary
outcome plus heart failure mortality, heart failure admission and
all-cause admission were judged to have low quality and quality of
life was judged to be very low quality indicating low/very low con-
fidence in the pooled result, but that the result could vary and is
likely to be affected by future research. The quality of evidence for
adverse events and cost, which were not pooled, were also judged
to be low. Quality of evidence was downgraded predominantly for
limitations in the study design and/or inconsistency in the data.
Potential biases in the review process
Whilst we did perform a thorough search with no date or language
restrictions, it is possible some studies may have been overlooked
in searching and study selection. We were unable to include data
from one study for the primary outcome. Whilst only 15 studies
contributed data for the funnel plot for all-cause mortality, the
graph does display a slight asymmetry with a lack of smaller studies
showing a beneficial control effect. This suggests the potential for
publication bias (see Figure 4).
Agreements and disagreements with other
studies or reviews
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At least 12 reviews have been undertaken on the effects of NP-
guided treatment: three narrative reviews (De Vecchis 2013a;
De Beradinis 2012; Richards 2012), one systematic review with
no meta-analysis ( Balion 2014), and eight reviews that included
meta-analyses (De Vecchis 2014; Felker 2009; Li 2013; Li 2014;
Porapakkham 2010; Savarese 2013; Troughton 2014; Xin 2015).
Of these meta-analyses, seven reported one or more of the same
outcome measures as this review, whilst De Vecchis 2014 only
examined a composite outcome.
Five of the seven previous reviews reported NP reduced all-cause
mortality in heart failure patients and the other two, similar to this
review, reported no effect for all-cause mortality. No previous re-
view has examined heart failure mortality as an outcome. All-cause
admission was analysed in three of the previous reviews and no
effect was reported in agreement with our findings. Similar to this
review, five previous reviews have reported an effect favouring NP-
guided treatment when examining heart failure admission and all
reported a moderate level of heterogeneity. Two reviews examined
adverse events and reported no reduction in events for NP-guided
patients compared to clinical assessment. To date, no review has
examined costs, and only one previous review (Xin 2015) has re-
ported on quality of life (see Table 5).
The meta-analysis published in 2014, Troughton 2014, included
individual patient data (IPD) from nine trials and aggregate data
sets from two trials and reported no effect in all-cause mortality.
Though, with the advantage of IPD Troughton and colleagues
were able to adjust for patient characteristics and used Kaplan
Meier curves to compare time to all-cause mortality between NP-
guided and clinically-guided treatment groups and they reported
a reduction in all-cause mortality (hazard ratio (HR) = 0.62;
95% CI, 0.45 to 0.86; P = 0.004, nine IPD studies). Similar to
Porapakkham 2010, but again using time to event data, mortality
was reduced in those under 75 years of age (HR 0.62; 95% CI,
0.45 to 0.85; P = 0.004), but not in those 75 years and older (HR
0.98; 95% CI, 0.75 to 1.3; P = 0.96), and the test of interaction
between age and treatment effect was significant (P = 0.028). Hos-
pitalisation due to heart failure was reduced in patients with NP-
guided therapy, both using time to event data (HR 0.80, 95% CI
0.67 to 0.94, P = 0.009), however, there was no effect for all-cause
hospitalisation using time to event data (HR 0.94, 95% CIs 0.84
to 1.07, P = 0.38).
While not directly comparable to this review, De Vecchis 2014
included six randomised controlled trials (RCTs) (n = 1775 pa-
tients) in a systemic review of BNP peptide-guided versus symp-
tom-guided therapy in outpatients with chronic heart failure. This
review reported guided therapy decreased a composite outcome
of mortality and heart failure hospitalisations during the follow-
up period (odds ratio (OR) 0.64; 95%CI: 0.43 to 0.95; P =
0.028, I2 = not reported).
Some subgroup analyses have been completed by previous reviews
which can be compared to this review’s subgroup analyses (see
Table 6). Only Porapakkham 2010 is directly comparable to this
review and similarly reported for all-cause mortality in patients
over 75 years old anuncertain result.However, in patients under 75
years, unlike this review, Porapakkham 2010 reported a significant
effect for NP monitoring compared to clinical assessment.
Li 2013 reported heart failure admissions were reduced in patients
with higher baseline BNP ≥2114 pg/mL (RR, 0.53; 95% CI,
0.39- to 0.72; P < 0.0001, I2 = 21.8%). Furthermore, Li 2014
completed sensitivity analyses to show a reduction in all-cause
mortality andheart failure admissionwas especially seen inpatients
with reduced ejection function.
This review is consistent with previous reviews in all outcomes
except all-cause mortality. For this outcome, the first (chrono-
logical) five reviews (Felker 2009; Porapakkham 2010; Li 2013;
Savarese 2013; Li 2014) found a reduction, while Troughton 2014
found a reduction after adjustment for patient characteristics. The
latest systematic review by Xin 2015 reported no effect on this
outcome, similar to this review. One of the latest published trial
(Schou 2013) reports higher all-cause mortality in the NP-guided
group. The pooled estimate of effect based on exclusion of this
study shows a reduction in all-cause mortality similar to previous
systematic reviews. Therefore, the inconsistency in this estimate
leads us to suggest that further evaluation is required.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review confirms the evidence base to date, with at least four
systematic reviews and one individual patient meta-analysis pub-
lished, of the efficacy of NP-guided treatment effects on heart fail-
ure admission. Our post hoc analysis for this outcome demon-
strates that effects are observed in shorter studies, less than two
years in duration. This effect observed in the shorter studies could
reflect the severity of the disease process whereby many patients
would be hospitalised or experience adverse eventswithNP-guided
treatment having an impact delaying short-term outcomes.
Although previous reviews consistently report a reduction for all-
cause mortality, our review, the largest to date reports low-qual-
ity evidence that long-term, all-cause mortality and heart failure
mortality show uncertainty. Furthermore, low-quality evidence
showed uncertainty for all-cause admissions and very low quality
of evidence showed uncertainty for quality of life outcomes.
Implications for research
There are a number of significant ongoing trials, therefore we do
not perceive the need for any more until these have reported their
results; but the significance around our results may change in the
light of new data. We will update our review once these new tri-
als are published, and we recommend updating the IPD analysis
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and using these data to perform cost-effective analyses. Cost-ef-
fectiveness data would aid decision making, particularly as length
of hospital stay and preventing readmissions are important for the
health service. In addition, it is important to clearly describe the
components of the intervention and of the control group, as subtle
changes in the control group in combination with a lack of blind-
ing could have significant effects on treatment escalation and the
overall efficacy of the intervention. In case a future update identi-
fies an effect in mortality, the potential mechanisms for this effect,
such as increased patient and physician adherence to treatment
regimens, would need to be explored.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anguita 2010
Methods Setting: Hospital in Spain
Duration of study: 18 months
Inclusion criteria: At least NYHA III, receiving at least one diuretic, an ACE inhibitor
or ARB and a beta blocker
Exclusion criteria: < 18 years old, acute coronary syndrome within 3 months, aetiolog-
ical treatment or cardiac transplantation pending, life expectancy < 1 year due to co-
morbidities
Participants Number of participants at baseline: Intervention 30; Control 30
Gender (male): Intervention 67%; Control 70%
Mean age (SD): Intervention 70 (8); Control 69 (12)
Interventions 1. BNP-guided treatment: Minimum four visits in first quarter, six visits in first year,
seven visits overall; structured clinical assessment including BNP data; if BNP levels
were higher than 100 pg/mL, the pharmacological treatment was increased.
Specifically: i) increased dose of loop diuretic; ii) doubling the dose of ACEi (max. 150
mg/d of captopril, 40 mg/d of enalapril, 10 mg/d of ramipril); iii) addition of
spironolactone 25 mg/d to 50 mg/d (if not previously administered); iv) double dose of
beta blocker (max. 50 mg/d of carvedilol or 10 mg/d of bisoprolol); v) addition of an
ARB, at recommended doses; vi) addition of chlorthalidone 50 mg/d; vii) addition of
digoxin 0.25 mg/d or adjusted to renal function; viii) other drugs: nitrates, amlodipine.
If the target BNP is achieved the patient will follow the same treatment regimen as
prior to the visit until the next scheduled visit.
2. Control: Visits same as intervention without BNP data and additional visit at two
weeks; treatment guided by less or greater Framingham score of two, recent events,
questions to patient and medical history. If target score achieved the patient follow the
same treatment regimen as prior to the visit until the next scheduled visit.
Intervention provider: Specialist (cardiology service)
Outcomes Review relevant: i) All-cause mortality; ii) HF admission
Additional outcomes: i) Cardiovascular events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, but no description of how
achieved
Allocation concealment (selection bias) Unclear risk Not stated
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Anguita 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition
Selective reporting (reporting bias) Low risk All outcomes reported as specified in the
publication
Other bias Unclear risk Source of funding: Not stated
Beck-da-Silva 2005
Methods Setting: Outpatient clinic in Canada
Duration of study: Three months
Inclusion criteria: Patients with symptomaticHF (NYHA II to IV) for 3months previous
or previous hospital admission due to HF, not on beta blockers, LVEF 40% or less,
receiving treatment with an ACE inhibitor or ARB plus loop diuretic and digoxin
Exclusion criteria: < 18 years old, one of the following: myocardial infarction or unstable
angina within 4 weeks, severe stenotic valvular heart disease or hepatic or renal disease
or a contraindication for beta blockers
Participants Number of participants at baseline: Intervention 21; Control 20
Gender (male): Intervention 33.3%; Control 35%
Mean age (SD): Intervention 64.5 (15.2); Control 65.6 (13.5)
Interventions 1. BNP-guided treatment: Minimum four visits in first quarter, four visits overall;
structured clinical assessment including BNP data, beta blocker up-titration based on
starting at 1.25-2.5 mg/d and titrated up to 10 mg/d. Action taken based on four
scenarios: i) clinically better, BNP decreasing: β blocker increased one step; ii)
clinically same or mildly worse, BNP decreasing: β blocker increased one step; iii)
clinically same or better, BNP increasing: β blocker unchanged; iv) clinically worse,
BNP increasing: β blocker decreased one step or discontinued
2. Clincial assessment (control): Visits same as intervention without BNP data,
treatment dose increase according to clinical status assessed by attending physician.
Up-titration of β blocker if worsening function
Intervention provider: Specialist (HF team)
Outcomes Review relevant: i) All-cause mortality; ii) All-cause admission iii); Quality of Life
Additional outcomes: i) LVEF change
Notes
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Beck-da-Silva 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomly assigned’. No description of
how achieved
Allocation concealment (selection bias) Low risk Email from author 19 September 14
“’opaque envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “BNP values were blinded to the attending
physician in the clinical group... (control)
... but the doctors were not blinded as to
which group the patient belonged”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Email from author 19 September 14
“There was very few missing data. I believe
the participants were then excluded”
Selective reporting (reporting bias) Low risk All outcomes reported as specified in the
publication
Other bias Unclear risk Source of funding: Not stated
Berger 2010
Methods Setting: Hospital and community in Austria
Duration of study: 18 months
Inclusion criteria: Clincial signs and symptoms of cardiac decompensation at hospitali-
sation, NYHA III or IV at admission, cardiothoracic ratio > 0.5 or LVEF < 40%
Exclusion criteria: None stated
Participants Number of participants at baseline: Intervention (BM) 92; Control (MC) 96; Control
(UC) 90
Gender (male): Intervention (BM) 63%; Control (MC) 70%; Control (UC) 69%
Mean age (SD): Intervention (BM) 70 (12); Control (MC) 73 (11); Control (UC) 71
(13)
Interventions 1. NT-proBNP-guided intensive management (BM): > 2200 pg/mL at hospital
discharge; minimum six visits in first quarter, eight in first year and 8 to 26 visits
overall; structured clinical assessment including NT-proBNP data at outpatient clinic;
as long as NT-proBNP remained above 2200 pg/mL drug treatments were dictated by
a flow chart until maximum or tolerated doses of HF drugs were established. If NT-
proBNP fell below 2200 pg/mL 3 or 6 months after discharge then patients reverted to
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Berger 2010 (Continued)
following the treatment schedule for the control group (MC)
2. Multidisplinary care (MC, control): < 2200 pg/mL at hospital discharge;
minimum four visits in first quarter, six in first year and six visits overall; structured
clinical assessment without NT-proBNP data via home visits; treatment dose increase
according to clinical status assessed by HF nurse
3. Usual care (UC, control): No visit schedule or structured follow-up. HF specialist
only on request
Intervention provider:HF specialist (BM),HFnurse (MC), Primary care physician (UC)
Outcomes Review relevant: i) All-cause mortality; ii) HF mortality; iii) HF admission; iv) All-cause
admission; v) Quality of life
Additional outcomes: i) Time to death or HF admission; ii) Ambulatory visits at HF
clinics
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated permuted block ran-
domisation. 6 patients per block
Allocation concealment (selection bias) Low risk Randomisation and concealment com-
pleted by independent medical project
management institute
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Patients and providers knew they were in
an intervention group (BM and MC)”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Independent data collectors obtained in-
formation from medical reports and inter-
views with relatives”. Cardologists blinded
to treatment classified the cause of hospi-
talisation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition
Selective reporting (reporting bias) High risk Planned outcomes specified in Berger
2010. Data not reported for HF mortality,
all-cause admission
Other bias Unclear risk Source of funding: AstraZeneca, Novartis,
RocheDiagnostics, RocheMedical,Merck,
Medtronic, andGuidant, whoprovided the
financial support for a clinical investigator,
a specialised chronic HF nurse, and data
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collection
Eurlings 2010
Methods ’PRIMA’
Setting: 12 hospitals in the Netherlands
Duration of study: 24 months
Inclusion criteria: European Society of Cardiology (ESC) diagnostic guideline criteria
for acute HF, NT-proBNP levels at admission were required to be at least 1,700 pg/mL,
NT-proBNP levels during hospitalisation were required to decrease more than 10%,
with a drop in NT-proBNP levels of at least 850 pg/mL, from admission to discharge
Exclusion criteria: Life-threatening cardiac arrhythmias during the index hospitalisation,
urgent invasive or surgical intervention performed or planned during the index hospi-
tal admission, severe COPD with a forced expiratory volume in 1 s (FEV1) of 1 l/s,
pulmonary embolism less than 3 months prior to admission, pulmonary hypertension
not caused by left ventricular systolic dysfunction (LVSD), a non-HF-related expected
survival of less than 1 year, and patients undergoing haemodialysis or CAPD
Participants Number of participants at baseline: Intervention 174; Control 171
Gender (male): Intervention 55%; Control 60%
Mean age (SD): Intervention 71.6 (12); Control 72.8 (11.7)
Interventions 1. NT-proBNP-guided treatment: minimum three visits in first quarter, six in first
year and estimated 10 visits overall; structured clinical assessment including NT-
proBNP data; individual patient NT-proBNP target value was set as the lowest level at
discharge or at 2 weeks follow-up. If NT-proBNP levels were more than 10% with a
minimum of 850 pg/mL above this individual target level, NT-proBNP level was
considered “off-target,” and therapy was intensified according to the ESC HF
treatment guidelines. They report changes in 10 different medications. Except for
calcium channel blockers, all changes in drug therapies concern the start or increase of
medication or change in the type of medication. It was not specifically stated if no/any
action was taken if the patient was below or at target.
2. Clincially-guided (control): Visits same as intervention without NT-proBNP
data, treatment dictated by clinical assessment alone.
Intervention provider: Specialist (HF cardiologists and nurses)
Outcomes Review relevant: i) All-cause mortality; ii) Quality of life
Additional outcomes: i) Survival free of hospitalisation; ii) Cardiovascular mortality; iii)
Cardiovascular admissions; vi)Composite of total cardiovascularmorbidity andmortality
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised to’. No description of how
achieved
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Eurlings 2010 (Continued)
Allocation concealment (selection bias) Low risk Email from author 23 October 14 “com-
pleted by non-transparent envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Email from author 23October 14 “Patients
were blinded to the treatment allocation.
The treating physician however was not.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All events were adjudicated by a blinded
event committee, consisting ofmedical spe-
cialists in cardiology, nephrology, vascular
medicine, pulmonology, and neurology.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk One-year attrition documented with rea-
sons. Unclear beyond 1 year
Selective reporting (reporting bias) High risk Planned outcomes specified in Eurlings
2010.Nodata reported for all-cause admis-
sion
Other bias Unclear risk Source of funding: Main funding from
the Netherlands heart foundation, Nether-
lands organisation for scientific research
and Royal Netherlands academy of arts and
sciences-inter university cardiology insti-
tute of the Netherlands. Minor funding of
an unrestricted fundwas provided by Pfizer
Januzzi 2011
Methods ’PROTECT’
Setting: Hospital in USA
Duration of study: 12 months
Inclusion criteria:≥ 21 years old, LVEF≤ 40%, NYHA class II - IV, hospital admission,
emergency dept. or outpatient therapy for destabilised HF at least once in last 6 months
Exclusion criteria: Serum creatinine >2.5 mg/dL, inoperable aortic valvular heart disease,
life expectancy < 1 year due to causes other than HF, cardiac implant or revascularisa-
tion indicated or expected within 6 months, severe obstructive or restrictive pulmonary
disease, unwilling or unable to give consent, coronary revascularisation within previous
3 months
Participants Number of participants at baseline: Intervention 75; Control 76
Gender (male): Intervention 88.2%; Control 81.3%
Mean age (SD): Intervention 63 (14.5); Control 63.5 (13.5)
Interventions 1. NT-proBNP-guided treatment: minimum two visits in first quarter, quarterly
visits up to a maximum of 12 months (median number of visits for both arms was five)
; however scheduled visits were every two weeks until optimal/maximal medical
therapy was achieved; structured clinical assessment including NT-proBNP data at
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Januzzi 2011 (Continued)
outpatient clinic; if NT-proBNP levels were higher than 1000 pg/mL the drug therapy
was intensified irrespective of clinical status; choice of medication therapy for either
intervention arm was made by the physician according to consensus guidelines
(American College of Cardiology foundation/American Association task force on
practical guidelines); no algorithm for drug titration as used; once the patient achieved
≤ 1000 pg/mL (NT-proBNP-targeted optimal medical regimen) or if the target was
not achieved but reached clear therapeutic limit then the patient will cease two weekly
visits and revert to quarterly schedule.
2. Standard of care treatment (control): Visits same as intervention without NT-
proBNP data, treatment dictated by clinical assessment and managed according to
consensus guidelines. Once the patient achieves optimal medical regimen they will
cease two-weekly visits and revert to quarterly schedule.
Intervention provider: Specialist (physicians skilled in HF care)
Outcomes Review relevant: i) HF admission; ii) Adverse events; iii) Cost; iv) Quality of life
Additional outcomes: i) Total cardiovascular events in one year; ii) Cardiac structure and
function; iii) Cost of care
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ’Neither caregivers nor the patients were
blinded to the NT-proBNP results’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Low risk All outcomes reported as specified in the
protocol
Other bias Unclear risk Source of funding: In part by Roche diag-
nostics, Inc. First author partly funded by
RocheDiagnostics, Inc., SiemensDiagnos-
tics, and Critical Diagnostics
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Jourdain 2007
Methods ’STARS-BNP’
Setting: 17 hospitals in France
Duration of study: Minimum six months
Inclusion criteria: > 18 years old, NYHA II to III, LVEF < 45%, stable condition (no
hospital stay in previousmonth) and treated by optimal therapy (ESCguidelines), dosages
of medication stable for at least 1 month, diuretics, ACEs, ARBs, and β blockers at
maximum tolerated doses
Exclusion criteria: Acute coronary syndrome in last 3 months, chronic renal failure
(plasma creatinine > 250 µmol/L), documented hepatic cirrhosis, asthma, or COPD
Participants Number of participants at baseline: Intervention 110; Control 110
Gender (male): Intervention 59%; Control 56%
Mean age (SD): Intervention 65 (5); Control 66 (6)
Interventions 1. BNP-guided treatment: minimum four visits in first quarter, six in first year and
overall; structured clinical assessment including BNP data at outpatient clinic;
treatment modified according to judgment of investigator based on ESC guidelines
2001. It was not specifically stated if no/any action was taken if the patient was below
or at target.
2. Clinically-guided treatment (control): Visits same as intervention without BNP
data, medical therapy adjusted according to opinion of the investigator on basis of
physical examination and biological parameters; treatment modified according to
judgment of investigator based on ESC guidelines 2001
Intervention provider: Specialist (highly qualified cardiologists)
Outcomes Review relevant: i) All-cause mortality; ii) HF mortality; iii) HF admission; iv) All-cause
admission
Additional outcomes: i) Composite of HF mortality or HF hospital admissions
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, but no description of how
achieved
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Patients blinded to BNP results. BNP re-
sults only available to investigator to guide
treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition
Selective reporting (reporting bias) Low risk All outcomes reported as specified in the
publication
Other bias Unclear risk Source of funding: Unrestricted grant from
Biosite Inc. (San Diego, Calafornia) to the
french working group on HF
Karlstrom 2011
Methods ’UPSTEP’
Setting: 19 hospitals in Sweden and Norway
Duration of study: Minimum 12 months
Inclusion criteria: > 18 years old, with verified systolic HF, worsening HF in last month
(requiring hospitalisation, and/or intravenous diuretic treatment, metolazone, or in-
creased daily doses of diuretics and /or need of intravenous inotropic support), LVEF
< 40% (measured in last 6 months)4. NYHA II-IV, ongoing standard HF treatment
according to guidelines (ACE, ACEI, ARB, BB and/or diuretics, AA and/or digoxin if
needed)
Exclusion criteria: If any of the following conditions existed: haemodynamically unstable
patients onwaiting list for cardiac surgery,myocardial infarctionwithin the last 3months,
patients with haemodynamically significant valvular heart disease, patients with impaired
renal function (s-creatinine >250 µmol/L) or liver function (> 3x normal value), patients
with severely decreased pulmonary function, patients with limited life expectancy
Participants Number of participants at baseline: Intervention 147; Control 132
Gender (male): Intervention 73%; Control 73%
Mean age (SD): Intervention 71.6 (9.7); Control 70.1 (10)
Interventions 1. BNP-guided treatment: minimum three visits in first quarter, seven in first year
and overall ; structured clinical assessment including BNP data at outpatient clinic;
treatment modified according to judgment of investigator based on ESC guidelines
2001. Specifically i) increase ACEi/ARB to maximum tolerated or target dose
according to guidelines; ii) increase BB to maximum tolerated or target dose according
to guidelines; iii) add AA in low dose (spironolactone 25 mg;) iv) add ARB and increase
to target dose according to guidelines; v) increase ACEi/ARB to up to twice the target
dose; vi) increase BB up to twice the target dose; vii) increase AA (spironolactone) to
50 mg. Adjustment of loop diuretic does was at the discretion of the investigator. It was
not specifically stated if no/any action was taken if the patient was below or at target.
2. Control: Visits same as intervention without BNP data, structured assessment at
the discretion of the investigator based on changes in clinical status and/or signs of
worsening HF in accordance with ESC guidelines 2001
Intervention provider: Specialist (treating physician experienced in managing patients
with HF)
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Outcomes Review relevant: i) All-cause mortality; ii) HF mortality; iii) HF admission; iv) All-cause
admission; v) Quality of life
Additional outcomes: i) Composite of mortality, need for hospitalisation and worsening
HF; ii) Cardiovascular mortality; iii) Cardiovascular hospital admissions; iv) Worsening
HF
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Email by author 21 October 14 “Opaque
envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded “patients were made aware of
their BNP value in order increase motiva-
tion to adhere to treatment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All endpoints were adjudicated using a
predefined endpoint protocol by a commit-
tee with two experienced cardiologists who
did not participate in the study and were
blinded to the results”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers provided, but not reasons
Selective reporting (reporting bias) Low risk All outcomes reported as specified in the
publication
Other bias Unclear risk Source of funding: Swedish Heart-Lung
foundation, Regional research foundation
in south eastern Sweden, regional foun-
dation in northern Sweden, and by un-
restricted grant from Biosite International
and InfinitiMedical ABwho supplied BNP
analysing equipment
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Methods ’OPTIMA’
Setting: Hospitals in Czech Republic
Duration of study: 24 months
Inclusion criteria: Newly diagnosed or acutely deteriorating advanced chronic failure
(NYHA III-IV), LVEF ≤ 45%
Exclusion criteria: Age under 18 or above 90 years old; acute coronary syndrome during
the last three months, pulmonary embolism during the last three months, history of
hepatic cirrhosis, severe renal insufficiency (creatinine >250 µmol/L), severe chronic lung
disease, current malignant disease
Participants Number of participants at baseline: Intervention 26; Control 26
Gender (male): Intervention 69%; Control 65%
Median age (range): Intervention 71 (36-89); Control 70 (45-84)
Interventions 1. BNP-guided treatment: minimum two visits in first quarter, five in first year and
nine overall ; structured clinical assessment including BNP data at outpatient clinic;
treatment intensified according to study algorithm: i) in case of congestion (lung
venostasis, peripheral oedema) either daily loop diuretic dose was increased or second
diuretic was added, thiazid if creatinine was below 180umol/L; ii) in patients without
congestion, ACEi daily dose was increased up to maximal recommended dose. In case
of ACEi intolerance, ARB was administered and subsequently titrated; iii) increase of
betablocker daily dose up to maximal recommended dose; iv) increase of MRA daily
dose up to maximal recommended dose. It was not specifically stated if no/any action
was taken if the patient was below or at target.
2. Clincally-guided treatment (control): Visits same as the intervention group
without BNP data, treatment according to standard clinical practice with respect to
current Czech guidelines for HF
Intervention provider: Specialist
Outcomes Review relevant: i) All-cause mortality; ii) HF mortality; iii) HF admission; iv) Adverse
events
Additional outcomes: i) Composite of cardiovascular mortality, hospitalisation for wors-
ening HF and outpatient episodes of worsening HF requiring to increase diuretic by at
least 50%
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’randomised’. No description of how
achieved
Allocation concealment (selection bias) Low risk Email from author 17 October 14 “opaque
envelopes”
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Email from the author 17 October 14
“Only the patients were blinded to the
group allocation”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Low risk All outcomes reported as specified in
Krupicka 2010
Other bias Unclear risk Source of funding: supported by an educa-
tional grant from the ZENTIVA company
(ZENTIVA is Czech generic pharmaceuti-
cal company)
Lainchbury 2010
Methods ’BATTLESCARRED’
Setting: Hospital in New Zealand
Duration of study: Three years
Inclusion criteria: > 18 years old with symptomatic CHF (as defined by Framingham
criteria and satisfying ESC guidelines for the diagnosis of HF), requiring admission to
hospital and able to give informed consent, pre-randomisation plasma NTproBNPmust
exceed 50 pmol/L (i.e. approximately 400 pg/mlL. Recruitment deliberately included
elderly patients and patients with a preserved LVEF
Exclusion criteria: Active myocarditis/pericarditis, life expectancy due to non-cardiovas-
cular disease of < 24 months, severe hepatic or pulmonary disease, renal impairment
(plasma creatinine > 250 µmol/L), transient HF frommyocardial infarction treated with
acute revascularisation and a subsequent ejection fraction during the index hospital ad-
mission of > 40%, severe valvular disease being considered for surgery, severe aortic
stenosis (valve area < 1 cm2), HF secondary to mitral stenosis or are under consideration
for cardiac transplantation
Participants Number of participants at baseline: Intervention 121; Control (CG) 121; Control (UC)
122
Gender (male): Intervention 63%; Control (CG) 67%; Control (UC) 62%
Median age (range): Intervention 76 (44 to 89); Control (CG) 76 (34 to 89); Control
(UC) 75 (31 to 89)
Interventions 1. NT-proBNP-guided treatment: minimum two visits in first quarter, five in first
year and nine overall ; structured clinical assessment including NT-proBNP data at
outpatient clinic; general education regarding HF; treatment triggered by NT-proBNP
level greater than 150 pmol/L and/or a HF score greater than 2, for values below this
threshold, treatment was not altered
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i) Algortihm for heart score >2: i) increase frusemide to 120 mg/day or
optimisation of ACE inhibitor dose if sub optimal; ii) addition of digoxin 0.25 mg/day
adjusted for creatinine clearance; iii) add spironolactone (up to 50 mg/day) in patients
with persisting class III or IV symptoms; iv) increase frusemide with twice-daily doses
up to a maximum of 500 mg twice daily with doubling increments; v) addition of
bendrofluazide or metolazone
ii) Algortihm for NT-proBNP >150 p/mol, heart score stable: i) optimisation
of ACE inhibitor to trial-based doses; ii) addition or titration of beta blockade to trial-
based doses; iii) addition of further therapy as for the clinically-guided group
2. Clinically-guided (CG, control): Visits same as intervention without NT-proBNP
data; treatment determined by HF score above or below 2
i) Algorithm for heart score < 2: i) optimisation of ACE inhibitor dose; ii)
addition and titration or optimisation of beta-blocker dose
ii) Algorithm for heart score > 2: same as NT-proBNP-guided treatment
3. Usual care (UC, control): No visit schedule or structured follow-up; management
in primary care with or without requested HF clinic referrals
Intervention provider: Specialist (research outpatient clinic) (NT-proBNP and CG),
Primary care physician (UC)
Outcomes Review relevant: i) All-cause mortality; ii) HF admission; iii) Quality of life
Additional outcomes: i) Mortality plus episodes of inpatient or outpatient HF decom-
pensation; ii)Mortality plus hospital admission for any cardiovascular event plus episodes
of outpatient decompensated HF requiring increased medication treatment for decom-
pensated HF; iii) Episodes of HF decompensation; iv) Episodes of HF decompensation;
(v) Changes in NTproBNP, NYHJA status, LVEF, six-minute walk distance
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified by age (≤75 or > 75) in permuted
blocks of 30
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “double blind”, “Patients will be blinded as
to their group allocation, and clinical as-
sessments will be made by a physician also
blinded. Intensification of drug treatment
will be made by an unblinded physician in
the research team”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “double blind”
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers provided, but not reasons
Selective reporting (reporting bias) High risk Planned outcomes specified in protocol.
No follow-up quality of life data for usual
care (UC) control group. Analyses for two
secondary outcomes were completed and
commented on, but data were not provided
Other bias Low risk Source of funding: Grants from the Health
Research Council of New Zealand and
the National Heart Foundation of New
Zealand
Li 2015
Methods Setting: Hospital in China
Duration of study: 1 month
Inclusion criteria: Moderate to severe HF (NYHA III - IV)
Exclusion criteria: Patients with severe renal function damage (serum creatinine > 265
umol/L), bronchial asthma or COPD were excluded, as well as end-stage HF patients
without response to intravenous drug treatment
Participants Number of participants at baseline: Intervention 96; Control 99
Gender (male): Intervention 56.3%; Control 55.4%
Average age (range): Intervention 57 (40 to 78); Control 58 (38 to 81)
Interventions 1. BNP-guided treatment: minimum five visits in first month and overall; structured
clinical assessment including BNP data; start-up and use of metoprolol succinate
according to BNP level; the BNP level was controlled every 3 to 5 days during the
application of intravenous cardiotonic, vasodilator and diuretic; metoprolol succinate
treatment triggered if more than 50 % reduction of basal BNP level or BNP < 300 pg/
mL. Ongoing dose of metoprolol succinate doubled every visit. If the BNP level did
not decrease, but was elevated more than 10% then the metoprolol succinate was
stopped or decreased whilst application of intravenous cardiotonic, vasodilator or
diuretic drugs took place until start up BNP level achieved then the metoprolol
succinate was recommenced
2. Observation group (control): Visits same as intervention group without BNP;
structured clinical assessment; start-up and use of metoprolol succinate according to
clinical manifestation; all other HF drugs stopped; after 3 days of stable weight initial
dose of 6.25 mg of metoprolol succinate; dose of metoprolol succinate doubled every
week until the maximum tolerated dose or target dose if no HF signs and symptoms
were observed. Otherwise metoprolol succinate was reduced and intravenous
cardiotonic, vasodilator or diuretic was applied until HF signs and symptoms improved
and the metoprolol succinate was gradually applied again.
Intervention provider: Specialist (highly placed medical profession in cardiology)
43B-type natriuretic peptide-guided treatment for heart failure (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Li 2015 (Continued)
Outcomes Review relevant: i) HF mortality
Additional outcomes: i) Average start up of metoprolol succinate; ii) Maximum dose of
metoprolol succinate; iii) Recurrance rate of additional drugs
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, but no description of how
achieved
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers and reasons provided. “.....due to
severe bradycardia”
Selective reporting (reporting bias) Low risk All outcomes reported as specified in the
publication
Other bias Unclear risk Source of funding: Not stated
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Maeder 2013
Methods ’TIME-CHF (Heart failure preserved LVEF (HFpEF))
Setting: 15 hospital outpatient clinics in Switzerland and Germany
Duration of study: 18 months
Inclusion criteria: 60 years or older with dyspnoea (NYHA class II with current therapy)
, a history of hospitalisation for HF within the last year, N-terminal BNP level of 400
pg/mL or higher in patients younger than 75 years and a level of 800 pg/mL or higher
in patients aged 75 years or older, > 45% LVEF
Exclusion criteria: patients with dyspnoea not mainly due to HF, with valvular disease
requiring surgery, acute coronary syndromes within the previous 10 days, angina pectoris
classified as being in the Canadian Cardiovascular Society Class higher than II, revascu-
larisation within the previous month, BMI (calculated as weight in kilograms divided by
height in meters squared) higher than 35, serum creatinine level higher than 2.49 mg/
dL, a life expectancy of less than 3 years for non cardiovascular diseases, unable to give
informed consent, no follow-up possible, or participating in another study
Participants Number of participants at baseline: Intervention 59; Control 64
Gender (male): Intervention 36%; Control 33%
Mean age (SD): Intervention 80.3 (6.8); Control 79.9 (7.2)
Interventions 1. NT-proBNP-guided treatment: minimum three visits in first quarter, five in first
year and six or more overall ; structured clinical assessment including NT-proBNP
data, treatment according to recommendations based on previous clinical trials, ESC
2001 and American College of Cardiology and American heart Association guidelines,
ongoing trials, pathophysiologic consideration and homogeneity of therapy within the
study: i) symptoms and fluid retention are treated with diuretics, all patients should be
on an angiotensin II receptor antagonist or ACE inhibitor; ii) if blood pressure is still
elevated (i.e. ≥ 140/90 mmHg), a beta blocker should be added. If treatment targets
are not reached then the algorithm as for reduced HF patients (Pfisterer 2009) will be
used for escalation of treatment: addition of spironolactone, escalating doses of ACE
inhibitors, angiotensin II receptor blockers, and -blockers, loop diuretics, low-dose
digoxin, long-acting nitrates, metalozone or another thiazide, molsidomide during
nitrate-free intervals, and intravenous diuretics or inotropes. Therapy was reduced in
cases of significant adverse effects, diuretics were recommended to be reduced prior to
prognostically relevant medication, all other therapies left to the discretion of the
treating physician. Further adjustment of treatment is only completed if criteria for
further adjustment are met.
2. Symptom-guided treatment (control): Visits same as intervention without NT-
proBNP data; pre-defined escalation rules to reduce symptoms to dyspnoea NYHA
class of II or less, all other therapies at discretion of treating physician.
Intervention provider: Specialist (HF outpatient clinic with collaboration of general
practitioner)
Outcomes Review relevant: i) All-cause mortality; ii) Adverse events; iii) Cost; iv) Qualtiy of life
Additional outcomes: i) Survival free of hospitalisation
Notes Linked to Pfisterer 2009. Two separate groups of participants in TIME-CHF
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified by 2 age groups using central al-
location in blocks of 8 patients
Allocation concealment (selection bias) Low risk “concealed”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Patients, but not treating physicians, were
blinded to group allocation”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers provided, but not reasons
Selective reporting (reporting bias) High risk Planned outcomes specified inBrunner-LA
Rocca 2006. Quality of life outcome not
reported
Other bias Unclear risk Source of funding: Sponsored by the
Horten Research Foundation (Lugano,
Switzerland; 55% of the study’s budget), as
well as by smaller unrestricted grants from
AstraZeneca Pharma, Novartis Pharma,
Menarini Pharma, Pfizer Pharma, Servier,
Roche Diagnostics, Roche Pharma, and
Merck Pharma
Persson 2010
Methods ’SIGNAL-HF’
Setting: Community in Sweden
Duration of study: Nine months
Inclusion criteria:Diagnosis of chronicHF, stableNYHAclass II-IV, LVEF50%, elevated
NT-proBNP levels (males 800, females 1000 ng/L)
Exclusion criteria: planned cardiovascular hospitalisation; stroke, acute myocardial in-
farction, or open heart surgery within the last 3months before enrolment,mitral stenosis,
aortic stenosis of clinical significance, patients already receiving optimal pharmacological
treatment for chronic HF according to the national guidelines, serum creatinine ≥265
mmol/L
Participants Number of participants at baseline: Intervention 126; Control 124
Gender (male): Intervention 76%; Control 66%
Mean age: Intervention 78; Control 77
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Interventions 1. NT-proBNP-guided treatment: minimum four visits in first quarter, six in first
year and six overall ; structured clinical assessment including NT-proBNP data at
outpatient clinic, treatment intensified until at least a 50% reduction from baseline
NT-proBNP, stepwise treatment to Swedish guidelines:
i) Patients with NYHA II: base therapy included an ACE-inhibitor and a
betablocker, Loop diuretics could be added and used based on signs of fluid retention.
In patients who did not tolerate ACE-inhibitor treatment, an ARB was to be used
instead.
ii) Patients with NYHA III-IV: base therapy as for NYHA II, in patients with
persistent CHF symptoms despite target or maximum tolerated doses of ACE-
inhibitor and beta-blocker, additional therapy with an ARB or spironolactone (or
eplerenone in the case of hormonal side effects) could be initiated. In addition, digoxin
could be added as an option for extra symptom relief, although the main indication for
this treatment was atrial fibrillation.
2. Not NT-proBNP group (control): Visits same as intervention without NT-
proBNP data; same stepwise treatment used based on clinical assessment only
It was not specifically stated if no or any action was taken if the patient was below or at
target
Intervention provider: Generalist plus 2-3 hours training about HF guidelines with local
cardiologist
Outcomes Review relevant: i) All-causemortality; ii) Adverse events; iii)Quality of life (not reported)
Additional outcomes: i) Composite endpoint of days alive, days out of hospital (for car-
diovascular reasons), and symptom score from the Kansas City Cardiomyopathy Ques-
tionnaire ii) Change in NT-proBNP, NYHA, level of titration and intensification of
treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, but no description of how
achieved
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “single-blind”, lack of details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “single-blind”, lack of details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers provided, but not reasons
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Selective reporting (reporting bias) High risk Planned outcomes specified in Persson
2010.Quality of life outcomes not reported
Other bias Unclear risk Source of funding: AstraZeneca
Pfisterer 2009
Methods ’TIME-CHF (Heart failure reduced LVEF (HFrEF))
Setting: 15 hospital outpatient clinics in Switzerland and Germany
Duration of study: 18 months
Inclusion criteria: 60 years or older with dyspnoea (NYHA class II with current therapy)
, a history of hospitalisation for HF within the last year, N-terminal BNP level of 400
pg/mL or higher in patients younger than 75 years and a level of 800 pg/mL or higher
in patients aged 75 years or older, ≤ 45% LVEF
Exclusion criteria: patients with dyspnoea not mainly due to HF, with valvular disease
requiring surgery, acute coronary syndromes within the previous 10 days, angina pectoris
classified as being in the Canadian Cardiovascular Society Class higher than II, revascu-
larisation within the previous month, BMI (calculated as weight in kilograms divided by
height in meters squared) higher than 35, serum creatinine level higher than 2.49 mg/
dL, a life expectancy of less than 3 years for non cardiovascular diseases, unable to give
informed consent, no follow-up possible, or participating in another study
Participants Number of participants at baseline: Intervention 251; Control 248
Gender (male): Intervention 68.1%; Control 62.9%
Mean age: Intervention 76; Control 77
Interventions 1. NT-proBNP-guided treatment: minimum three visits in first quarter, five in first
year and six or more overall ; structured clinical assessment including NT-proBNP
data, treatment according to ESC 2001 and American College of Cardiology and
American heart Association guidelines. Algortihm for escalation of treatment: addition
of spironolactone, escalating doses of ACE inhibitors, angiotensin II receptor blockers,
and -blockers, loop diuretics, low-dose digoxin, long-acting nitrates, metalozone or
another thiazide, molsidomide during nitrate-free intervals, and intravenous diuretics
or inotropes, therapy was reduced in cases of significant adverse effects, diuretics were
recommended to be reduced prior to prognostically-relevant medication, all other
therapies left to the discretion of the treating physician. Further adjustment of
treatment is only completed if criteria for further adjustment are met.
2. Symptom-guided treatment (control): Visits same as intervention without NT-
proBNP data; pre-defined escalation rules to reduce symptoms to dyspnoea NYHA
class of II or less, all other therapies at discretion of treating physician.
Intervention provider: Specialist (HF outpatient clinic with collaboration of general
practitioner)
Outcomes Review relevant: i) All-cause mortality; ii) Adverse events; iii) Cost; iv) Qualtiy of life
Additional outcomes: i) Survival free of hospitalisation
Notes Linked to Maeder 2013. Two separate groups of participants in TIME-CHF
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified by 2 age groups using central al-
location in blocks of 8 patients
Allocation concealment (selection bias) Low risk “concealed”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Patients, but not treating physicians, were
blinded to group allocation”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers provided, but not reasons
Selective reporting (reporting bias) Low risk Planned outcomes specified inprotocol. All
outcomes reported
Other bias Unclear risk Source of funding: Sponsored by the
Horten Research Foundation (Lugano,
Switzerland; 55% of the study’s budget), as
well as by smaller unrestricted grants from
AstraZeneca Pharma, Novartis Pharma,
Menarini Pharma, Pfizer Pharma, Servier,
Roche Diagnostics, Roche Pharma, and
Merck Pharma
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Schou 2013
Methods ’NorthStar’
Setting: 18 HF clinics in Denmark
Duration of study: 30 months
Inclusion criteria: > 18 years old, LVEF < 45%, educated inHF disease andmanagement,
on optimal medical therapy (ACE inhibitor/ARB, beta-blocker, aldosterone receptor
antagonist) or an implantable cardioverter-defibrillator and/or CRT, if indicated,and
NT-proBNP≥ 1000 pg/mL after up-titration (high-risk patients were included, but not
as target since the patients should receive guideline treatment based on LVEF, functional
class, and QRS duration on the ECG before randomisation), euvolaemic and clinically
stable according to the pre-defined stability criteria
Exclusion criteria: Plasma creatinine >200 µmol/l200720, waiting for a heart transplant,
valvular or Ischaemic heart disease with planned surgery or PCI, withdrawal of ACE
inhibitors/ARBs, BB, and ARAs due to a reversible cause of cardiomyopathy, malignancy
with life expectancy, 5 years, dementia
Participants Number of participants at baseline: Intervention 199; Control 208
Gender (male): Intervention 76%; Control 76%
Median age (range): Intervention 72 (56 to 85); Control 74 (51 to 89)
Interventions 1. NT-proBNP-guided treatment: minimum two visits in first quarter, five in first
year and 17 or more overall; structured clinical assessment including NT-proBNP data,
if NT-proBNP increased to >30% compared with randomisation visit then treatment
algorithm triggered (complex algorithm - see article)
2. Clinical management (control): Visits potentially same as intervention without
NT-proBNP data, but at discretion of the investigators; no treatment algorithm,
medical treatment controlled at each visit.
Intervention provider: Specialist (HF nurse supervised by local cardiologist)
Outcomes Review relevant: i) All-cause mortality; ii) HF admission; iii) All-cause admission; iv)
Quality of life
Additional outcomes: i) Composite of all-cause mortality or admission for a protocol-
specified cardiovascular cause; ii) Cardiovascular hospital admissions; iii) Change in
NYHA class and NT-proBNP levels; iv) Admission days; v) Number of admissions
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomisation performed”. No descrip-
tion of how achieved
Allocation concealment (selection bias) Unclear risk “sealed envelopes kept at the local site”.Not
stated whether opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “NT-proBNP levels are neither blinded for
the patients, cardiologists, HFC nurses, or
the GPs.”
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “vital status and admissions evaluated by an
independent endpoint committee whose
members were unaware of the study group
assignments”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition
Selective reporting (reporting bias) High risk Planned outcomes specified in protocol.
Cost not reported
Other bias Unclear risk Source of funding: Supported by unre-
stricted grants from Roche Diagnostics In-
ternational, Schwitzerland; Merck, Sharp
and Dohme, Denmark supported develop-
ment of the electronic case report form;
M.S. was supported by a grant from the
Copenhagen Hospital Corporation
Shah 2011
Methods ’STARBRITE’
Setting: Three hospitals in USA
Duration of study: Four months
Inclusion criteria: LVEF≤ 35%, NYHA class III/IV on admission, follow-up in the HF
program of each site, and regular access to a telephone
Exclusion criteria: Diagnosed with an acute coronary syndrome during the index hospi-
talisation, serum creatinine level >3.5 mg/dL, required haemodialysis
Participants Number of participants at baseline: Intervention 68; Control 69
Gender (male): Intervention 67.7%; Control 72.3%
Median age (IQR): Intervention 59 (50,70); Control 63 (52,74)
Interventions 1. BNP-guided treatment: minimum five visits in first quarter, six in first year and
overall; structured clinical assessment including BNP data, treatment triggered if BNP
increased by more than two times or less than the hospital discharge value of BNP,
treatment based on general guidelines and clinician’s judgement, telephone follow-up
after visits. Guidelines: i) ≥ target BNP & ≥ target congestion score (CS): Double
loop diuretics or add metolazone/HCTZ, check electrolytes and supplement KCl and
Mg during visit as needed, ii) ≥ 2x target BNP & < target CS: Double loop diuretics,
check electrolytes and supplement KCl and Mg during visit as needed iii) ≥ 2x target
BNP & orthostatic hypotension or renal insufficiency: Consider hospital admission if
patient unstable and/or has CS 3-5, check electrolytes and supplement KCl and Mg
during visit as needed iv) < 2x target BNP & > target CS plus < 2x target BNP & ≤
target CS : Continue current medical regimen v) < 2x target BNP & orthostatic
hypotension or renal insufficiency: Consider admission to hospital if patient is
unstable, if patient is stable, discontinue thiazide/metolazone; if not taking thiazide/
metolazone, reduce daily dose of loop diuretics by half, check electrolytes and
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supplement KCl and Mg during visit as needed. For all guidelines optimise ACE
inhibitors, nitrates, beta-blockers, spironolactone, and digoxin.
2. Congestion score strategy (control): Visits same as intervention without BNP
data; clinical assessment based on congestion score (method to quantify key variables of
the clinical assessment, congestion score at hospital discharge used as a target).
Guidelines: i) > Target CS: Double loop diuretics or add metolazone/HCTZ, check
electrolytes and supplement KCl and Mg during visit as needed; ii) > Target CS &
orthostatic hypotension or renal insufficiency: Consider admission to hospital if
patient unstable and/or has CS 3-5. If patient is stable and/or has CS 1-2: Discontinue
thiazide/metolazone; if patient not taking thiazide/metolazone, reduce daily dose of
loop diuretics by half, check electrolytes and supplement KCl and Mg during visit as
needed; iii) ≤ Target CS: Continue current medical regimen; iv) ≤ Target CS &
orthostatic hypotension or renal insufficiency: Discontinue thiazide/metolazone; if
patient not taking thiazide/metolazone, reduce daily dose of loop diuretics by half,
check electrolytes and supplement KCl and Mg during visit as needed. For all guidelines
optimise ACE inhibitors, nitrates, beta-blockers, spironolactone, and digoxin.
It was not specifically stated if no or any action was taken if the patient was below or at
target
Intervention provider: Specialist (HF clinic clinicians, plus HF nurses for follow-up
telephone calls)
Outcomes Review relevant: i) All-cause mortality; ii) All-cause admission
Additional outcomes: i) Survival free of hospitalisation during 90 days; ii) Number of
days alive during the study period; iii) Number of diuretic adjustments; iv) Cost (not
reported)
Trial stopped early due to poor enrolment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “stratified by site with randomisation
blocks of 6 through a central telephone cen-
tre”
Allocation concealment (selection bias) Low risk Email by author 7 October 2014 “opaque
envelopes were used”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Clinicians were aware of the treatment al-
location but were blinded to BNP levels
in patients in the congestion score strategy
arm. Patients were blinded to the randomi-
sation arm.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Email from author 7 October 2014: “No
blinding. Outcomes were based on case re-
port forms”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition
Selective reporting (reporting bias) High risk Planned outcomes specified in protocol.
Cost not reported.
Other bias Unclear risk Source of funding: Sponsored by the Amer-
ican Heart Association, the American Col-
lege of Cardiology/Merck Foundation, and
the Duke Clinical Research Institute
Shochat 2012
Methods Setting: Hospital in Israel
Duration of study: 16 (±11) months
Inclusion criteria:≥ 18 years old, known chronic HF, HF hospitalisation within last year
before recruitment, GFR > 30 ml/mi, signed agreement, NYHA II - IV, NT-ProBNP
>2000 at day of randomisation
Exclusion criteria: None
Participants Number of participants at baseline: Intervention 60; Control 60
Gender (male): Intervention 88.3%; Control 83%
Mean age (SD): Intervention 70.2 (11); Control 69.4 (10.5)
Interventions 1. NT-proBNP-guided treatment: minimum two visits in first quarter, remainder
unclear, visits on average every 45 (SD 19) days; clinical assessment including NT-
proBNP data, treatment intensified if NT-proBNP higher by more than 30% since last
visit and < 2000 pg/mL. Algorrithm (email from author 12 November 14): i) diuretics
increased; ii) ACE/ AT1 blocker and/or beta blockers increased. Doses at discretion of
clinician
2. Conventional treatment (control): Visit schedule same as NT-proBNP group,
conventionally-guided treatment without BNP data; No algorithm reported.
Intervention provider: Specialist (HF clinic)
Outcomes Review relevant: i) All-cause mortality; ii) HF mortality (data not confirmed); iii) HF
admission (data not confirmed); iv) All-cause admission (data not confirmed)
Additional outcomes: i) Cardiovascular mortality
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomised’ by computer”
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Allocation concealment (selection bias) Unclear risk Email from author 12 November 14 “com-
puter generated”.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Email from author 12 November 14 “Pa-
tients and physicians blinded to group allo-
cation. Study co-ordinator not blinded but
did not participate in study process”. Cor-
respondence with author makes evaluation
of bias unclear as it is not known if par-
ticipants and clinicians were blinded to the
monitoring process (intervention)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers provided, but not reasons
Selective reporting (reporting bias) Unclear risk Insufficient information to assess risk
Other bias Unclear risk Source of funding: ’Rosh’ Company
granted sets for NT-proBNP determina-
tion, no additional funding
Skvortsov 2015
Methods Setting: Hospital outpatients in Russia
Duration of study: One year
Inclusion criteria: Hospital admission due to acute decompensation HF, NYHA class III
- IV at admission, LVEF < 40%, high risk at hospital discharge (> 1400 pg/mL NT-
proBNP)
Exclusion criteria: Participant unable or unwilling to provide written informed consent,
inoperable aortic or mitral valve disease, coronary revascularisation (PCI or CABG)
within the previous 3 months, acute myocardial infarction in previous 6 month, inflam-
matory myocardium disease, serum creatinine > 220 mkmol/mL, severe obstructive or
restrictive pulmonary disease, high degree atrioventricular block, alcohol abuse, oncol-
ogy
Participants Number of participants at baseline: Intervention 35; Control 35
Gender (male): Intervention 61%; Control 89%
Mean age (SD): Intervention 63.7 (8.6); Control 62.5 (13.3)
Interventions 1. NT-proBNP-guided treatment: Minimum four visits in first quarter, eight in first
year, visits monthly in first six months and then every three months up to one year,
structured clinical assessment including NT-proBNP data, target NP of < 1000 pg/mL
pr at least 50% of initial NP measurement at discharge, algorithm for treatment: i)
increase in NT-proBNP, but no clinical deterioration then patients revisited in two
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weeks. If the trend of increased NT-proBNP continued without deterioration of
clinical symptoms then diuretics were recommended with further visit in 2 weeks
(though this may coincide with a scheduled visit); ii) increase in NT-proBNP with
increase in clinical HF symptoms then patients immediately received correction of
diuretic therapy; iii) decrease in NT-proBNP plus increase in clinical symptoms then
patients immediately received correction of diuretic therapy (this did effect did not
happen in the study), the choice of medications and dose titration was individually
determined and continued until the maximum-tolerated doses of drugs were
administered.
2. Standard therapy (control): Minimum four visits in first quarter, eight in first
year, visits monthly in first six months and then every three months up to one year,
treatment same as intervention group without NT-proBNP data, treatment adjusted
according to ESC and ACCF/AHATF guidelines.
Intervention provider: Specialist (HF clinic)
Outcomes Review relevant: i) All-cause mortality; ii) HF mortality; iii) HF admission; iv) Quality
of life
Additional outcomes: i) Total cardiovascular events; ii) Changes in NT-proBNP, LVEF,
functional capacity i) Cardiovascular events; ii) Cardiovascular mortality; iii) Alternative
biomarkers; iv) Clinical and functional status; v) LV systolic and diastolic function; vi)
Episodes of HF deterioration needing additional i/v diuretics vii) Blood pressure viii)
Serum creatinine ix) Recovery of patients
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomisation 1:1” using block design,
email from author 17.4.16 confirms ran-
domisation by independent investigator
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Email from author 17 April 16 con-
firms patients and clinicians blinded to
NT-proBNP measurements in the control
group, but unclear if blinded to group al-
location
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Email from author 17 April 16 confirms
outcomes not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers provided with reasons
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Selective reporting (reporting bias) Unclear risk Planned outcomes specified in Skvortsov
2015. Not all outcomes reported. Email
from author 17 April 16 confirmed further
publications due shortly
Other bias Unclear risk Source of funding: Not stated
Troughton 2000
Methods Setting: Hospital in New Zealand
Duration of study: Maximum 17 months
Inclusion criteria: Aged 35 to 85, after hospital admission with decompensated HF or
from a specialist cardiology outpatient clinic, LVEF < 40%, NYHA class II-IV, treated
with ACE inhibitors, loop diuretic with or without digoxin
Exclusion criteria: Acute coronary syndrome (within 3 months), pending cardiac trans-
plant or revascularisation, severe stenotic valvular heart disease, or by severe pulmonary
(forced expiratory volume in 1 s <1 L) hepatic or renal (plasma creatinine > 0·2 mmol/
L) disease
Participants Number of participants at baseline: Intervention 33; Control 36
Gender (male): Intervention 78%; Control 75%
Mean age: Intervention 68; Control 72
Interventions 1. NT-proBNP-guided treatment: minimum one visits in first quarter, four in first
year, visits two-weekly until target met and then three-monthly, structured clinical
assessment including NT-proBNP data, HF score used based on Framingham criteria
(score of two or more indicates HF) treatment intensified if BNP target (200 pmol/L)
not met.Stepwise increase in therapy: i) maximisation of ACE inhibitors (up to
enalapril equivalent of 20 mg twice a day); ii) increase in loop diuretic to furosemide
500 mg twice a day; iii) addition of digoxin up to 0·25 mg/day; additional diuretic
(spironolactone 25 mg to 50 mg once a day, then metolazone 2·5 mg to 5 mg once a
day) iv) additional vasodilator (isosorbide mononitrate 60 mg to 120 mg once a day
then felodipine 2·5 mg to 5 mg once a day)
2. Clinically-guided treatment (control): minimum one visits in first quarter, two in
first year and four overall, treatment same as intervention group without NT-proBNP
data, treatment intensified same as intervention group when triggered by HF score of
two or more
Intervention provider: Specialist (HF clinic)
Outcomes Review relevant: i) All-cause mortality; ii) HF mortality; iii) HF admission; iv) All-cause
admission; v) Adverse events; vi) Qualtiy of life (no
Additional outcomes: i) Total cardiovascular events; ii) Changes in NT-proBNP, LVEF,
functional capacity
Notes
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomised” by computer. Email from au-
thor 21 October 2014 “Computer gener-
ated randomisation schedule”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Investigator intensifying treatment aware
of group allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition.
Selective reporting (reporting bias) Low risk Planned outcomes specified in Troughton
2000. All outcomes reported
Other bias Unclear risk Source of funding: grants from Health Re-
search Council of New Zealand and Lot-
tery Health
ACE: angiotensin-converting enzyme
ACEi: angiotensin-converting enzyme inhibitor
ARB: angiotensin receptor blocker
BMI: body mass index
BNP: brain natriuretic peptide or b-type natriuretic peptide
CABG: coronary artery bypass graft
CHF: chronic heart failure
CAPD: continuous ambulatory peritoneal dialysis
COPD: chronic obstructive pulmonary disease
CRT: cardiac resynchronisation therapy
ECG: electrocardiogram
ESC: European Society of Cardiology
FEV1: forced expiratory volume
GFR: glomerular filtration rate
HF: heart failure
KCL: potassium chloride
LVEF: left ventricular ejection fraction
Mg: magnesium
MRA: mineralocorticoid receptor antagonists
NT-proBNP: N-terminal pro b-type natriuretic peptide
NYHA: New York Heart Association
PCI: percutaneous coronary intervention
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SD: standard deviation
[STEMI: segment elevation myocardial infarction}
/d: per day
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Brunner-La Rocca 2015 Not RCT. Further analysis from Troughton 2014 individual patient data meta analysis
ChiCTR-TRC-08000284 Not NP-guided treatment
Cocco 2015 Not RCT
Dandamudi 2012 Not RCT
De Vecchis 2013 Not RCT
Di Somma 2008 Not RCT
Dong 2014 Not RCT
El-Muayed 2004 Not RCT
Felker 2006 Not RCT
Gaggin 2013 Not RCT
Gonzalez 2012 Not RCT
Green 2009 Not RCT
Jernberg 2003 Not treatment for heart failure
Kociol 2011 Not NP-guided treatment
Koitabashi 2005 Not RCT
Komajda 2006 Not NP-guided treatment
Krackhardt 2008 Not RCT
Krackhardt 2011 Not RCT
Ledwidge 2013 Not heart failure population
Leuchte 2005 Not RCT
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Li 2007 Not NP-guided treatment
Lindahl 2005 Not NP-guided treatment
Luchner 2012 Not NP-guided treatment
Maisel 2013 Not RCT
McNairy 2002 Not RCT
Miller 2009 Not RCT
Murdoch 1999 No prespecified outcomes
NCT00206856 Trial terminated
NCT00622531 Trial terminated
NCT01299350 Not NP-guided treatment
Pascual-Figal 2008 Not RCT
Tang 2005 Not RCT
Troughton 2004 Not RCT
Valle 2008 Not RCT
Wasywich 2009 Not RCT
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Felker 2014
Trial name or title NCT01685840
’GUIDE-IT’
Methods Setting: USA & Canada
Duration of study: 12-24 months
Inclusion criteria: ≥18 years old, LVEF ≤ 40% within 12 months of randomisation, High risk HF (HF
hospitalisation, treatment in emergency department, outpatient treatment with intravenous diuretics in the
prior 12 months) AND NT-proBNP greater than 2000 pg/mL or BNP greater than 400 pg/mL at any time
during the 30 days prior to randomisation, willing to provide informed consent
Exclusion criteria: Acute coronary syndrome or cardiac revascularisation procedure within 30 days, cardiac
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resynchronisation therapy (CRT) within prior 3 months or current plan to implant CRT device, active my-
ocarditis, hypertrophic obstructive cardiomyopathy, pericarditis, or restrictive cardiomyopathy, severe stenotic
valvular disease, anticipated heart transplantation or ventricular assist device within 12 months, chronic in-
otropic therapy, complex congenital heart disease, end stage renal disease with renal replacement therapy, non
cardiac terminal illness with expected survival less than 12 months, women who are pregnant or planning to
become pregnant, inability to comply with planned study procedures, enrolment or planned enrolment in
another clinical trial
Participants Number of participants at baseline: 1100 (all groups)
Interventions 1. NT-proBNP-guided treatment: Visits every two weeks until optimal doses of therapies achieved, then
every three months. Titration of HF treatment using guideline recommended therapies with a target of
achieving and maintaining NT-proBNP level <1000 pg/mL
2. Usual care: Visit schedule same as for first arm. Ttitration of HF treatment based on target doses of
evidence-based guidelines (American Heart Association and American College of Cardiology)
Intervention provider: Treating physician for all arms
Outcomes Review relevant: i) quality of life; ii) adverse events; iii) medical costs, resource and cost-effectiveness
Additional outcomes: i) time to cardiovascular death or HF hospitalisation; ii) time to all-cause mortality and
cardiovascular mortality; iii) cumulative morbidity; iv) time to first HF hospitalisation
Starting date December 2012
Contact information gayle.e.paynter@duke.edu michael.felker@duke.edu
Notes Unblinded. Except blinded clinical committee to adjudicate all deaths and hospitalisations
Analysis on intention-to-treat basis
Due to finish in December 2017
Jourdain 2014
Trial name or title NCT02110433
Methods Setting: Hospitals in France
Duration of study: 12 months
Inclusion criteria: > 18 years old, HF diagnosed on a first hospitalisation for acute exacerbation during the
last 12 months, without high age limit, minimal knowledge of the French language (patient or his relatives),
informed written consent, resides or is treated in Ile de France, insured under the social security system
Exclusion criteria: Myocardial infarction or revascularisation or heart valve surgery < 3 months, inability to
execute the feasibility test, major cognitive disorders do not allow access to the platform, patient does not
have the necessary autonomy to use the equipment, patient enrolled in another clinical trial, renal failure with
creatininemia clearance (cockcroft) <15 mL/min 24h/day oxygen
Participants Number of participants at baseline: 330 (all groups)
Interventions 1. BNP-guided treatment plus Cordiva system: Cordiva system plus BNP home monitoring (weekly)
2. Cordiva system (tele monitoring system): scheduled visit with cardiologist every three months, monthly
phone contact, daily questions via Cordiva system (eight questions for decompensation and body weight)
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3. Placebo (control): unlimited visits, managed according to ESC guidelines
Outcomes Review relevant: i) all-cause mortality; ii) HF admission; iii) quality of life; vi) cost
Additional outcomes: i) composite end point including unplanned hospitalisations for CHFwith hospital stay
> 1 day / all-cause death/ non-programmed emergency department admission related to CHF; ii) emergency
admission; iii) adherence to strategy; iv) false positive induced by the system; v) false positive induced by the
system
Starting date December 2013
Contact information patrick.jourdain@ch-pontoise.fr, maryline.delattre@ch-pontoise.fr
Notes Due to finish in December 2015
Metra 2012
Trial name or title
Methods Setting: Italy
Participants Number of participants at baseline: 300 (all groups)
Interventions 1. BNP-guided treatment
2. Control
Outcomes
Starting date January 2005
Contact information metramarco@libero.it
Notes Recrutiment finished in August 2009
Currently in write up
Moe 2007
Trial name or title EX-IMPROVE-CHF (NCT00601679)
Methods Setting: Three hospitals in Canada
Duration of study: 24 months
Inclusion criteria: ≥ 18 years old, NYHA class II-IV, followed in a programmed HF management setting
Exclusion criteria: Life expectancy <1 year due to causes other than HF such as advanced cancer, any other
conditions that may render the patient ineligible according to the investigator’s judgment
Participants Number of participants at baseline: 400 (all groups)
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Interventions 1. NT-proBNP-guided treatment: minimum two visits in first quarter, five in first year, surveillance NT-
proBNP levels disclosed to physicians
2. Usual care (control): minimum two visits in first quarter, five in first year, no intervention, surveillance
NT-proBNP levels blinded
Intervention provider: HF clinic specialists
Outcomes Review relevant: i) All-cause mortality
Additional outcomes: i) HF hospitalisation and death; ii) time to hospitalisation/admission to emergency
department due to HF; iii) total number of HF events; iv) total number of hospitalisations for cardiovascular
events; v) cardiovascular mortality; vi) worsening in clinical status but not requiring hospital admission
Starting date December 2007
Contact information moeg@smh.ca fernandoc@smh.ca
Notes Due to finish in December 2014
Saraya 2015
Trial name or title
Methods Setting: Hospital in Eygpt
Duration of study: Six months
Inclusion criteria: Patients with HF and reduced ejection fraction
Exclusion criteria: acute or chronic renal failure, chronic lung disease, massive pericardial effusion, acute
coronary syndrome
Participants Number of participants at baseline: Intervention 25; Control 25 (2 further groups: ultrasound lung comets
[n = 25], Doppler imaging [n = 25])
Interventions 1. BNP-guided treatment: Plus clinical findings, point of care device for BNP, target level below 200 pg/
mL
2. Clinical findings alone (control)
3. Ultrasound lung comets: Plus clinical findings, targeting a score below 15
4. Doppler imaging: Plus clinical findings, targeting a mean below 10 E/E
Outcomes Review relevant: i) HF admission
Starting date July 2012
Contact information Not stated
Notes Finished August 2014
Limited data in the conference abstract, awaiting full publication
Source of funding: Eygptian Society of Cardiology
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Trial name or title PRIMA II (NTR3279)
Methods Setting: Hospitals in the Netherlands
Duration of study: Six months
Inclusion criteria: Acute decompensated HF (either de novo or acute-on-chronic HF) and NT-proBNP levels
of N1,700 ng/L (ie, 200 pmol/L) measured within 24 hours of hospital admission
Exclusion criteria: COPD with FEV1 of <1 L, pulmonary embolism within 1 month before admission and
pulmonary hypertension not caused by left ventricle dysfunction, undergoing CAPD/haemodialysis patients,
planned coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), cardiac resynchro-
nisation therapy (CRT), and/or valvular surgery before randomisation, cardiogenic shock at admission re-
quiring invasive treatment, history of STEMI, CABG, PCI, CRTand/or valvular surgery within 1 month
before admission, signed informed consent for any current interventional study, presence of severe noncar-
diac-related life-threatening disease before inclusion with an expected survival of < 6 months after inclusion,
unwillingness to give or mental or physical status not allowing written informed consent, circumstances that
prevent follow-up (no permanent home address, transient, etc)
Participants Number of participants at baseline: Intervention 170; Control 170
Interventions 1. NT-proBNP-guided treatment: minimum three plus visits in first quarter, four plus in first year, four
plus visits overall, structured clinical assessment including NT-proBNP data in hospital, when patients
achieve over 30% reduction in NT-proBNP values hospital discharge and follow-up occurs. Under 30%
NT-proBNP measurements triggers a drug algorithm: For patients with reduced ejection fractions: i) up-
titration or addition of ACE inhibitor, β-blocker, and/or aldosterone antagonist; ii) CRT for patients who
meet current guideline criteria; iii) electrical cardioversion for new-onset atrial fibrillation; iv) coronary
artery angiography (CAG) or intervention when ischemia is suspected. For patients with preserved ejection
fractions: i) adequately treat hypertension and myocardial ischaemia; ii) ventricular rate control in atrial
fibrillation; iii) electrical cardioversion for new-onset atrial fibrillation; iv) CAG or intervention when
ischaemia is suspected
2. Conventional therapy (control): Discharge and follow-up of the patients can be planned at the
discretion of the treating physician, physicians are discouraged from taking NT-proBNP measurements
Intervention provider: Physicians (control), HF nurses/cardiologists (intervention)
Outcomes Review relevant: i) all-cause mortality; ii) HF admission; iii) cost; iv) quality of life
Additional outcomes: i) composite all-cause mortality and HF hospitalisations; ii) hospital free survival in the
first 180 days
Starting date November 2011
Contact information w.e.kok@amc.uva.nl
Notes Due to finish in December 2014
Source of funding: Netherlands Heart Foundation, Dutch Organization for Scientific Research (NWO), the
RoyalDutch Academy of Arts and Sciences (KNAW) - Interuniversity Cardiology Institute of theNetherlands,
Pfizer, Astra-Zeneca, Medtronic, and Roche Diagnostics
ACE: angiotensin-converting enzyme
CHF: chronic heart failure
CAPD: continuous ambulatory peritoneal dialysis
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COPD: chronic obstructive pulmonary disease
ESC: European Society of Cardiology
FEV1: forced expiratory volume
HF: heart failure
LVEF: left ventricular ejection fraction
NYHA: New York Heart Association
STEMI: segment elevation myocardial infarction
64B-type natriuretic peptide-guided treatment for heart failure (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
D A T A A N D A N A L Y S E S
Comparison 1. Primary objective BNP vs no BNP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 15 3169 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.76, 1.01]
2 Heart failure mortality 6 853 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.54, 1.30]
3 Heart failure admission 10 1928 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.61, 0.80]
4 All-cause admission 6 1142 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.84, 1.03]
5 Quality of life 8 1812 Mean Difference (IV, Fixed, 95% CI) -0.03 [-1.18, 1.13]
Comparison 2. Clincal vs UC in primary objectives
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 15 3169 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.76, 1.01]
1.1 Clinical assessment 15 2850 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.76, 1.04]
1.2 Usual care 2 319 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.56, 1.13]
2 Heart failure mortality 6 853 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.54, 1.30]
2.1 Clinical assessment 6 853 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.54, 1.30]
2.2 Usual care 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Heart failure admission 10 1928 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.61, 0.80]
3.1 Clinical assessment 10 1609 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.60, 0.81]
3.2 Usual care 2 319 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.53, 0.99]
4 All-cause admission 6 1142 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.84, 1.03]
4.1 Clinical assessment 6 1142 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.84, 1.03]
4.2 Usual care 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Quality of life 8 1812 Mean Difference (IV, Fixed, 95% CI) -0.03 [-1.18, 1.13]
5.1 Clincial assessment 8 1812 Mean Difference (IV, Fixed, 95% CI) -0.03 [-1.18, 1.13]
5.2 Usual care 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Subgroup analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality and age 3 830 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.83, 1.27]
1.1 Equal or greater than 75
yrs old
3 410 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.96, 1.57]
1.2 Under 75 yrs old 3 420 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.49, 1.10]
2 Heart failure admission and age 1 365 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.69, 1.25]
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2.1 Equal or greater than 75
yrs old
1 188 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.77, 1.64]
2.2 Under 75 yrs old 1 177 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.45, 1.17]
Comparison 4. Sensitivity analyses: Outcome blinding
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 5 1663 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.80, 1.11]
2 Heart failure mortality 1 268 Risk Ratio (M-H, Fixed, 95% CI) 1.2 [0.66, 2.20]
3 Heart failure admission 4 1318 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.71, 0.98]
4 All-cause admission 2 675 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.88, 1.10]
5 Quality of life 3 994 Mean Difference (IV, Fixed, 95% CI) -0.01 [-1.28, 1.27]
Comparison 5. Sensitivity analyses: Attrition
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 7 1229 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.65, 1.07]
2 Heart failure mortality 4 533 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.26, 1.03]
3 Heart failure admission 5 814 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.49, 0.81]
4 All-cause admission 4 833 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.83, 1.07]
5 Quality of life 3 534 Mean Difference (IV, Fixed, 95% CI) -0.57 [-1.92, 0.78]
Comparison 6. Duration of FU BNP vs no BNP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 15 3169 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.76, 1.01]
1.1 ≤ 1 yr 5 555 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.25, 0.85]
1.2 1-2 yrs 8 1842 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.69, 0.99]
1.3 > 2 yrs 2 772 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.87, 1.41]
2 Heart failure mortality 6 853 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.54, 1.30]
2.1 ≤ 1 yr 3 313 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.28, 1.48]
2.2 1 - 2 yrs 3 540 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.56, 1.57]
2.3 > 2 yrs 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Heart failure admission 10 1928 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.61, 0.80]
3.1 ≤ 1 yr 3 278 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.23, 0.58]
3.2 1 - 2 yrs 5 878 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.54, 0.79]
3.3 > 2 ys 2 772 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.77, 1.23]
4 All-cause admission 6 1142 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.84, 1.03]
4.1 ≤ 1 yr 3 247 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.58, 1.07]
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4.2 1 - 2 yrs 2 488 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.77, 1.03]
4.3 > 2 yrs 1 407 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.89, 1.21]
5 Quality of life 8 1812 Mean Difference (IV, Fixed, 95% CI) -0.03 [-1.18, 1.13]
5.1 ≤ 1 yr 5 561 Mean Difference (IV, Fixed, 95% CI) -3.14 [-6.46, 0.19]
5.2 1 - 2 yrs 2 844 Mean Difference (IV, Fixed, 95% CI) 1.98 [-0.76, 4.72]
5.3 > 2 yrs 1 407 Mean Difference (IV, Fixed, 95% CI) 0.0 [-1.38, 1.38]
Comparison 7. Subgroup: BNP vs NT-proBNP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 15 3169 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.76, 1.01]
1.1 NT-proBNP 9 2391 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.75, 1.01]
1.2 BNP 6 778 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.62, 1.28]
2 Heart failure mortality 6 853 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.54, 1.30]
2.1 NT-proBNP 2 127 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.08, 1.19]
2.2 BNP 4 726 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.61, 1.56]
3 Heart failure admission 10 1928 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.53, 0.84]
3.1 NT-proBNP 6 1328 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.48, 0.89]
3.2 BNP 4 600 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.43, 1.05]
4 All-cause admission 6 1142 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.84, 1.03]
4.1 NT-proBNP 2 476 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.85, 1.14]
4.2 BNP 4 666 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.77, 1.01]
5 Quality of life 8 1812 Mean Difference (IV, Fixed, 95% CI) -0.03 [-1.18, 1.13]
5.1 NT-proBNP 7 1771 Mean Difference (IV, Fixed, 95% CI) -0.02 [-1.19, 1.14]
5.2 BNP 1 41 Mean Difference (IV, Fixed, 95% CI) -0.20 [-15.30, 14.
90]
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Analysis 1.1. Comparison 1 Primary objective BNP vs no BNP, Outcome 1 All-cause mortality.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 1 Primary objective BNP vs no BNP
Outcome: 1 All-cause mortality
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anguita 2010 4/30 3/30 0.9 % 1.33 [ 0.33, 5.45 ]
Beck-da-Silva 2005 1/21 2/20 0.6 % 0.48 [ 0.05, 4.85 ]
Berger 2010 (1) 10/46 21/96 4.2 % 0.99 [ 0.51, 1.93 ]
Berger 2010 (2) 10/46 35/90 7.3 % 0.56 [ 0.30, 1.03 ]
Eurlings 2010 46/174 57/171 17.7 % 0.79 [ 0.57, 1.10 ]
Jourdain 2007 7/110 11/110 3.4 % 0.64 [ 0.26, 1.58 ]
Karlstrom 2011 31/140 29/128 9.3 % 0.98 [ 0.63, 1.53 ]
Krupicka 2010 4/26 3/26 0.9 % 1.33 [ 0.33, 5.38 ]
Lainchbury 2010 (3) 20/61 40/122 8.2 % 1.00 [ 0.64, 1.55 ]
Lainchbury 2010 (4) 20/61 40/121 8.3 % 0.99 [ 0.64, 1.54 ]
Persson 2010 7/126 7/124 2.2 % 0.98 [ 0.36, 2.72 ]
Pfisterer 2009 40/251 55/248 17.1 % 0.72 [ 0.50, 1.04 ]
Schou 2013 46/199 38/208 11.5 % 1.27 [ 0.86, 1.86 ]
Shah 2011 1/68 3/69 0.9 % 0.34 [ 0.04, 3.17 ]
Shochat 2012 13/60 7/60 2.2 % 1.86 [ 0.80, 4.33 ]
Skvortsov 2015 4/31 10/27 3.3 % 0.35 [ 0.12, 0.98 ]
Troughton 2000 1/33 7/36 2.1 % 0.16 [ 0.02, 1.20 ]
Total (95% CI) 1483 1686 100.0 % 0.87 [ 0.76, 1.01 ]
Total events: 265 (BNP monitoring), 368 (No BNP monitoring)
Heterogeneity: Chi2 = 19.13, df = 16 (P = 0.26); I2 =16%
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Primary objective BNP vs no BNP, Outcome 2 Heart failure mortality.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 1 Primary objective BNP vs no BNP
Outcome: 2 Heart failure mortality
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jourdain 2007 3/110 9/110 22.7 % 0.33 [ 0.09, 1.20 ]
Karlstrom 2011 21/140 16/128 42.2 % 1.20 [ 0.66, 2.20 ]
Krupicka 2010 2/26 1/26 2.5 % 2.00 [ 0.19, 20.72 ]
Li 2015 6/94 5/92 12.8 % 1.17 [ 0.37, 3.71 ]
Skvortsov 2015 2/31 6/27 16.2 % 0.29 [ 0.06, 1.32 ]
Troughton 2000 0/33 1/36 3.6 % 0.36 [ 0.02, 8.61 ]
Total (95% CI) 434 419 100.0 % 0.84 [ 0.54, 1.30 ]
Total events: 34 (BNP monitoring), 38 (No BNP monitoring)
Heterogeneity: Chi2 = 6.35, df = 5 (P = 0.27); I2 =21%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Primary objective BNP vs no BNP, Outcome 3 Heart failure admission.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 1 Primary objective BNP vs no BNP
Outcome: 3 Heart failure admission
Study or subgroup NP monitoring No NP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anguita 2010 9/30 8/30 2.3 % 1.13 [ 0.50, 2.52 ]
Berger 2010 (1) 13/46 55/90 10.8 % 0.46 [ 0.28, 0.75 ]
Berger 2010 (2) 13/46 38/96 7.2 % 0.71 [ 0.42, 1.20 ]
Januzzi 2011 11/75 27/76 7.8 % 0.41 [ 0.22, 0.77 ]
Jourdain 2007 22/110 48/110 14.0 % 0.46 [ 0.30, 0.70 ]
Karlstrom 2011 55/140 57/128 17.3 % 0.88 [ 0.67, 1.17 ]
Krupicka 2010 6/26 13/26 3.8 % 0.46 [ 0.21, 1.03 ]
Lainchbury 2010 (3) 22/61 41/122 7.9 % 1.07 [ 0.71, 1.63 ]
Lainchbury 2010 (4) 22/61 49/121 9.6 % 0.89 [ 0.60, 1.33 ]
Schou 2013 37/199 40/208 11.4 % 0.97 [ 0.65, 1.45 ]
Skvortsov 2015 4/31 14/27 4.4 % 0.25 [ 0.09, 0.67 ]
Troughton 2000 5/33 13/36 3.6 % 0.42 [ 0.17, 1.05 ]
Total (95% CI) 858 1070 100.0 % 0.70 [ 0.61, 0.80 ]
Total events: 219 (NP monitoring), 403 (No NP monitoring)
Heterogeneity: Chi2 = 27.54, df = 11 (P = 0.004); I2 =60%
Test for overall effect: Z = 5.08 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Primary objective BNP vs no BNP, Outcome 4 All-cause admission.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 1 Primary objective BNP vs no BNP
Outcome: 4 All-cause admission
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Beck-da-Silva 2005 2/21 4/20 1.3 % 0.48 [ 0.10, 2.32 ]
Jourdain 2007 51/110 60/110 18.3 % 0.85 [ 0.65, 1.11 ]
Karlstrom 2011 90/140 90/128 28.7 % 0.91 [ 0.77, 1.08 ]
Schou 2013 122/199 123/208 36.8 % 1.04 [ 0.89, 1.21 ]
Shah 2011 22/68 25/69 7.6 % 0.89 [ 0.56, 1.42 ]
Troughton 2000 17/33 25/36 7.3 % 0.74 [ 0.50, 1.10 ]
Total (95% CI) 571 571 100.0 % 0.93 [ 0.84, 1.03 ]
Total events: 304 (BNP monitoring), 327 (No BNP monitoring)
Heterogeneity: Chi2 = 4.29, df = 5 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Primary objective BNP vs no BNP, Outcome 5 Quality of life.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 1 Primary objective BNP vs no BNP
Outcome: 5 Quality of life
Study or subgroup BNP monitoring No BNP monitoring
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Beck-da-Silva 2005 21 -12.1 (24.1514) 20 -11.9 (25.1314) 0.6 % -0.20 [ -15.30, 14.90 ]
Eurlings 2010 174 -27 (21.5182) 171 -25 (19.5995) 7.1 % -2.00 [ -6.34, 2.34 ]
Januzzi 2011 75 -10.5 (24.491) 76 -6 (25.0523) 2.1 % -4.50 [ -12.40, 3.40 ]
Lainchbury 2010 (1) 121 -7.7 (22.1705) 121 -10.1 (16.0253) 5.6 % 2.40 [ -2.47, 7.27 ]
Pfisterer 2009 251 -10.1 (19.0337) 248 -14.7 (21.052) 10.8 % 4.60 [ 1.08, 8.12 ]
Schou 2013 199 0 (5.93) 208 0 (8.19) 69.9 % 0.0 [ -1.38, 1.38 ]
Skvortsov 2015 31 -24.1 (14.48413) 27 -7.6 (14.68095) 2.4 % -16.50 [ -24.03, -8.97 ]
Troughton 2000 33 -2 (24.0624) 36 0 (16.7755) 1.4 % -2.00 [ -11.87, 7.87 ]
Total (95% CI) 905 907 100.0 % -0.03 [ -1.18, 1.13 ]
Heterogeneity: Chi2 = 28.16, df = 7 (P = 0.00021); I2 =75%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Clincal vs UC in primary objectives, Outcome 1 All-cause mortality.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 2 Clincal vs UC in primary objectives
Outcome: 1 All-cause mortality
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Clinical assessment
Anguita 2010 4/30 3/30 0.9 % 1.33 [ 0.33, 5.45 ]
Beck-da-Silva 2005 1/21 2/20 0.6 % 0.48 [ 0.05, 4.85 ]
Berger 2010 (1) 10/46 21/96 4.2 % 0.99 [ 0.51, 1.93 ]
Eurlings 2010 46/174 57/171 17.7 % 0.79 [ 0.57, 1.10 ]
Jourdain 2007 7/110 11/110 3.4 % 0.64 [ 0.26, 1.58 ]
Karlstrom 2011 31/140 29/128 9.3 % 0.98 [ 0.63, 1.53 ]
Krupicka 2010 4/26 3/26 0.9 % 1.33 [ 0.33, 5.38 ]
Lainchbury 2010 (2) 20/61 40/121 8.3 % 0.99 [ 0.64, 1.54 ]
Persson 2010 7/126 7/124 2.2 % 0.98 [ 0.36, 2.72 ]
Pfisterer 2009 40/251 55/248 17.1 % 0.72 [ 0.50, 1.04 ]
Schou 2013 46/199 38/208 11.5 % 1.27 [ 0.86, 1.86 ]
Shah 2011 1/68 3/69 0.9 % 0.34 [ 0.04, 3.17 ]
Shochat 2012 13/60 7/60 2.2 % 1.86 [ 0.80, 4.33 ]
Skvortsov 2015 4/31 10/27 3.3 % 0.35 [ 0.12, 0.98 ]
Troughton 2000 1/33 7/36 2.1 % 0.16 [ 0.02, 1.20 ]
Subtotal (95% CI) 1376 1474 84.5 % 0.89 [ 0.76, 1.04 ]
Total events: 235 (BNP monitoring), 293 (No BNP monitoring)
Heterogeneity: Chi2 = 16.56, df = 14 (P = 0.28); I2 =15%
Test for overall effect: Z = 1.51 (P = 0.13)
2 Usual care
Berger 2010 (3) 10/46 35/90 7.3 % 0.56 [ 0.30, 1.03 ]
Lainchbury 2010 (4) 20/61 40/122 8.2 % 1.00 [ 0.64, 1.55 ]
Subtotal (95% CI) 107 212 15.5 % 0.79 [ 0.56, 1.13 ]
Total events: 30 (BNP monitoring), 75 (No BNP monitoring)
Heterogeneity: Chi2 = 2.35, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 1.28 (P = 0.20)
Total (95% CI) 1483 1686 100.0 % 0.87 [ 0.76, 1.01 ]
Total events: 265 (BNP monitoring), 368 (No BNP monitoring)
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(. . . Continued)
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 19.13, df = 16 (P = 0.26); I2 =16%
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
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Analysis 2.2. Comparison 2 Clincal vs UC in primary objectives, Outcome 2 Heart failure mortality.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 2 Clincal vs UC in primary objectives
Outcome: 2 Heart failure mortality
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Clinical assessment
Jourdain 2007 3/110 9/110 22.7 % 0.33 [ 0.09, 1.20 ]
Karlstrom 2011 21/140 16/128 42.2 % 1.20 [ 0.66, 2.20 ]
Krupicka 2010 2/26 1/26 2.5 % 2.00 [ 0.19, 20.72 ]
Li 2015 6/94 5/92 12.8 % 1.17 [ 0.37, 3.71 ]
Skvortsov 2015 2/31 6/27 16.2 % 0.29 [ 0.06, 1.32 ]
Troughton 2000 0/33 1/36 3.6 % 0.36 [ 0.02, 8.61 ]
Subtotal (95% CI) 434 419 100.0 % 0.84 [ 0.54, 1.30 ]
Total events: 34 (BNP monitoring), 38 (No BNP monitoring)
Heterogeneity: Chi2 = 6.35, df = 5 (P = 0.27); I2 =21%
Test for overall effect: Z = 0.77 (P = 0.44)
2 Usual care
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(. . . Continued)
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (BNP monitoring), 0 (No BNP monitoring)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 434 419 100.0 % 0.84 [ 0.54, 1.30 ]
Total events: 34 (BNP monitoring), 38 (No BNP monitoring)
Heterogeneity: Chi2 = 6.35, df = 5 (P = 0.27); I2 =21%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NP-guided Favours control
Analysis 2.3. Comparison 2 Clincal vs UC in primary objectives, Outcome 3 Heart failure admission.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 2 Clincal vs UC in primary objectives
Outcome: 3 Heart failure admission
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Clinical assessment
Anguita 2010 9/30 8/30 2.3 % 1.13 [ 0.50, 2.52 ]
Berger 2010 (1) 13/46 38/96 7.2 % 0.71 [ 0.42, 1.20 ]
Januzzi 2011 11/75 27/76 7.8 % 0.41 [ 0.22, 0.77 ]
Jourdain 2007 22/110 48/110 14.0 % 0.46 [ 0.30, 0.70 ]
Karlstrom 2011 55/140 57/128 17.3 % 0.88 [ 0.67, 1.17 ]
Krupicka 2010 6/26 13/26 3.8 % 0.46 [ 0.21, 1.03 ]
Lainchbury 2010 (2) 22/61 49/121 9.6 % 0.89 [ 0.60, 1.33 ]
Schou 2013 37/199 40/208 11.4 % 0.97 [ 0.65, 1.45 ]
Skvortsov 2015 4/31 14/27 4.4 % 0.25 [ 0.09, 0.67 ]
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(. . . Continued)
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Troughton 2000 5/33 13/36 3.6 % 0.42 [ 0.17, 1.05 ]
Subtotal (95% CI) 751 858 81.2 % 0.70 [ 0.60, 0.81 ]
Total events: 184 (BNP monitoring), 307 (No BNP monitoring)
Heterogeneity: Chi2 = 20.82, df = 9 (P = 0.01); I2 =57%
Test for overall effect: Z = 4.65 (P < 0.00001)
2 Usual care
Berger 2010 (3) 13/46 55/90 10.8 % 0.46 [ 0.28, 0.75 ]
Lainchbury 2010 (4) 22/61 41/122 7.9 % 1.07 [ 0.71, 1.63 ]
Subtotal (95% CI) 107 212 18.8 % 0.72 [ 0.53, 0.99 ]
Total events: 35 (BNP monitoring), 96 (No BNP monitoring)
Heterogeneity: Chi2 = 6.66, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 2.05 (P = 0.040)
Total (95% CI) 858 1070 100.0 % 0.70 [ 0.61, 0.80 ]
Total events: 219 (BNP monitoring), 403 (No BNP monitoring)
Heterogeneity: Chi2 = 27.54, df = 11 (P = 0.004); I2 =60%
Test for overall effect: Z = 5.08 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
0.01 0.1 1 10 100
Favours NP-guided Favours control
(1) Multidisciplinary care
(2) Clinically guided care
(3) Usual care
(4) Usual care
76B-type natriuretic peptide-guided treatment for heart failure (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 2.4. Comparison 2 Clincal vs UC in primary objectives, Outcome 4 All-cause admission.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 2 Clincal vs UC in primary objectives
Outcome: 4 All-cause admission
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Clinical assessment
Beck-da-Silva 2005 2/21 4/20 1.3 % 0.48 [ 0.10, 2.32 ]
Jourdain 2007 51/110 60/110 18.3 % 0.85 [ 0.65, 1.11 ]
Karlstrom 2011 90/140 90/128 28.7 % 0.91 [ 0.77, 1.08 ]
Schou 2013 122/199 123/208 36.8 % 1.04 [ 0.89, 1.21 ]
Shah 2011 22/68 25/69 7.6 % 0.89 [ 0.56, 1.42 ]
Troughton 2000 17/33 25/36 7.3 % 0.74 [ 0.50, 1.10 ]
Subtotal (95% CI) 571 571 100.0 % 0.93 [ 0.84, 1.03 ]
Total events: 304 (BNP monitoring), 327 (No BNP monitoring)
Heterogeneity: Chi2 = 4.29, df = 5 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
2 Usual care
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (BNP monitoring), 0 (No BNP monitoring)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 571 571 100.0 % 0.93 [ 0.84, 1.03 ]
Total events: 304 (BNP monitoring), 327 (No BNP monitoring)
Heterogeneity: Chi2 = 4.29, df = 5 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Clincal vs UC in primary objectives, Outcome 5 Quality of life.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 2 Clincal vs UC in primary objectives
Outcome: 5 Quality of life
Study or subgroup BNP monitoring No BNP monitoring
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Clincial assessment
Beck-da-Silva 2005 21 -12.1 (24.1514) 20 -11.9 (25.1314) 0.6 % -0.20 [ -15.30, 14.90 ]
Eurlings 2010 174 -27 (21.5182) 171 -25 (19.5995) 7.1 % -2.00 [ -6.34, 2.34 ]
Januzzi 2011 75 -10.5 (24.491) 76 -6 (25.0523) 2.1 % -4.50 [ -12.40, 3.40 ]
Lainchbury 2010 (1) 121 -7.7 (22.1705) 121 -10.1 (16.0253) 5.6 % 2.40 [ -2.47, 7.27 ]
Pfisterer 2009 251 -10.1 (19.0337) 248 -14.7 (21.052) 10.8 % 4.60 [ 1.08, 8.12 ]
Schou 2013 199 0 (5.93) 208 0 (8.19) 69.9 % 0.0 [ -1.38, 1.38 ]
Skvortsov 2015 31 -24.1 (14.48413) 27 -7.6 (14.68095) 2.4 % -16.50 [ -24.03, -8.97 ]
Troughton 2000 33 -2 (24.0624) 36 0 (16.7755) 1.4 % -2.00 [ -11.87, 7.87 ]
Subtotal (95% CI) 905 907 100.0 % -0.03 [ -1.18, 1.13 ]
Heterogeneity: Chi2 = 28.16, df = 7 (P = 0.00021); I2 =75%
Test for overall effect: Z = 0.04 (P = 0.97)
2 Usual care
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 905 907 100.0 % -0.03 [ -1.18, 1.13 ]
Heterogeneity: Chi2 = 28.16, df = 7 (P = 0.00021); I2 =75%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Subgroup analyses, Outcome 1 All-cause mortality and age.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 3 Subgroup analyses
Outcome: 1 All-cause mortality and age
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Equal or greater than 75 yrs old
Eurlings 2010 29/82 36/90 29.5 % 0.88 [ 0.60, 1.30 ]
Lainchbury 2010 (1) 15/32 20/58 12.2 % 1.36 [ 0.81, 2.27 ]
Lainchbury 2010 (2) 15/32 23/66 12.9 % 1.35 [ 0.82, 2.21 ]
Shochat 2012 13/22 6/28 4.5 % 2.76 [ 1.25, 6.08 ]
Subtotal (95% CI) 168 242 59.1 % 1.23 [ 0.96, 1.57 ]
Total events: 72 (BNP monitoring), 85 (No BNP monitoring)
Heterogeneity: Chi2 = 7.08, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 1.63 (P = 0.10)
2 Under 75 yrs old
Eurlings 2010 17/92 21/81 19.2 % 0.71 [ 0.40, 1.25 ]
Lainchbury 2010 (3) 4/29 20/64 10.7 % 0.44 [ 0.17, 1.18 ]
Lainchbury 2010 (4) 4/29 17/55 10.1 % 0.45 [ 0.17, 1.20 ]
Shochat 2012 9/38 1/32 0.9 % 7.58 [ 1.01, 56.66 ]
Subtotal (95% CI) 188 232 40.9 % 0.73 [ 0.49, 1.10 ]
Total events: 34 (BNP monitoring), 59 (No BNP monitoring)
Heterogeneity: Chi2 = 7.18, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 1.50 (P = 0.13)
Total (95% CI) 356 474 100.0 % 1.02 [ 0.83, 1.27 ]
Total events: 106 (BNP monitoring), 144 (No BNP monitoring)
Heterogeneity: Chi2 = 19.85, df = 7 (P = 0.01); I2 =65%
Test for overall effect: Z = 0.22 (P = 0.82)
Test for subgroup differences: Chi2 = 4.51, df = 1 (P = 0.03), I2 =78%
0.01 0.1 1 10 100
Favours NP-guided Favours control
(1) Usual care
(2) Clinically guided care
(3) Usual care
(4) Clinically guided care
79B-type natriuretic peptide-guided treatment for heart failure (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 3.2. Comparison 3 Subgroup analyses, Outcome 2 Heart failure admission and age.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 3 Subgroup analyses
Outcome: 2 Heart failure admission and age
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Equal or greater than 75 yrs old
Lainchbury 2010 (1) 13/32 18/58 21.3 % 1.31 [ 0.74, 2.31 ]
Lainchbury 2010 (2) 13/32 27/66 29.4 % 0.99 [ 0.60, 1.65 ]
Subtotal (95% CI) 64 124 50.7 % 1.13 [ 0.77, 1.64 ]
Total events: 26 (BNP monitoring), 45 (No BNP monitoring)
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
2 Under 75 yrs old
Lainchbury 2010 (3) 8/29 22/64 22.9 % 0.80 [ 0.41, 1.58 ]
Lainchbury 2010 (4) 8/29 23/55 26.5 % 0.66 [ 0.34, 1.29 ]
Subtotal (95% CI) 58 119 49.3 % 0.73 [ 0.45, 1.17 ]
Total events: 16 (BNP monitoring), 45 (No BNP monitoring)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Total (95% CI) 122 243 100.0 % 0.93 [ 0.69, 1.25 ]
Total events: 42 (BNP monitoring), 90 (No BNP monitoring)
Heterogeneity: Chi2 = 2.66, df = 3 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Chi2 = 2.00, df = 1 (P = 0.16), I2 =50%
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Analysis 4.1. Comparison 4 Sensitivity analyses: Outcome blinding, Outcome 1 All-cause mortality.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 4 Sensitivity analyses: Outcome blinding
Outcome: 1 All-cause mortality
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Berger 2010 (1) 10/46 21/96 6.3 % 0.99 [ 0.51, 1.93 ]
Berger 2010 (2) 10/46 35/90 11.0 % 0.56 [ 0.30, 1.03 ]
Eurlings 2010 46/174 57/171 26.7 % 0.79 [ 0.57, 1.10 ]
Karlstrom 2011 31/140 29/128 14.0 % 0.98 [ 0.63, 1.53 ]
Lainchbury 2010 (3) 20/61 40/122 12.4 % 1.00 [ 0.64, 1.55 ]
Lainchbury 2010 (4) 20/61 40/121 12.4 % 0.99 [ 0.64, 1.54 ]
Schou 2013 46/199 38/208 17.2 % 1.27 [ 0.86, 1.86 ]
Total (95% CI) 727 936 100.0 % 0.94 [ 0.80, 1.11 ]
Total events: 183 (BNP monitoring), 260 (No BNP monitoring)
Heterogeneity: Chi2 = 6.36, df = 6 (P = 0.38); I2 =6%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Sensitivity analyses: Outcome blinding, Outcome 2 Heart failure mortality.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 4 Sensitivity analyses: Outcome blinding
Outcome: 2 Heart failure mortality
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Karlstrom 2011 21/140 16/128 100.0 % 1.20 [ 0.66, 2.20 ]
Total (95% CI) 140 128 100.0 % 1.20 [ 0.66, 2.20 ]
Total events: 21 (BNP monitoring), 16 (No BNP monitoring)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Sensitivity analyses: Outcome blinding, Outcome 3 Heart failure admission.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 4 Sensitivity analyses: Outcome blinding
Outcome: 3 Heart failure admission
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Berger 2010 (1) 13/46 55/90 16.9 % 0.46 [ 0.28, 0.75 ]
Berger 2010 (2) 13/46 38/96 11.2 % 0.71 [ 0.42, 1.20 ]
Karlstrom 2011 55/140 57/128 27.0 % 0.88 [ 0.67, 1.17 ]
Lainchbury 2010 (3) 22/61 41/122 12.4 % 1.07 [ 0.71, 1.63 ]
Lainchbury 2010 (4) 22/61 49/121 14.9 % 0.89 [ 0.60, 1.33 ]
Schou 2013 37/199 40/208 17.7 % 0.97 [ 0.65, 1.45 ]
Total (95% CI) 553 765 100.0 % 0.83 [ 0.71, 0.98 ]
Total events: 162 (BNP monitoring), 280 (No BNP monitoring)
Heterogeneity: Chi2 = 8.11, df = 5 (P = 0.15); I2 =38%
Test for overall effect: Z = 2.23 (P = 0.026)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Sensitivity analyses: Outcome blinding, Outcome 4 All-cause admission.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 4 Sensitivity analyses: Outcome blinding
Outcome: 4 All-cause admission
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Karlstrom 2011 90/140 90/128 43.9 % 0.91 [ 0.77, 1.08 ]
Schou 2013 122/199 123/208 56.1 % 1.04 [ 0.89, 1.21 ]
Total (95% CI) 339 336 100.0 % 0.98 [ 0.88, 1.10 ]
Total events: 212 (BNP monitoring), 213 (No BNP monitoring)
Heterogeneity: Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Sensitivity analyses: Outcome blinding, Outcome 5 Quality of life.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 4 Sensitivity analyses: Outcome blinding
Outcome: 5 Quality of life
Study or subgroup BNP monitoring No BNP monitoring
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Eurlings 2010 174 -27 (21.5182) 171 -25 (19.5995) 8.6 % -2.00 [ -6.34, 2.34 ]
Lainchbury 2010 (1) 121 -7.7 (22.1705) 121 -10.1 (16.0253) 6.8 % 2.40 [ -2.47, 7.27 ]
Schou 2013 199 0 (5.93) 208 0 (8.19) 84.6 % 0.0 [ -1.38, 1.38 ]
Total (95% CI) 494 500 100.0 % -0.01 [ -1.28, 1.27 ]
Heterogeneity: Chi2 = 1.75, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Sensitivity analyses: Attrition, Outcome 1 All-cause mortality.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 5 Sensitivity analyses: Attrition
Outcome: 1 All-cause mortality
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anguita 2010 4/30 3/30 2.8 % 1.33 [ 0.33, 5.45 ]
Berger 2010 (1) 10/46 21/96 12.5 % 0.99 [ 0.51, 1.93 ]
Berger 2010 (2) 10/46 35/90 21.8 % 0.56 [ 0.30, 1.03 ]
Jourdain 2007 7/110 11/110 10.1 % 0.64 [ 0.26, 1.58 ]
Schou 2013 46/199 38/208 34.2 % 1.27 [ 0.86, 1.86 ]
Shah 2011 1/68 3/69 2.7 % 0.34 [ 0.04, 3.17 ]
Skvortsov 2015 4/31 10/27 9.8 % 0.35 [ 0.12, 0.98 ]
Troughton 2000 1/33 7/36 6.2 % 0.16 [ 0.02, 1.20 ]
Total (95% CI) 563 666 100.0 % 0.83 [ 0.65, 1.07 ]
Total events: 83 (BNP monitoring), 128 (No BNP monitoring)
Heterogeneity: Chi2 = 13.19, df = 7 (P = 0.07); I2 =47%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Sensitivity analyses: Attrition, Outcome 2 Heart failure mortality.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 5 Sensitivity analyses: Attrition
Outcome: 2 Heart failure mortality
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jourdain 2007 3/110 9/110 41.1 % 0.33 [ 0.09, 1.20 ]
Li 2015 6/94 5/92 23.1 % 1.17 [ 0.37, 3.71 ]
Skvortsov 2015 2/31 6/27 29.3 % 0.29 [ 0.06, 1.32 ]
Troughton 2000 0/33 1/36 6.6 % 0.36 [ 0.02, 8.61 ]
Total (95% CI) 268 265 100.0 % 0.52 [ 0.26, 1.03 ]
Total events: 11 (BNP monitoring), 21 (No BNP monitoring)
Heterogeneity: Chi2 = 3.01, df = 3 (P = 0.39); I2 =0%
Test for overall effect: Z = 1.87 (P = 0.062)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Sensitivity analyses: Attrition, Outcome 3 Heart failure admission.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 5 Sensitivity analyses: Attrition
Outcome: 3 Heart failure admission
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anguita 2010 9/30 8/30 6.5 % 1.13 [ 0.50, 2.52 ]
Jourdain 2007 22/110 48/110 39.2 % 0.46 [ 0.30, 0.70 ]
Schou 2013 37/199 40/208 31.9 % 0.97 [ 0.65, 1.45 ]
Skvortsov 2015 4/31 14/27 12.2 % 0.25 [ 0.09, 0.67 ]
Troughton 2000 5/33 13/36 10.1 % 0.42 [ 0.17, 1.05 ]
Total (95% CI) 403 411 100.0 % 0.63 [ 0.49, 0.81 ]
Total events: 77 (BNP monitoring), 123 (No BNP monitoring)
Heterogeneity: Chi2 = 12.59, df = 4 (P = 0.01); I2 =68%
Test for overall effect: Z = 3.58 (P = 0.00034)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Sensitivity analyses: Attrition, Outcome 4 All-cause admission.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 5 Sensitivity analyses: Attrition
Outcome: 4 All-cause admission
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jourdain 2007 51/110 60/110 26.2 % 0.85 [ 0.65, 1.11 ]
Schou 2013 122/199 123/208 52.5 % 1.04 [ 0.89, 1.21 ]
Shah 2011 22/68 25/69 10.8 % 0.89 [ 0.56, 1.42 ]
Troughton 2000 17/33 25/36 10.4 % 0.74 [ 0.50, 1.10 ]
Total (95% CI) 410 423 100.0 % 0.94 [ 0.83, 1.07 ]
Total events: 212 (BNP monitoring), 233 (No BNP monitoring)
Heterogeneity: Chi2 = 3.45, df = 3 (P = 0.33); I2 =13%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 Sensitivity analyses: Attrition, Outcome 5 Quality of life.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 5 Sensitivity analyses: Attrition
Outcome: 5 Quality of life
Study or subgroup BNP monitoring No BNP monitoring
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schou 2013 199 0 (5.93) 208 0 (8.19) 94.9 % 0.0 [ -1.38, 1.38 ]
Skvortsov 2015 31 -24.1 (14.48413) 27 -7.6 (14.68095) 3.2 % -16.50 [ -24.03, -8.97 ]
Troughton 2000 33 -2 (24.0624) 36 0 (16.7755) 1.9 % -2.00 [ -11.87, 7.87 ]
Total (95% CI) 263 271 100.0 % -0.57 [ -1.92, 0.78 ]
Heterogeneity: Chi2 = 17.94, df = 2 (P = 0.00013); I2 =89%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Duration of FU BNP vs no BNP, Outcome 1 All-cause mortality.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 6 Duration of FU BNP vs no BNP
Outcome: 1 All-cause mortality
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1≤ 1 yr
Beck-da-Silva 2005 1/21 2/20 0.6 % 0.48 [ 0.05, 4.85 ]
Persson 2010 7/126 7/124 2.2 % 0.98 [ 0.36, 2.72 ]
Shah 2011 1/68 3/69 0.9 % 0.34 [ 0.04, 3.17 ]
Skvortsov 2015 4/31 10/27 3.3 % 0.35 [ 0.12, 0.98 ]
Troughton 2000 1/33 7/36 2.1 % 0.16 [ 0.02, 1.20 ]
Subtotal (95% CI) 279 276 9.1 % 0.46 [ 0.25, 0.85 ]
Total events: 14 (BNP monitoring), 29 (No BNP monitoring)
Heterogeneity: Chi2 = 3.56, df = 4 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
2 1-2 yrs
Anguita 2010 4/30 3/30 0.9 % 1.33 [ 0.33, 5.45 ]
Berger 2010 (1) 10/46 21/96 4.2 % 0.99 [ 0.51, 1.93 ]
Berger 2010 (2) 10/46 35/90 7.3 % 0.56 [ 0.30, 1.03 ]
Eurlings 2010 46/174 57/171 17.7 % 0.79 [ 0.57, 1.10 ]
Jourdain 2007 7/110 11/110 3.4 % 0.64 [ 0.26, 1.58 ]
Karlstrom 2011 31/140 29/128 9.3 % 0.98 [ 0.63, 1.53 ]
Krupicka 2010 4/26 3/26 0.9 % 1.33 [ 0.33, 5.38 ]
Pfisterer 2009 40/251 55/248 17.1 % 0.72 [ 0.50, 1.04 ]
Shochat 2012 13/60 7/60 2.2 % 1.86 [ 0.80, 4.33 ]
Subtotal (95% CI) 883 959 63.0 % 0.83 [ 0.69, 0.99 ]
Total events: 165 (BNP monitoring), 221 (No BNP monitoring)
Heterogeneity: Chi2 = 7.78, df = 8 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.043)
3 > 2 yrs
Lainchbury 2010 (3) 20/61 40/122 8.2 % 1.00 [ 0.64, 1.55 ]
Lainchbury 2010 (4) 20/61 40/121 8.3 % 0.99 [ 0.64, 1.54 ]
Schou 2013 46/199 38/208 11.5 % 1.27 [ 0.86, 1.86 ]
Subtotal (95% CI) 321 451 27.9 % 1.11 [ 0.87, 1.41 ]
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(. . . Continued)
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 86 (BNP monitoring), 118 (No BNP monitoring)
Heterogeneity: Chi2 = 0.91, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Total (95% CI) 1483 1686 100.0 % 0.87 [ 0.76, 1.01 ]
Total events: 265 (BNP monitoring), 368 (No BNP monitoring)
Heterogeneity: Chi2 = 19.13, df = 16 (P = 0.26); I2 =16%
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Chi2 = 8.08, df = 2 (P = 0.02), I2 =75%
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Analysis 6.2. Comparison 6 Duration of FU BNP vs no BNP, Outcome 2 Heart failure mortality.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 6 Duration of FU BNP vs no BNP
Outcome: 2 Heart failure mortality
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1≤ 1 yr
Li 2015 6/94 5/92 12.8 % 1.17 [ 0.37, 3.71 ]
Skvortsov 2015 2/31 6/27 16.2 % 0.29 [ 0.06, 1.32 ]
Troughton 2000 0/33 1/36 3.6 % 0.36 [ 0.02, 8.61 ]
Subtotal (95% CI) 158 155 32.6 % 0.64 [ 0.28, 1.48 ]
Total events: 8 (BNP monitoring), 12 (No BNP monitoring)
Heterogeneity: Chi2 = 2.23, df = 2 (P = 0.33); I2 =10%
Test for overall effect: Z = 1.03 (P = 0.30)
2 1 - 2 yrs
Jourdain 2007 3/110 9/110 22.7 % 0.33 [ 0.09, 1.20 ]
Karlstrom 2011 21/140 16/128 42.2 % 1.20 [ 0.66, 2.20 ]
Krupicka 2010 2/26 1/26 2.5 % 2.00 [ 0.19, 20.72 ]
Subtotal (95% CI) 276 264 67.4 % 0.94 [ 0.56, 1.57 ]
Total events: 26 (BNP monitoring), 26 (No BNP monitoring)
Heterogeneity: Chi2 = 3.55, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 0.24 (P = 0.81)
3 > 2 yrs
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (BNP monitoring), 0 (No BNP monitoring)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 434 419 100.0 % 0.84 [ 0.54, 1.30 ]
Total events: 34 (BNP monitoring), 38 (No BNP monitoring)
Heterogeneity: Chi2 = 6.35, df = 5 (P = 0.27); I2 =21%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Chi2 = 0.56, df = 1 (P = 0.45), I2 =0.0%
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Analysis 6.3. Comparison 6 Duration of FU BNP vs no BNP, Outcome 3 Heart failure admission.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 6 Duration of FU BNP vs no BNP
Outcome: 3 Heart failure admission
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1≤ 1 yr
Januzzi 2011 11/75 27/76 7.8 % 0.41 [ 0.22, 0.77 ]
Skvortsov 2015 4/31 14/27 4.4 % 0.25 [ 0.09, 0.67 ]
Troughton 2000 5/33 13/36 3.6 % 0.42 [ 0.17, 1.05 ]
Subtotal (95% CI) 139 139 15.8 % 0.37 [ 0.23, 0.58 ]
Total events: 20 (BNP monitoring), 54 (No BNP monitoring)
Heterogeneity: Chi2 = 0.82, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 4.30 (P = 0.000017)
2 1 - 2 yrs
Anguita 2010 9/30 8/30 2.3 % 1.13 [ 0.50, 2.52 ]
Berger 2010 (1) 13/46 38/96 7.2 % 0.71 [ 0.42, 1.20 ]
Berger 2010 (2) 13/46 55/90 10.8 % 0.46 [ 0.28, 0.75 ]
Jourdain 2007 22/110 48/110 14.0 % 0.46 [ 0.30, 0.70 ]
Karlstrom 2011 55/140 57/128 17.3 % 0.88 [ 0.67, 1.17 ]
Krupicka 2010 6/26 13/26 3.8 % 0.46 [ 0.21, 1.03 ]
Subtotal (95% CI) 398 480 55.4 % 0.65 [ 0.54, 0.79 ]
Total events: 118 (BNP monitoring), 219 (No BNP monitoring)
Heterogeneity: Chi2 = 11.46, df = 5 (P = 0.04); I2 =56%
Test for overall effect: Z = 4.51 (P < 0.00001)
3 > 2 ys
Lainchbury 2010 (3) 22/61 49/121 9.6 % 0.89 [ 0.60, 1.33 ]
Lainchbury 2010 (4) 22/61 41/122 7.9 % 1.07 [ 0.71, 1.63 ]
Schou 2013 37/199 40/208 11.4 % 0.97 [ 0.65, 1.45 ]
Subtotal (95% CI) 321 451 28.9 % 0.97 [ 0.77, 1.23 ]
Total events: 81 (BNP monitoring), 130 (No BNP monitoring)
Heterogeneity: Chi2 = 0.40, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
Total (95% CI) 858 1070 100.0 % 0.70 [ 0.61, 0.80 ]
Total events: 219 (BNP monitoring), 403 (No BNP monitoring)
Heterogeneity: Chi2 = 27.54, df = 11 (P = 0.004); I2 =60%
Test for overall effect: Z = 5.08 (P < 0.00001)
Test for subgroup differences: Chi2 = 15.52, df = 2 (P = 0.00), I2 =87%
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(1) Multidisciplinary care
(2) Usual care
(3) Clinically guided care
(4) Usual care
Analysis 6.4. Comparison 6 Duration of FU BNP vs no BNP, Outcome 4 All-cause admission.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 6 Duration of FU BNP vs no BNP
Outcome: 4 All-cause admission
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1≤ 1 yr
Beck-da-Silva 2005 2/21 4/20 1.3 % 0.48 [ 0.10, 2.32 ]
Shah 2011 22/68 25/69 7.6 % 0.89 [ 0.56, 1.42 ]
Troughton 2000 17/33 25/36 7.3 % 0.74 [ 0.50, 1.10 ]
Subtotal (95% CI) 122 125 16.1 % 0.79 [ 0.58, 1.07 ]
Total events: 41 (BNP monitoring), 54 (No BNP monitoring)
Heterogeneity: Chi2 = 0.76, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
2 1 - 2 yrs
Jourdain 2007 51/110 60/110 18.3 % 0.85 [ 0.65, 1.11 ]
Karlstrom 2011 90/140 90/128 28.7 % 0.91 [ 0.77, 1.08 ]
Subtotal (95% CI) 250 238 47.1 % 0.89 [ 0.77, 1.03 ]
Total events: 141 (BNP monitoring), 150 (No BNP monitoring)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
3 > 2 yrs
Schou 2013 122/199 123/208 36.8 % 1.04 [ 0.89, 1.21 ]
Subtotal (95% CI) 199 208 36.8 % 1.04 [ 0.89, 1.21 ]
Total events: 122 (BNP monitoring), 123 (No BNP monitoring)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Total (95% CI) 571 571 100.0 % 0.93 [ 0.84, 1.03 ]
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(. . . Continued)
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 304 (BNP monitoring), 327 (No BNP monitoring)
Heterogeneity: Chi2 = 4.29, df = 5 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 3.24, df = 2 (P = 0.20), I2 =38%
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Analysis 6.5. Comparison 6 Duration of FU BNP vs no BNP, Outcome 5 Quality of life.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 6 Duration of FU BNP vs no BNP
Outcome: 5 Quality of life
Study or subgroup BNP monitoring No BNP monitoring
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1≤ 1 yr
Beck-da-Silva 2005 21 -12.1 (24.1514) 20 -11.9 (25.1314) 0.6 % -0.20 [ -15.30, 14.90 ]
Januzzi 2011 75 -10.5 (24.491) 76 -6 (25.0523) 2.1 % -4.50 [ -12.40, 3.40 ]
Lainchbury 2010 (1) 121 -7.7 (22.1705) 121 -10.1 (16.0253) 5.6 % 2.40 [ -2.47, 7.27 ]
Skvortsov 2015 31 -24.1 (14.48413) 27 -7.6 (14.68095) 2.4 % -16.50 [ -24.03, -8.97 ]
Troughton 2000 33 -2 (24.0624) 36 0 (16.7755) 1.4 % -2.00 [ -11.87, 7.87 ]
Subtotal (95% CI) 281 280 12.1 % -3.14 [ -6.46, 0.19 ]
Heterogeneity: Chi2 = 17.37, df = 4 (P = 0.002); I2 =77%
Test for overall effect: Z = 1.85 (P = 0.064)
2 1 - 2 yrs
Eurlings 2010 174 -27 (21.5182) 171 -25 (19.5995) 7.1 % -2.00 [ -6.34, 2.34 ]
Pfisterer 2009 251 -10.1 (19.0337) 248 -14.7 (21.052) 10.8 % 4.60 [ 1.08, 8.12 ]
Subtotal (95% CI) 425 419 17.9 % 1.98 [ -0.76, 4.72 ]
Heterogeneity: Chi2 = 5.35, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 1.42 (P = 0.16)
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(. . . Continued)
Study or subgroup BNP monitoring No BNP monitoring
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
3 > 2 yrs
Schou 2013 199 0 (5.93) 208 0 (8.19) 69.9 % 0.0 [ -1.38, 1.38 ]
Subtotal (95% CI) 199 208 69.9 % 0.0 [ -1.38, 1.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 905 907 100.0 % -0.03 [ -1.18, 1.13 ]
Heterogeneity: Chi2 = 28.16, df = 7 (P = 0.00021); I2 =75%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 5.43, df = 2 (P = 0.07), I2 =63%
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Analysis 7.1. Comparison 7 Subgroup: BNP vs NT-proBNP, Outcome 1 All-cause mortality.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 7 Subgroup: BNP vs NT-proBNP
Outcome: 1 All-cause mortality
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NT-proBNP
Berger 2010 (1) 10/46 21/96 4.2 % 0.99 [ 0.51, 1.93 ]
Berger 2010 (2) 10/46 35/90 7.3 % 0.56 [ 0.30, 1.03 ]
Eurlings 2010 46/174 57/171 17.7 % 0.79 [ 0.57, 1.10 ]
Lainchbury 2010 (3) 20/61 40/122 8.2 % 1.00 [ 0.64, 1.55 ]
Lainchbury 2010 (4) 20/61 40/121 8.3 % 0.99 [ 0.64, 1.54 ]
Persson 2010 7/126 7/124 2.2 % 0.98 [ 0.36, 2.72 ]
Pfisterer 2009 40/251 55/248 17.1 % 0.72 [ 0.50, 1.04 ]
Schou 2013 46/199 38/208 11.5 % 1.27 [ 0.86, 1.86 ]
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(. . . Continued)
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shochat 2012 13/60 7/60 2.2 % 1.86 [ 0.80, 4.33 ]
Skvortsov 2015 4/31 10/27 3.3 % 0.35 [ 0.12, 0.98 ]
Troughton 2000 1/33 7/36 2.1 % 0.16 [ 0.02, 1.20 ]
Subtotal (95% CI) 1088 1303 83.9 % 0.87 [ 0.75, 1.01 ]
Total events: 217 (BNP monitoring), 317 (No BNP monitoring)
Heterogeneity: Chi2 = 16.79, df = 10 (P = 0.08); I2 =40%
Test for overall effect: Z = 1.78 (P = 0.075)
2 BNP
Anguita 2010 4/30 3/30 0.9 % 1.33 [ 0.33, 5.45 ]
Beck-da-Silva 2005 1/21 2/20 0.6 % 0.48 [ 0.05, 4.85 ]
Jourdain 2007 7/110 11/110 3.4 % 0.64 [ 0.26, 1.58 ]
Karlstrom 2011 31/140 29/128 9.3 % 0.98 [ 0.63, 1.53 ]
Krupicka 2010 4/26 3/26 0.9 % 1.33 [ 0.33, 5.38 ]
Shah 2011 1/68 3/69 0.9 % 0.34 [ 0.04, 3.17 ]
Subtotal (95% CI) 395 383 16.1 % 0.89 [ 0.62, 1.28 ]
Total events: 48 (BNP monitoring), 51 (No BNP monitoring)
Heterogeneity: Chi2 = 2.33, df = 5 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Total (95% CI) 1483 1686 100.0 % 0.87 [ 0.76, 1.01 ]
Total events: 265 (BNP monitoring), 368 (No BNP monitoring)
Heterogeneity: Chi2 = 19.13, df = 16 (P = 0.26); I2 =16%
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
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Analysis 7.2. Comparison 7 Subgroup: BNP vs NT-proBNP, Outcome 2 Heart failure mortality.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 7 Subgroup: BNP vs NT-proBNP
Outcome: 2 Heart failure mortality
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NT-proBNP
Skvortsov 2015 2/31 6/27 16.2 % 0.29 [ 0.06, 1.32 ]
Troughton 2000 0/33 1/36 3.6 % 0.36 [ 0.02, 8.61 ]
Subtotal (95% CI) 64 63 19.8 % 0.30 [ 0.08, 1.19 ]
Total events: 2 (BNP monitoring), 7 (No BNP monitoring)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
2 BNP
Jourdain 2007 3/110 9/110 22.7 % 0.33 [ 0.09, 1.20 ]
Karlstrom 2011 21/140 16/128 42.2 % 1.20 [ 0.66, 2.20 ]
Krupicka 2010 2/26 1/26 2.5 % 2.00 [ 0.19, 20.72 ]
Li 2015 6/94 5/92 12.8 % 1.17 [ 0.37, 3.71 ]
Subtotal (95% CI) 370 356 80.2 % 0.98 [ 0.61, 1.56 ]
Total events: 32 (BNP monitoring), 31 (No BNP monitoring)
Heterogeneity: Chi2 = 3.62, df = 3 (P = 0.31); I2 =17%
Test for overall effect: Z = 0.10 (P = 0.92)
Total (95% CI) 434 419 100.0 % 0.84 [ 0.54, 1.30 ]
Total events: 34 (BNP monitoring), 38 (No BNP monitoring)
Heterogeneity: Chi2 = 6.35, df = 5 (P = 0.27); I2 =21%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Chi2 = 2.51, df = 1 (P = 0.11), I2 =60%
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Analysis 7.3. Comparison 7 Subgroup: BNP vs NT-proBNP, Outcome 3 Heart failure admission.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 7 Subgroup: BNP vs NT-proBNP
Outcome: 3 Heart failure admission
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 NT-proBNP
Berger 2010 (1) 13/46 55/90 9.3 % 0.46 [ 0.28, 0.75 ]
Berger 2010 (2) 13/46 38/96 8.8 % 0.71 [ 0.42, 1.20 ]
Januzzi 2011 11/75 27/76 7.4 % 0.41 [ 0.22, 0.77 ]
Lainchbury 2010 (3) 22/61 41/122 10.4 % 1.07 [ 0.71, 1.63 ]
Lainchbury 2010 (4) 22/61 49/121 10.7 % 0.89 [ 0.60, 1.33 ]
Schou 2013 37/199 40/208 10.6 % 0.97 [ 0.65, 1.45 ]
Skvortsov 2015 4/31 14/27 4.2 % 0.25 [ 0.09, 0.67 ]
Troughton 2000 5/33 13/36 4.6 % 0.42 [ 0.17, 1.05 ]
Subtotal (95% CI) 552 776 66.1 % 0.65 [ 0.48, 0.89 ]
Total events: 127 (BNP monitoring), 277 (No BNP monitoring)
Heterogeneity: Tau2 = 0.12; Chi2 = 18.84, df = 7 (P = 0.01); I2 =63%
Test for overall effect: Z = 2.68 (P = 0.0073)
2 BNP
Anguita 2010 9/30 8/30 5.5 % 1.13 [ 0.50, 2.52 ]
Jourdain 2007 22/110 48/110 10.2 % 0.46 [ 0.30, 0.70 ]
Karlstrom 2011 55/140 57/128 12.6 % 0.88 [ 0.67, 1.17 ]
Krupicka 2010 6/26 13/26 5.6 % 0.46 [ 0.21, 1.03 ]
Subtotal (95% CI) 306 294 33.9 % 0.68 [ 0.43, 1.05 ]
Total events: 92 (BNP monitoring), 126 (No BNP monitoring)
Heterogeneity: Tau2 = 0.12; Chi2 = 8.70, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 1.73 (P = 0.084)
Total (95% CI) 858 1070 100.0 % 0.67 [ 0.53, 0.84 ]
Total events: 219 (BNP monitoring), 403 (No BNP monitoring)
Heterogeneity: Tau2 = 0.10; Chi2 = 27.54, df = 11 (P = 0.004); I2 =60%
Test for overall effect: Z = 3.36 (P = 0.00077)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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Analysis 7.4. Comparison 7 Subgroup: BNP vs NT-proBNP, Outcome 4 All-cause admission.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 7 Subgroup: BNP vs NT-proBNP
Outcome: 4 All-cause admission
Study or subgroup BNP monitoring No BNP monitoring Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NT-proBNP
Schou 2013 122/199 123/208 36.8 % 1.04 [ 0.89, 1.21 ]
Troughton 2000 17/33 25/36 7.3 % 0.74 [ 0.50, 1.10 ]
Subtotal (95% CI) 232 244 44.1 % 0.99 [ 0.85, 1.14 ]
Total events: 139 (BNP monitoring), 148 (No BNP monitoring)
Heterogeneity: Chi2 = 2.37, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.16 (P = 0.87)
2 BNP
Beck-da-Silva 2005 2/21 4/20 1.3 % 0.48 [ 0.10, 2.32 ]
Jourdain 2007 51/110 60/110 18.3 % 0.85 [ 0.65, 1.11 ]
Karlstrom 2011 90/140 90/128 28.7 % 0.91 [ 0.77, 1.08 ]
Shah 2011 22/68 25/69 7.6 % 0.89 [ 0.56, 1.42 ]
Subtotal (95% CI) 339 327 55.9 % 0.88 [ 0.77, 1.01 ]
Total events: 165 (BNP monitoring), 179 (No BNP monitoring)
Heterogeneity: Chi2 = 0.85, df = 3 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.075)
Total (95% CI) 571 571 100.0 % 0.93 [ 0.84, 1.03 ]
Total events: 304 (BNP monitoring), 327 (No BNP monitoring)
Heterogeneity: Chi2 = 4.29, df = 5 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 1.24, df = 1 (P = 0.27), I2 =19%
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Analysis 7.5. Comparison 7 Subgroup: BNP vs NT-proBNP, Outcome 5 Quality of life.
Review: B-type natriuretic peptide-guided treatment for heart failure
Comparison: 7 Subgroup: BNP vs NT-proBNP
Outcome: 5 Quality of life
Study or subgroup BNP monitoring No BNP monitoring
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 NT-proBNP
Eurlings 2010 174 -27 (21.5182) 171 -25 (19.5995) 7.1 % -2.00 [ -6.34, 2.34 ]
Januzzi 2011 75 -10.5 (24.491) 76 -6 (25.0523) 2.1 % -4.50 [ -12.40, 3.40 ]
Lainchbury 2010 (1) 121 -7.7 (22.1705) 121 -10.1 (16.0253) 5.6 % 2.40 [ -2.47, 7.27 ]
Pfisterer 2009 251 -10.1 (19.0337) 248 -14.7 (21.052) 10.8 % 4.60 [ 1.08, 8.12 ]
Schou 2013 199 0 (5.93) 208 0 (8.19) 69.9 % 0.0 [ -1.38, 1.38 ]
Skvortsov 2015 31 -24.1 (14.48413) 27 -7.6 (14.68095) 2.4 % -16.50 [ -24.03, -8.97 ]
Troughton 2000 33 -2 (24.0624) 36 0 (16.7755) 1.4 % -2.00 [ -11.87, 7.87 ]
Subtotal (95% CI) 884 887 99.4 % -0.02 [ -1.19, 1.14 ]
Heterogeneity: Chi2 = 28.16, df = 6 (P = 0.00009); I2 =79%
Test for overall effect: Z = 0.04 (P = 0.97)
2 BNP
Beck-da-Silva 2005 21 -12.1 (24.1514) 20 -11.9 (25.1314) 0.6 % -0.20 [ -15.30, 14.90 ]
Subtotal (95% CI) 21 20 0.6 % -0.20 [ -15.30, 14.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Total (95% CI) 905 907 100.0 % -0.03 [ -1.18, 1.13 ]
Heterogeneity: Chi2 = 28.16, df = 7 (P = 0.00021); I2 =75%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Subgroup data: Setting, NYHA, LVEF (considered post-hoc)
Study Participants
treated
in commu-
nity or sec-
ondary care
Baseline NYHA classification (stages I - IV) Baseline left ventricular ejection fraction
(LVEF, %)
Study inclu-
sion criteria
Intervention
group
Control
group
Comment
in text
Study inclu-
sion criteria
Intervention
group
(mean, SD
unless
stated)
Control
group
(mean, SD
unless
stated)
Anguita
2010
Hospital Stage ≥ III Stage
III 73%, IV
27%
Stage
III 63%, IV
37%
Not in-
clusion cri-
terion
44 (18) 46 (18)
Beck-da-
Silva 2005
Hospital
(outpatient)
Stages II - III 2.6 ± 0.7
(mean, SD)
2.4 ± 0.6
(mean, SD)
<40% 23.8 ± 8.8 20.9 ± 9.2
Berger 2010 Hospital &
community
Stages III -
IV
Not stated Not stated <40% NS NS
Eurlings
2010
Hospital Not in-
clusion cri-
terion
Stage I = 11.
5%, II = 64.
9%, III = 23.
6%
stage I = 9.
9%, II = 70.
8%, III = 19.
3%
Not in-
clusion cri-
terion
34.9 ± 13.7 36.7 ± 14.8
Januzzi
2011
Hospital Stages II - IV Stage II or
III = 85.5%
Stage II or
III = 84.2%
≤ 40% 28 ± 8.7 25.9 ± 8.3
Jourdain
2007
Hospital
(outpatient)
Stages II - III 2.29 ±0.6
(mean, SD)
2.21 ± 0.62
(mean, SD)
<45% 29.9 ± 7.7 31.8 ± 8.4
Karlstrom
2011
Hospital Stages II - IV Stage II =
32%, III =
52%, IV =
15%
Stage II =
27%, III =
59%, IV =
14%
<40% <30% =
57%
<30% =
58%
Krupicka
2010
Hospital Stages III -
IV
2.1 (0.3)
(mean, SD)
2.1 (0.3)
(mean, SD)
≤ 45% 36.1% (7.2) 32.3% (9.6)
Lainchbury
2010
Hospital &
community
Not in-
clusion cri-
terion
NT-
proBNP
group:
stage I 12%,
II 68%, III
18%, IV 2%
Clinically-
guided
group: Stage
I
7%, II 66%,
III 25%, IV
Not inclu-
sion crite-
rion though
deliberated
included pa-
tients with
40 ±15 CG = 39 ±
15, UC = 37
± 15
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Table 1. Subgroup data: Setting, NYHA, LVEF (considered post-hoc) (Continued)
2%; Usual
care: stage I
7%, II 67%,
III 25%, IV
1%
preserved
LVEF
Li 2015 Hospital Stages III -
IV
NS NS Not in-
clusion cri-
terion
30 ± 8.1 28 ± 7.9
Maeder
2013
Hospital
(outpatient)
Stages ≤ II 49 (83) ≥
III (median,
IQR)
53 (83) ≥
III (median,
IQR)
’symptoms
improved
similarly’ (at
6 months)
> 45% 56 ± 6 56 ± 7
Persson
2010
Community Stage II - IV Stage
II 62%, III
38%
Stage
II 61%, III
39%
’Improve-
ments in
NYHA class
and dys-
pnoea symp-
toms
were seen in
both alloca-
tion groups,
but with no
significant
differences
between the
groups’
<50% 31 (9) 33 (7)
Pfisterer
2009
Hospital
(outpatient)
Stages ≤ II 186 ≥ III
(n)
185 ≥ III
(n)
≤ 45% 29.8 (7.7) 29.7 (7.9)
Schou 2013 Hospital Not in-
clusion cri-
terion
Stage I - II
86 %
Stage I - II
85 %
<45% 30
(14-45) me-
dian (range)
30
(15-45) me-
dian (range)
Shah 2011 Hospital Stage III - IV Authors
have no data
for baseline
NYHA
Authors
have no data
for baseline
NYHA
<35% 20
(15-25) me-
dian (range)
20
(15-25) me-
dian (range)
Shochat
2012
Hospital Not stated 2.53 (mean) 2.34 (mean) Not in-
clusion cri-
terion
23 (6) 23 (7)
Skvortsov
2015
Hospital
(outpatient)
Stage III - IV Stage
III 23%, IV
76%
Stage
III 26%, IV
74%
At hospital
admission
<40% 29.2 (6.1) 29.4 (6.1)
103B-type natriuretic peptide-guided treatment for heart failure (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 1. Subgroup data: Setting, NYHA, LVEF (considered post-hoc) (Continued)
Troughton
2000
Hospital Stages II - IV Stage II
72%, overall
2.3 (mean)
Stage II
67%, overall
2.3 (mean)
<40% 28 26
Table 2. Subgroup data: Biomarker target, baseline and change from baseline measurements
Study Tar-
get BNP/NT-
proBNP (pg/
mL, unless
stated)
Baseline BNP or NT-proBNP measurement
(units in pg/mL and given as mean (SD), unless stated)
BNP/NT-
proBNP drop
(as % of base-
line)
(units in pg/
mL and given
as mean (SD),
unless stated)
Biomarker Study inclu-
sion criteria
Intervention
group
Control group Comment in
text
Anguita 2010 100 BNP No inclusion
threshold
57 (77) 65 (97) No percentage
drop reported.
BNP at 18
months fol-
low-up: BNP-
guided group
14 (20); con-
trol group 111
(71)
Beck-da-Silva
2005
No target set/
stated
BNP No inclusion
threshold
502.3 (411.3) 701.6 (409.9) No percentage
drop reported.
BNP at fol-
low-up: con-
trol arm 626.8
(325.8);
BNP arm 477.
8 (406.9)
Berger 2010 < 2200 NT
= proBNP (re-
ported in IPD
analysis
by Troughton
2014)
NT-proBNP No inclusion
threshold
2216 (355-
9649) mean
(95% CI)
Multi-
displinary care
2469 (355 -
18487; Usual
care
2359 (355 -
15603) mean
(95% CI)
No percentage
drop reported.
NT -proBNP
change
from baseline
to FU graphi-
cally shown in
Berger 2010 (
Figure 4). De-
crease in NT-
proBNP more
104B-type natriuretic peptide-guided treatment for heart failure (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 2. Subgroup data: Biomarker target, baseline and change from baseline measurements (Continued)
apparent in
NT-proBNP-
guided group
than multidis-
plinary group.
No decrease in
usual care
group
Eurlings 2010 Set individu-
ally for each
participant as
the low-
est level at dis-
charge or at 2
weeks follow-
up
NT-proBNP NT-proBNP
levels at ad-
mission: mini-
mum 1,700
pg/ml. Addi-
tionally NT-
proBNP levels
during hospi-
talisation, de-
fined as a de-
crease of more
than
10%, with a
drop in NT-
proBNP levels
of at least 850
pg/
ml, from ad-
mission to dis-
charge
2961 (1383 -
5144) median
(IQR)
2936 (1291-
5525) median
(IQR)
Outcome data
avail-
able by sub-
group baseline
BNP (above or
below
discharge NT-
proBNP 2950
pg/ml)
No percentage
drop reported.
Median (IQR)
at 12 months
follow-up:
NT-proBNP-
guided group -
432 (-1392 to
297);
Clincially-
guided group -
572 (-1329 to
434)
Januzzi 2011 ≤ 1000 NT-proBNP No inclusion
threshold
2344
(median)
1946
(median)
No percentage
drop reported.
Median NT-
proBNP
at follow-up:
Standard care
group 1844 (P
= 0.61 follow-
up vs baseline)
; NT-
proBNP-
guided group
1125 (P=0.01
vs baseline)
Jourdain 2007 < 100 BNP No inclusion
threshold
352 (260)
mean (SD)
Not measured No percentage
drop reported.
BNP-
guided group
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Table 2. Subgroup data: Biomarker target, baseline and change from baseline measurements (Continued)
only shown
graphically in
Jourdain 2007
(figure
5): mean BNP
level drops
over time and
% of patients
achieving tar-
get increases
Karlstrom
2011
<150 ng/L in
patients under
75; <300 ng/
L in patients
over 75 yrs
BNP No inclusion
threshold
808.2 (676.
1) ng/L, mean
(SD)
898.
9 (915.3 ng/L,
mean (SD)
No percentage
drop reported.
BNP at fol-
low-up: con-
trol group 457
(603), BNP-
guided group
403 (468)
Krupicka
2010
<100 BNP No inclusion
threshold
704 (228-
2852) median
(range)
633 (276-
3756) median
(range)
No percentage
drop reported.
In the BNP
group 90% of
patients man-
age to reduce
BNP to <400
pg/mL; of this
90%, 2/
3 of patients to
achieve <100
pg/mL. Email
from
author “We do
not have BNP
values of the
Clinical group
at the
end of follow-
up. Median
BNP value af-
ter 6 months
in BNP group
was 235pg/
ml. (At hos-
pital discharge
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Table 2. Subgroup data: Biomarker target, baseline and change from baseline measurements (Continued)
704pg/ml; af-
ter 1 month
328.5pg/ml;
after 3 months
253pg/ml).”
Lainchbury
2010
< 150 µmol/L NT-proBNP No inclusion
threshold
2012 (516-
10233)
median (IQR)
Clinically-
guided group:
1996 (425-
6588); Usual
care: 2012
(425-10571)
median (IQR)
No percentage
drop reported.
No follow-
up data. Com-
ment in text
’Plasma NT-
proBNP lev-
els fell simi-
larly within 6
months
of randomisa-
tion in
both the NT-
proBNP and
CG groups
(by 20%
and 23%, re-
spectively; P 0.
001)’
Li 2015 50% of basal
level or < 300
BNP No inclusion
threshold
1167.8 (219.
9) mean (SD)
1145.8 (224.
9) mean (SD)
No percentage
drop reported.
Change
in BNP level
shown in Fig-
ure
2 (Li 2015)
. ’BNP value
decreased dra-
matically over
the duration
of medication,
but there was
no
difference be-
tween the two
groups.’
Maeder 2013 < 400 in pa-
tients younger
than 75 years;
< 800 in pa-
tients aged 75
NT-proBNP N-terminal
BNP level of
400 pg/mL or
higher in pa-
tients younger
2210 (1514-
4081) ng/L,
median (IQR)
2191 (1478-
4890) ng/L,
median (IQR)
Maeder 2013
reports: ’NT-
proBNP was
reduced simi-
larly in
107B-type natriuretic peptide-guided treatment for heart failure (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 2. Subgroup data: Biomarker target, baseline and change from baseline measurements (Continued)
years or older than 75 years
and a level of
800 pg/mL or
higher in pa-
tients aged 75
years or older
patients allo-
cated to NT-
proBNP-
guided
or symptom-
guided man-
agement. The
proportion of
patients with
NT-proBNP
below the tar-
get was
low through-
out the study
period and did
not
significantly
differ between
groups (Figure
2C) although
it tended to be
lower in the
NT-proBNP-
guided group
Persson 2010 At least a 50%
reduction
from baseline
NT-proBNP
NT-proBNP Elevated NT-
proBNP levels
(males > 800
ng/L, females
> 1000 ng/L)
2661 (2.1)
ng/L, geomet-
ric mean(coef-
ficient of vari-
ation, %)
2429 (2.1)
ng/L, geomet-
ric mean(coef-
ficient of vari-
ation, %)
No percentage
drop reported.
Geometric
Mean (SD)
at follow-up:
NT-proBNP-
guided group
- 301 ng/L to
2360 ng/L;
control group
-362 ng/L
to 2067 ng/
L. Comment
in text ’sim-
ilar modest
decrease (
10%) in NT-
proBNP from
baseline to
end-of study
was observed
in both
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Table 2. Subgroup data: Biomarker target, baseline and change from baseline measurements (Continued)
groups……NT-
proBNP levels
were reduced
by .50% in
24 (19%) and
27 (22%), of
patients with
and without
NT-proBNP-
guided treat-
ment, respec-
tively’
Pfisterer 2009 < 400 in pa-
tients younger
than 75 years;
< 800 in pa-
tients aged 75
years or older
NT-proBNP N-terminal
BNP level of
400 pg/mL or
higher in pa-
tients younger
than 75 years
and a level of
800 pg/mL or
higher in pa-
tients aged 75
years or older
3998 (2075-
7220) median
(IQR)
4657 (2455-
7520) median
(IQR)
No percentage
drop reported.
No follow-up
data. Pfisterer
2009 (fig-
ure 3b) graph-
ically
shows data for
NT-proBNP
changes over
6 months (by
age)
. Comment in
text ’There
were no sig-
nificant differ-
ences between
the 2 treat-
ment groups
by
by N-terminal
BNP level (P=
.06 vs P=.30).’
Schou 2013 No target set/
stated
NT-proBNP NT-proBNP
≥ 1000 pg/
mL
after up-titra-
tion (i.e. at
the randomi-
sation visit)
1884 (1033-
10435)
average statis-
tic not stated)
2042 (1023-
9668) average
statistic not
stated
No percentage
drop reported.
Change in
NT-
proBNP dur-
ing follow-up:
NT-proBNP-
guided group -
129 (-722 to
674) median
(IQR); Clini-
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Table 2. Subgroup data: Biomarker target, baseline and change from baseline measurements (Continued)
cally managed
group -26 (-
681 to 751)
median (IQR)
. Comment in
text: ’Patients
in whom NT-
proBNP
increased
≤ 30% dur-
ing the follow
up period had
a higher fre-
quency of ad-
mission (69%
vs. 47%, P = 0.
002), a higher
number of ad-
mission
days (median)
(14 days vs.
5 days, P= 0.
003), a higher
number of ad-
missions (me-
dian) (2 vs. 1,
P = 0.009), a
lower quality
of life (mean
difference) (6
points, P = 0.
032)
, and a poorer
functional
class (37% vs.
18% in func-
tional class III-
IV, P = 0.001)
.’
Shah 2011 Discharge
BNP
BNP No inclusion
threshold
453 (221-
1135) median
(IQR)
440 (189
-981) median
(IQR)
No percentage
drop reported.
Median (IQR)
BNP at fol-
low-up: BNP-
guided group
412.
5 (111,894);
control (con-
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Table 2. Subgroup data: Biomarker target, baseline and change from baseline measurements (Continued)
gestion score)
group 471
(235.5, 1180)
Shochat 2012 No target set/
stated
NT-proBNP Email from
author
confirmed
’NT-ProBNP
> 2000 at day
of randomisa-
tion’
5868 (2532) 5820 (2434) No percentage
drop reported.
Skvortsov
2015
<1000 pg/mL
or at least 50%
reduction
from baseline
NT-proBNP
at discharge
NT-proBNP > 1400 pg/mL
at hospital ad-
mission
3750 (2224-
6613)
median (IQR)
2783.0 (2021.
5- 4827.5)
median (IQR)
At hospital
discharge
At 6 months:
NT-proBNP-
guided group:
53% (Median
drop (QR)
: 1585.5 (976.
6, 2742.5))
Con-
trol group: 10.
2% (median
(IQR):
2189.0 (1954.
0, 3688.5))
Troughton
2000
200 µmol/L NT-proBNP No inclusion
threshold
217 µmol/L,
mean
251 µmol/l,
mean
No percentage
drop reported.
At 6 months
follow-up:Nt-
proBNP-
guided group
decreased
by 79 pmol/
L, mean; clin-
ically-
guided group
decreased by 3
pmol/L, mean
(P = 0.16)
Table 3. Adverse event data
Study Adverse events
Participants (N) Missing participants (N) Number of adverse events (defini-
tions not
consistent or not stated; not clear
Additional
data either from
published articles
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Table 3. Adverse event data (Continued)
whether first event per participant
or every event)
or supplied by au-
thor
Interven-
tion
group
Control
group
Total Interven-
tion group
Control
group
Total Interven-
tion
group
Control
group
Total
Januzzi
2011
75 76 151 6 6 12 30 23 53 No signif-
icant differences
between groups.
No specific event
showed a signifi-
cant difference
between groups
Events in inter-
ven-
tion group: Ab-
dominal pain (1);
acute renal failure
(4); anaemia (1)
; atrial fibrillation
(2); cough (2); di-
arrhoea (2); dizzi-
ness (5); fever (1)
; gastrointestinal
bleeding (1); hy-
per/
hypokalaemia (3)
; hypotension (4);
respiratory infec-
tion (2); syncope
(2)
Events in con-
trol group: Ab-
dominal pain (1);
acute renal failure
(3); anaemia (0)
; atrial fibrillation
(5); cough (1); di-
arrhoea (1); dizzi-
ness (4); fever (1)
; gastrointestinal
bleeding (1); hy-
per/
hypokalaemia (1)
; hypotension (0);
respiratory infec-
tion (4); syncope
(1)
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Table 3. Adverse event data (Continued)
Krupicka
2010
26 26 52 0 0 0 7 0 7 Email
from author 17.
10.14 confirmed:
Hyper-
kalaemia (n = 2)
; orthostatic hy-
potension (n = 2)
; bradycardia (n =
3)
Maeder
2013
59 64 123 12 12 24 Not
reported
Not
reported
66 Maeder 2013 re-
ported: “58% of
the patients in
theNT-proBNP-
guided and 50%
in the symptom-
guided group had
at least one SAE
(p=0.32). SAE’s
related to renal
failure (14% ver-
sus 2%, p=0.01)
were
more common in
theNT-proBNP-
guided group,
whereas hypoten-
sion tended to
be less common
(0% versus 8%,
p=0.06).” No ad-
ditional informa-
tion
Persson
2010
126 124 250 8 7 15 42 39 81 No additional in-
formation
provided
Pfisterer
2009
251 248 499 32 29 61 123 113 236 P = 0.47
Renal im-
pairment: inter-
vention group n =
4, control group
n = 5 (P = 0.64)
Hypotension: in-
tervention group
n = 6, control
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Table 3. Adverse event data (Continued)
group n = 3 (P =
0.22)
No other type of
adverse event de-
scribed.
Adverse events ≥
75 years old pa-
tients: interven-
tion group 10.
5% vs control
group 5.5% (P =
0.12)
Adverse events in
< 75 years old pa-
tients: interven-
tion group 3.7%
vs. control group
4.9% (P = 0.74)
Troughton
2000
33 36 69 0 0 0 13 9 22 P = 0.32
No additional in-
formation
provided
Table 4. Sensitivity Analyses
Outcome Studies(N) Participants (n) Risk ratio 95% Confidence intervals
Outcome blinding (low risk of bias studies only)
Analysis 4.1 All-cause mortality 5 1663 0.94 0.80 to 1.11
Analysis 4.2 Heart failure mortal-
ity
1 268 1.20 0.66 to 2.20
Analysis 4.3 Heart failure admis-
sion
4 1318 0.83 0.71 to 0.98
Analysis 4.4 All-cause admission 2 675 0.98 0.88 to 1.10
Analysis 4.5 Quality of life 3 994 -0.01 -1.28 to 1.27
Incomplete data (low risk of bias studies only)
Analysis 5.1 All-cause mortality 7 1229 0.83 0.65 to 1.07
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Table 4. Sensitivity Analyses (Continued)
Analysis 5.2 Heart failure mortal-
ity
4 533 0.52 0.26 to 1.03
Analysis 5.3 Heart failure admis-
sion
5 814 0.63 0.49 to 0.81
Analysis 5.4 All-cause admission 4 833 0.94 0.83 to 1.07
Analysis 5.5 Quality of life 3 534 -0.57 -1.92 to 0.78
Table 5. Agreements and disagreements with other reviews
Outcome Review Number of
RCTs
N Summary measure
(hazard ratio HR,
risk ratio RR, odds
ratio OR,
weighted mean dif-
ference WMD)
95% Confi-
dence intervals
p-value Heterogeneity
(I2)
All-
cause mor-
tality (all pa-
tients)
Felker 2009 6 1627 HR 0.69 0.55 to 0.86 Not reported Not reported
Pora-
pakkham
2010
8 1726 RR 0.76 0.63 to 0.91 0.003 Not reported
Li 2013 11 2414 RR 0.83 0.69 to 0.99 0.0.35 0%
Savarese
2013
12 2686 OR 0.74 0.6 to 0.91 0.005 0%
Li 2014 Not
reported
Not
reported
RR 0.79 0.67 to 0.92 0.004 Not reported
Troughton
2014
10 2280 HR 0.82 0.67 to 1.00 0.05 0%
Xin 2015 14 3004 RR 0.94 0.81 to 1.08 0.39 3%
This review 15 3169 RR 0.87 0.76 to 1.01 0.06 16%
Heart failure
admission
Li 2013 7 1190 RR 0.65 0.5 to 0.84 0.001 52.30%
Savarese
2013
8 1920 OR 0.55 0.4 to 0.77 <0.0001 58.20%
Li 2014 Not
reported
Not
reported
RR 0.67 0.46 to 0.97 0.03 Not reported
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Table 5. Agreements and disagreements with other reviews (Continued)
Troughton
2014
11 2431 HR 0.74 0.60 to 0.90 0.002 24.00%
Xin 2015 11 2572 RR 0.79 0.63 to 0.98 0.03 67.00%
This review 10 1928 RR 0.7 0.61 to 0.80 <0.0001 60.00%
All-cause
admission
Pora-
pakkham
2010
3 330 RR 0.82 0.64 to 1.05 0.12 Not reported
Savarese
2013
5 1108 OR 0.8 0.63- 1.02 0.077 0%
Xin 2015 7 1627 RR 0.97 0.89 to 1.07 0.56 8%
This review 6 1142 RR 0.93 0.84 to 1.03 0.15 0%
Adverse
events
Li 2014 Not
reported
Not
reported
RR 1.15 0.99 to 1.342 0.69 Not reported
Ad-
verse events
(symp-
tomatic hy-
potension)
Xin 2015 4 838 RR 1.72 0.59 to 5.05 0.32 43%
Ad-
verse events
(hyper/hy-
pokalemia)
Xin 2015 2 354 RR 1.34 0.42 to 4.34 0.62 0%
Adverse
events (renal
dysfunc-
tion)
Xin 2015 3 769 RR 1.46 0.34 to 6.24 0.21 0%
Adverse
events (se-
vere cough)
Xin 2015 2 220 RR 1.93 0.69 to 5.37 0.21 0%
Quality of
life
Xin 2015 5 1172 WMD -1.29 -3.81 to 1.22 0.31 49%
This review 8 1812 WMD -0.03 -1.18 to 1.13 0.97 75%
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Table 6. Subgroup agreements and disagreements with other reviews
Outcome Review Number of
RCTs
N Summary measure
(hazard ratio HR,
risk ratio RR, odds
ratio OR, weighted
mean difference
WMD)
95%
Confidence in-
tervals
P value Heterogeneity (I
2)
All-cause
mortality (<
75 years)
Pora-
pakkham
2010
2 741 RR 0.52 0.33 to 0.82 0.005 Not reported
This review 3 420 RR 0.73 0.49 to 1.10 0.13 58%
All-cause
mortality (>
75 years)
Pora-
pakkham
2010
2 741 RR 0.94 0.71 to 1.25 0.7 Not reported
This review 3 410 RR 1.23 0.96 to 1.57 0.1 58%
All-cause
mortality (<
72 years)
Xin 2015 7 Not
reported
RR 0.82 0.58 to 1.17 Not reported 0%
All-cause
mortality (≥
72 years)
Xin 2015 7 Not
reported
RR 0.96 0.83 to 1.13 Not reported 24%
Heart failure
admission
(<70 years)
Li 2013 Not
reported
Not
reported
RR 0.45 0.33 to 0.61 < 0.0001 0%
Li 2014 Not
reported
Not
reported
RR 0.44 0.31 to 0.63 Not reported Not reported
Heart failure
admission
(>70 years)
Li 2013 Not reported
Li 2014 Not
reported
Not
reported
RR 0.89 0.74 - 1.07 Not reported Not reported
All-cause
admission (<
72 years)
Xin 2015 5 Not
reported
RR 0.61 0.41 to 0.93 Not reported 65%
All-
cause admis-
sion (≥ 72
years)
Xin 2015 6 Not
reported
RR 0.95 0.79 to 1.14 Not reported 38%
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Table 6. Subgroup agreements and disagreements with other reviews (Continued)
All-cause
admission (<
72 years)
Xin 2015 4 Not
reported
RR 0.88 0.77 to 1.00 Not reported 0%
A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Central Register of Controlled Trials Database [the Cochrane Library, Wiley] (Issue 2 of 12, 2016), Database of
Abstracts of reviews of Effectiveness & NHS Economic Evaluation Database [the Cochrane Library, Wiley] (Issue 2 of 4, 2015)
#1 MeSH descriptor: [Heart Failure] this term only
#2 heart failure or chf or hf:ti,ab,kw (Word variations have been searched)
#3 #1 or #2
#4 MeSH descriptor: [Natriuretic Peptide, Brain] explode all trees
#5 b type natriuretic peptide*:ti,ab,kw (Word variations have been searched)
#6 brain natriuretic peptide*:ti,ab,kw (Word variations have been searched)
#7 brain type natriuretic peptide*:ti,ab,kw (Word variations have been searched)
#8 pro bnp:ti,ab,kw (Word variations have been searched)
#9 probnp:ti,ab,kw (Word variations have been searched)
#10 ntpprobnp:ti,ab,kw (Word variations have been searched)
#11 natriuretic peptide type b:ti,ab,kw (Word variations have been searched)
#12 #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
# 13 MeSH descriptor: [Monitoring, Physiologic] this term only
#14 MeSH descriptor: [Prognosis] this term only
#15 MeSH descriptor: [Treatment Outcome] this term only
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(Continued)
#16 monitor*:ti,ab,kw (Word variations have been searched)
#17 ((serial or routine or longterm or long term) near/2 (measure* or test* or follow up)):ti,ab,kw (Word variations have been
searched)
#18 ((guide* or target*) near/2 (therap* or treatment* or pharmacotherap* or strateg*)):ti,ab,kw (Word variations have been
searched)
#19 prognos*:ti,ab,kw (Word variations have been searched)
#20 retest*:ti,ab,kw (Word variations have been searched)
#21 #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20
#22 #3 and #12 and #21
Embase (OvidSP)(1974-14/3/16)
1 Heart Failure/
2 Congestive Heart Failure/
3 (heart failure or hf or chf ).tw.
4 1 or 2 or 3
5 brain natriuretic peptide/
6 b type natriuretic peptide*.tw.
7 brain natriuretic peptide*.tw.
8 brain type natriuretic peptide*.tw.
9 bnp*.tw.
10 probnp*.tw.
11 pro bnp*.tw.
12 nt probnp.tw.
13 ntprobnp.tw.
14 natriuretic peptide type b.tw.
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(Continued)
15 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16 Patient monitoring/
17 Biologic monitoring/
18 Prognosis/
19 treatment outcome/
20 Follow up/
21 monitor*.tw.
22 ((serial or routine or longterm or long term) adj2 (measure* or test* or follow up)).tw
23 ((guide* or target*) adj2 (therap* or treatment* or pharmacotherap* or strateg*)).tw
24 prognos*.tw.
25 retest*.tw.
26 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25
27 4 and 15 and 26
28 randomized controlled trial/
29 controlled clinical trial/
30 single blind procedure/ or double blind procedure/
31 crossover procedure/
32 random*.tw.
33 placebo*.tw.
34 ((singl* or doubl*) adj (blind* or mask*)).tw.
35 (crossover or cross over or factorial* or latin square).tw.
36 (assign* or allocat* or volunteer*).tw.
37 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38 27 and 37
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(Continued)
39 (exp animal/ or nonhuman/) not human/
40 38 not 39
MEDLINE (OvidSP)(1946-15/3/16)
1 Heart Failure/
2 (heart failure or hf or chf ).tw.
3 1 or 2
4 Natriuretic Peptide, Brain/
5 b type natriuretic peptide*.tw.
6 brain natriuretic peptide*.tw.
7 brain type natriuretic peptide*.tw.
8 bnp*.tw.
9 probnp*.tw.
10 pro bnp*.tw.
11 nt probnp.tw.
12 ntprobnp.tw.
13 natriuretic peptide type b.tw.
14 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15 Monitoring, Physiologic/
16 Prognosis/
17 treatment outcome/
18 monitor*.tw.
19 ((serial or routine or longterm or long term) adj2 (measure* or test* or follow up)).tw
20 ((guide* or target*) adj2 (therap* or treatment* or pharmacotherap* or strateg*)).tw
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(Continued)
21 prognos*.tw.
22 retest*.tw.
23 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24 3 and 14 and 23
25 randomized controlled trial.pt.
26 controlled clinical trial.pt.
27 randomized.ab.
28 placebo.ab.
29 drug therapy.fs.
30 randomly.ab.
31 trial.ab.
32 groups.ab.
33 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34 exp animals/ not humans.sh.
35 33 not 34
36 24 and 35
Science Citation Index & Conference Proceedings Citation Index - Science. (ISI Web of Science)(1945 - 15/3/16)
# 1 752,670 TS=(“b-type natriuretic peptide*”)ORTS=(btype natriuretic peptide*)ORTS=(“b type natriuretic peptide*”)OR
TS=(“type-b natriuretic peptide*”) OR TS=(“natriuretic peptide* type-b”) OR TS=(“brain natriuretic peptide*”)
ORTS=(“brain type natriuretic peptide*”)ORTS=(bnp*) ORTS=(probnp* or “pro bnp*”)ORTS=(“nt probnp”
or ntprobnp) OR TS=(“natriuretic peptide type b”)
# 2 17,530 TS=(monitor*) OR TS=(((serial OR routine OR longterm OR long term) SAME (measure* or test* or follow
up))) OR TS=(((serial OR routine OR longterm OR long term) SAME (measure* or test* or follow up))) OR
TS=(prognos*) OR TS=(retest*)
# 3 1,559,464 2 AND 1
# 4 5,037 TS=(((random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)))
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(Continued)
# 5 2,233,989 4 AND 3
ClinicalTrials.gov (15/3/16)
Title=natriuretic peptide OR bnp OR pro bnp OR probnp OR ntprobnp OR pro-bnp OR nt-probnp
Intervention=natriuretic peptide OR bnp OR pro bnp OR probnp OR ntprobnp OR pro-bnp OR nt-probnp
WHO ICTRP (15/3/16)
Title=natriuretic peptide OR bnp OR pro bnp OR probnp OR ntprobnp OR pro-bnp OR nt-probnp
Intervention=natriuretic peptide OR bnp OR pro bnp OR probnp OR ntprobnp OR pro-bnp OR nt-probnp
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The search strategies in the final review differ slightly from those published in the protocol. Since the original protocol Cochrane
updated the filter for Embase, which introduced terms making the search more specific for trial design. The current search reflects these
updates.
Post hoc subgroup analyses were considered for baseline left ventricular ejection fraction (LVEF), control type and duration of follow-
up. LVEF was considered after extraction of data from the studies when it was identified that LVEF frequently formed one of the
inclusion/exclusion criteria for participants and was usually recorded in the baseline characteristics of participants in studies. It was
not anticipated that there could be more than one type of control group in the original protocol. Finally, most included studies had
a follow-up period of one to two years, only two studies monitored for a longer period and only two concentrated on up-titration of
heart failure drug(s). Similarly, this had not been anticipated in the original protocol. We wanted to assess if studies subgrouped by
either of these aspects could lead to further understanding of NP-guided treatment.
Post hoc, in response to peer reviewer comments, we completed a sensitivity analysis for all outcomes to evaluate the impact of any
differences between the two biomarkers: BNP and NT-proBNP.
Whilst not pre-specified in the protocol, a ’Summary of findings’ table and GRADE assessment were completed. These now form a
mandatory, and desirable, part of the Cochrane review process.
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